The effect of age, sex, and end-stage heart failure on the human cardiac transcriptome by Stefani, Maurizio
Copyright and use of this thesis
This thesis must be used in accordance with the 
provisions of the Copyright Act 1968.
Reproduction of material protected by copyright 
may be an infringement of copyright and 
copyright owners may be entitled to take 
legal action against persons who infringe their 
copyright.
Section 51 (2) of the Copyright Act permits 
an authorized officer of a university library or 
archives to provide a copy (by communication 
or otherwise) of an unpublished thesis kept in 
the library or archives, to a person who satisfies 
the authorized officer that he or she requires 
the reproduction for the purposes of research 
or study. 
The Copyright Act grants the creator of a work 
a number of moral rights, specifically the right of 
attribution, the right against false attribution and 
the right of integrity. 
You may infringe the author’s moral rights if you:
-  fail to acknowledge the author of this thesis if 
you quote sections from the work 
- attribute this thesis to another author 
-  subject this thesis to derogatory treatment 
which may prejudice the author’s reputation
For further information contact the University’s 
Director of Copyright Services
sydney.edu.au/copyright
The Effect of Age, Sex, and End-Stage 
Heart Failure on the Human Cardiac 
Transcriptome 
 
Dr. Maurizio Stefani, MB BS, B.Sc. (Hons I) 
 
A thesis submitted in fulfilment for the award of  
Doctor of Philosophy 
 
 
 
School of Medical Sciences, Sydney Medical School 
The University of Sydney, 2015
  ii
Statement of Originality 
 
In accordance with the laws of The University of Sydney, the author declares that this 
thesis describes original work performed under the auspices of the Sydney Medical 
School at The University of Sydney, Sydney, Australia, as well as at the Victor Chang 
Cardiac Research Institute, Sydney, Australia and the Université de Nantes, Nantes, 
France between 2006 and 2012. 
 
All the experimental work and results reported herein are solely by the author except for 
the following contributions: 
1) mRNA microarrays were constructed by Catherine Chevalier of the Université de 
Nantes, Nantes, France. 
2) Blocks of paraffin-embedded formalin-fixed LV samples prepared by the author 
were cut and arranged into tissue microarrays by Darryl Cameron of The 
University of Sydney, Sydney, Australia. 
 
This work has not been submitted for any other degree at this or any other institution. 
Maurizio Stefani 
  iii
Abstract 
This thesis aimed to describe the transcriptomic changes in the human left ventricle as a 
result of age and gender, and to relate these changes to the pathophysiology of heart 
failure, in order to understand why ageing and gender modifies our susceptibility to, and 
progression of heart failure. Many genes were discovered to be affected by age and 
gender, in particular, the set of genes that code for the r-proteins, i.e ribosomal subunit 
coding proteins, are downregulated with age, and are expressed at a lower level in males. 
I hypothesised that this may compromise the ability of myocardium to engage in 
necessary hypertrophy/hyperplasia to recover from a myocardial insult such as a 
myocardial infarction, and thus increases the risk of heart failure developing. However, 
no evidence of changes in nucleolar abundance, the site of ribosome synthesis, was found 
with age and gender. In heart failure of a variety of aetiologies, the expression of r-protein 
mRNA and 45s rRNA was found to be reduced, and the reduction of r-protein mRNA 
expression was ameliorated by left ventricular assist device support. A reduction in 
nucleolar abundance was also demonstrated in certain aetiologies of heart failure. I 
hypothesised that this may be due to an energy shortage in heart failure, partly 
ameliorated by left ventricular assist device support, leading to a reduction in 
energetically costly ribosome synthesis which is pathological in the long term.  
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Chapter 1: General Introduction  
 
1.1 The Heart and My Thesis: An overview 
In this thesis, I would like to address the issue of why people are more susceptible to 
developing heart failure (HF) after any particular cardiac insult, at greater ages. I would 
also like to explore the influence of gender on the development of HF. In order to come to 
grips with these questions, I will first begin by describing the heart, from an anatomical 
and then functional point of view. I will then discuss the changes that occur within the 
human heart throughout the adult lifespan that might underlie this increased risk, as well 
as the differences in cardiac structure and function according to gender. I will also 
introduce the pathophysiology of HF, and the various clinical entities associated with it 
that are investigated in this thesis. 
 The heart is the organ that generates the pressure that drives the flow of blood to 
all the organs and tissues of the body, including to itself. It must generate sufficient 
pressure such that adequate flow occurs, and be able to alter the pressure it generates in 
response to dynamic changes in the requirements of the various tissues of the body. The 
heart begins to contract at 4 weeks post fertilisation in the embryo, and must never stop. 
 The function of the heart is dependent on its anatomical architecture, and a myriad 
of hormonal, nervous and biochemical signalling pathways. These elements are altered 
during ageing and with the onset of pathology, and affect the ability of the heart to 
generate sufficient pressure to ensure adequate blood flow to the body. Understanding 
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how the ageing process and gender and pathology interact to affect the heart, is the 
purpose and scope of this thesis. 
 
1.2 The Structure of the Heart 
1.2.1 Gross Anatomy 
The human heart is located in the thorax within the middle mediastinum, an anatomical 
space that includes all structures enclosed by the pericardial sac. It is a four-chambered 
organ: left (LA) and right atria (RA), left (LV) and right ventricles (RV) (Fig. 1.1). 
Separating the atria and ventricles are the atrioventricular valves: the mitral valve 
separates the left side chambers, and the tricuspid, the right. The aortic and pulmonary 
semi-lunar valves separate the LV and RV from the aorta and pulmonary trunk, 
respectively. Deoxygenated blood returning from the systemic circulation passes into the 
RA from the superior and inferior venae cavae. Oxygenated blood from the pulmonary 
circulation passes into the left atrium from four pulmonary veins (Fig 1.2(b)).  
  
  3
 
Figure 1.1: The gross structure of the heart, indicating the chambers, valves and vessels. The image was 
taken from http://info.med.yale.edu/intmed/cardio/imaging/anatomy. 
 
1.2.2 Layers of the Heart 
The pericardial sac is composed of two layers. The outer fibrous pericardium has a serous 
parietal lining that is continuous at the base of the heart with the serous epicardium (or 
visceral pericardium). The space enclosed by these two layers is the pericardial space, 
which contains a small amount of serous fluid that allows the two layers to slide over 
each other as the heart beats. Within the epicardium, are located the major coronary 
vessels, and variable amounts of adipose tissue. Beneath the pericardium, the next layer is 
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myocardium, which forms the bulk of the mass of the heart, and is comprised principally 
of cardiomyocytes, which are the contractile cells of the heart. The myocardium of the 
LV is typically 3 times thicker than that of the RV, which reflects the differing amounts of 
pressure that must be generated to drive blood through the systemic and pulmonary 
circulations, respectively. The inner surface of the atria and ventricles are lined with 
endocardium, which is continuous with the endothelium of the blood vessels that take 
blood to and away from the heart. It is comprised of an epithelial cell layer with 
underlying connective tissue containing fibroblasts and smooth muscle cells.  
 
1.2.3 Coronary Vessels 
The heart, like every other tissue in the body, needs an adequate blood supply. The 
endocardium is nourished sufficiently by the blood that is continuously flowing through 
the atria and ventricles, but the remainder of the tissue of the heart has a dedicated blood 
vessel network (Fig. 1.2). The wall of the proximal aorta contains three small dilations: 
the left, right, and posterior aortic sinuses. From the left aortic sinus, arises the left 
coronary artery, which divides into the anterior interventricular artery (also known as the 
left anterior descending), and the left circumflex artery. These arteries usually supply the 
anterior, left lateral, apical, and sometimes the posterior surfaces of the heart, as well as 
the anterior portion of the interventricular septum. From the right aortic sinus, arises the 
right coronary artery, which supplies the right lateral, as well as the posterior surface of 
the heart in the majority of people, in which it branches to form the posterior 
interventricular artery. Branches from these epicardial arteries penetrate the myocardium 
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and supply the cardiomyocytes (and accompanying fibroblasts), as well as the electrical 
conduction system that regulates the activity of these contractile cells.  
 
(a) 
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(b) 
 
Figure 1.2(a) Anterior and 1.2(b) posterior views of the heart showing coronary arteries and veins. Images 
taken from Putz, R. et al. (2001). 
 
Deoxygenated blood flows from heart tissue through veins that follow the coronary 
arteries and eventually drain into the coronary sinus (located in the posterior wall of the 
heart) and then into the RA. A small portion of deoxygenated blood flows directly into 
the chambers of the heart through small venous channels called Thebesian veins (or 
venae cordis minimae). Blood flow to the heart tissue occurs mainly during diastole, the 
period during which the ventricles are not contracting. 
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1.2.4 Conduction System of the Heart 
The sinoatrial (SA) node is located in the RA, adjacent to the entry point of the superior 
vena cava. This group of specialised SA nodal cells generate the wave of depolarisation 
that initiates heart contraction (Fig. 1.3). From this node, action potentials spread across 
the two atria, to the atrioventricular (AV) node, a group of conducting cells, located at the 
base of the interatrial septum.  From the AV node, a bundle of conductive cells known as 
the Bundle of His traverses the fibrous tissue separating the atria and the ventricles. The 
Bundle of His divides early in the interventricular septum into left (that splits into the 
anterior and posterior hemi-bundles or fascicles) and right bundle branches. From these 
bundles, branches split off to form what are known as the Purkinje fibres, and these 
conduct the action potential to all the cardiomyocytes within the ventricular myocardium. 
 
Figure 1.3: A diagram of conduction system in the heart. The image was taken from  
http://www.bioen.utah.edu/faculty/sri/Lab8_humancardiovascular.htm. 
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1.2.5 Ultrastructure of the Heart 
The myocardium is by volume, ~ 80% cardiomyocytes, with the remainder made up of 
blood vessels and connective tissue. Human ventricular cardiomyocytes are 
approximately cylindrical, measuring 10 to 25 μm in width, and 50 to 100 μm in length. 
They branch and connect with adjacent cardiomyocytes via specialised junctions known 
as intercalated discs (Fig. 1.4). These are sites of low electrical resistance that allow the 
wave of depolarisation to traverse between the cardiomyocytes. The atrial 
cardiomyocytes are more elliptical, and smaller, measuring approximately 20 μm in 
width and 50 to 60 μm in length.   
 Cardiomyocytes contain a centrally located nucleus that comprises about ~ 5% of 
cell volume, held in place by microtubules supported by the surrounding myofibrils. 
Between 50 and 60 % of the volume of the cardiomyocyte is occupied by myofibrils, 
which are the structural units responsible for tension generation. The mitochondria, which 
are the site of adenosine triphosphate (ATP) generation, make up 25% of the cell volume. 
Most of the rest of the volume of cardiomyocytes comprises the sarcoplasmic reticulum 
(the cardiomyocyte equivalent of the endoplasmic reticulum, SR), as well as the T-tubules 
which are invaginations of the sarcolemma (plasma membrane of cardiomyocytes), and 
the Golgi apparatus. Numerous lysosomes and ribosomes occupy only a small fraction of 
the cell volume, but as will be discussed, play an important role in ageing. 
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Figure 1.4: A diagram demonstrating the spatial relationships of ventricular cardiomyocytes connected by 
intercalated discs (above), the ultrastructure of the ventricular cardiomyocytes (middle) with myofibrils, 
mitochondria (purple), SR (pink), sarcolemma and T-tubules (blue), and the structure of the sarcomeres 
located within the myofibrils (below). Image taken from Zipes, D. P. and Brauwald, E. (2005). 
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1.2.5.1 Sarcomere 
Myofibrils consist of a chain of sarcomeres, defined as the structures between successive 
Z-disks (or Z-bands). These are the basic functional units of the cardiomyocyte and are 
responsible for force generation (Figs. 1.4 and 1.5). Sarcomeres are made up of thick 
filaments containing myosin, thin filaments composed mainly of actin, plus a third 
filament, titin, that interact during the cross-bridge cycle converting chemical energy 
(Mg2+-ATP) into force. Actin is a globular protein that polymerises to form filaments that 
wind around each other to form a double helix structure. The thin filaments also contain 
the Ca2+ regulatory molecules, tropomyosin and troponins I, T, and C (Fig. 1.9). Myosin 
consists of two myosin heavy chains and two pairs of myosin light chains that form a 
complex resembling a golf club with two heads. The “shafts” of the “golf club” self-
assemble to form the bipolar thick filaments at the M-line with the “heads” oriented 
towards the Z-disks. In the A-bands, the myosin and actin filaments interdigitate and their 
interaction produces changes in sarcomere length. Titin (nearly 4 mDa) extends as a 
single molecule from the Z-disk all the way to the M-line.  
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Figure 1.5: A transmission electron micrograph (EM) of a cardiomyocyte demonstrating the striated 
appearance and various structures of the myofibrils including the the A-band (A), I-band (I), M-line (M), Z-
disc (Z), H-band (H), as well as surrounding mitochondria (mit), glycogen granules (g), and a T-tubule (T). 
Image taken from  Zipes, D. P. and Brauwald, E. (2005).  
 
Sarcomeres (and the myofibrils they make up) contain many other proteins that maintain 
their longitudinal orientation and stability. These include microtubules, -actin filaments, 
titin, -actinin and intermediate filament proteins, such as desmin and vimentin, as well 
as many others (Fig. 1.6). These proteins also anchor the myofibrils to the protein 
complexes of the sarcolemma and extracellular matrix. 
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Figure 1.6: Major cytoskeletal proteins that connect myofibrils to the other parts of the cardiomyocyte 
(Dalakas, M. C. et al. 2000). 
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1.2.5.2 Mitochondria 
The mitochondria are cocoon-shaped organelles that lie between myofibrils (myofibrillar 
mitochondria) and adjacent to the sarcolemma (subsarcolemmal mitochondria) and 
supply ATP for muscle contraction and cellular metabolism in cardiomyocytes (Fig. 1.7). 
The mitochondria have a double membrane structure, with the inner mitochondrial 
membrane being greatly folded to maximise surface area. There are button-shaped 
outpouchings on the inner mitochondrial membrane called cristae, which contain the 
enzymes for oxidative phosphorylation and ATP synthesis. The predominant fuels used 
for cardiac metabolism under physiological conditions are fatty acids, with lactate 
playing a minor role from a quantitative perspective.  
 
Figure 1.7: The structure of the mitochondrion with demonstration of the various cellular substrates it can 
take up and use as fuel for ATP synthesis and the output molecules generated. Image taken from Opie, L. H. 
(2004). 
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1.2.5.3 Sarcolemma and T-Tubules 
The cardiomyocyte sarcolemma contains many channels, pumps, and receptors essential 
to cell functioning. In particular, it contains the voltage-gated Na+ channels that open in 
response to a wave of depolarisation, which leads to the influx of Ca2+ through 
sarcolemmal L-type Ca2+ channels that is ultimately responsible for triggering 
contraction. The T-tubules (Fig. 1.4) are invaginations of sarcolemma that allow Ca2+ 
entry to occur directly across from the SR and the nearby myofibrils. This allows 
synchronous activation of all myofibrils within the cardiomyocyte (explained in more 
detail later). 
 
1.2.5.4 Sarcoplasmic Reticulum  
The SR (Fig. 1.4) is a specialised form of endoplasmic reticulum which plays a major 
role in the Ca2+ handling that is integral to cardiomyocyte contraction. It is composed of a 
fine network of tubing throughout the cytoplasm with bulbous swellings juxtaposed to the 
T-tubules. Ca2+ is stored within the SR bound to Calsequestrin, and its release triggers the 
contraction of atrial and ventricular cardiomyocytes. 
 
1.2.5.5 Ribosomes 
Ribosomes are massive ribonucleoprotein complexes involved in translating the triplet 
code within messenger ribonucleic acid (mRNA) molecules into the corresponding amino 
acid sequence to produce all the proteins in the heart. The human ribosome has 2 
subunits, a smaller 40S and a larger 60S subunit. The 40S subunit is composed of 33 
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different r-proteins plus the 18s ribosomal ribonucleic acid (rRNA), and is responsible for 
decoding the mRNA strand. The 60s subunit is composed of 46 r-proteins plus the 5S, the 
28S, and the 5.8S rRNAs and is responsible for forming peptidyl bonds during peptide 
chain elongation. Ribosomes are found both in the cytosol as well as on the surface of the 
SR. They are also abundant in the non-cardiomyocyte cells of the heart. 
 Synthesis of ribosomes is reviewed in Lafontaine, D. L. and Tollervey, D. (2001). 
Briefly, a large polycistronic 45s rRNA is transcribed by RNA polymerase I,  covalently 
modified and cleaved into the mature 18s, 28s and 5.8s rRNA strands. The 5s rRNA is 
transcribed from a different region in the genome by RNA polymerase III. R-proteins are 
translated in the cytoplasm by pre-formed ribosomes and are imported into the nucleus 
and then into the nucleolus where they are assembled with the rRNA into pre-ribosome 
subunits that are exported into the cytoplasm and undergo final structural rearrangements 
to become mature ribosome subunits.   
 Protein synthesis, i.e. translation of mRNA, is a complex process and is reviewed 
in Lafontaine, D. L. and Tollervey, D. (2001) and Hannan, R. D. et al. (2003). Briefly, the 
first step is that a methionyl-transfer ribonucleic acid (tRNA) binds to several eukaryotic 
initiation factors (eIF) and to the 40s ribosome subunit, this quaternary structure is termed 
the 43s pre-initiation complex. Then, 43s binds to the eIF4F complex (composed of 
proteins eIF4A, eIF4E, and EIF4G) which then imbues the complex with the ability to 
search for mRNA bearing the 5' 7-methylguanosine cap. An mRNA is bound and the 
complex moves along the 5' untranslated region until it encounters the codon for 
methionine (AUG). At this point, the eIFs are displaced, and the 60s subunit binds to 
form the functional 80s ribosome.  
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There are three key sites on the ribosome that are important in mRNA translation, the A, 
P and E sites (Fig. 1.8). The methionyl-tRNA is bound at the P site, and the A site is 
occupied by a complex containing an aminoacyl-tRNA with anticodon complementary to 
the codon on the mRNA (with the corresponding amino acid), guanosine triphosphate 
(GTP), GTPase elongation factor 1-α. When correct tRNA-mRNA binding occurs, the 
GTP is hydrolysed, and the peptide chain (or in the beginning just the methionine) is 
cleaved from the bound tRNA in the P site and attached to the amino acid via a peptide 
bond on the aminoacyl-tRNA in the A site. After peptidyl transfer, GTPase elongation 
factor-G attaches and hydrolyses GTP which leads to translocation of the mRNA along 
the interface of the two ribosome subunits with the tRNA in the P site moving to the E 
site, and the tRNA with the growing polypeptide chain in the A site moving to the P site. 
The process continues until the ribosome reaches a stop codon on the mRNA and the 
nascent polypeptide is released. 
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Figure 1.8: Schematic of the eukaryotic 80s ribosome with the 40s and 60s subunits labelled, as well as the 
mRNA being translated, the E site, the growing polypeptide chain attached by a tRNA (not shown) to the P 
site, and the incoming aminoacyl-tRNA bound to the A site. Image adapted from Lafontaine, D. L. and 
Tollervey, D. (2001). 
 
1.3 Functions of the Heart 
1.3.1 Introduction to Cardiac Contraction 
Cardiomyocytes contract and shorten in response to electrical signals generated originally 
by the conduction system of the heart, and this results in pressure being generated by the 
chambers of the heart, which drives blood flow. Blood flow from the heart is usually 
measured as the cardiac output (CO), defined as the total volume of blood ejected by the 
ventricles into the pulmonary or systemic circulation, per minute. Cardiac index (CI), a 
related measure, is CO corrected for body surface area (BSA). 
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Figure 1.8: Depiction on the various phases of the cardiac cycle (bottom), along with the associated 
pressures in the LA, LV, and aorta, heart sounds, jugular venous pressure (JVP), and electrical events on the 
electrocardiogram. 'Iso' refers to isovolumic contraction and relaxation, respectively, in the bottom 
sequence of LA and LV depictions. Image taken from Zipes, D. P. and Brauwald, E. (2005).  
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The atria and ventricles contract during different phases of the cardiac cycle. The two 
phases are systole (when the ventricles contract and propel blood to the pulmonary and 
systemic circulations) and diastole (when the ventricles are relaxing and filling with the 
aid of atrial contraction in readiness for the next phase of systole). For more detail, see 
Fig. 1.8. 
 The heart can vary the force of contraction with each beat, to match the CO to the 
dynamically changing needs of the tissues of the body. There are multiple mechanisms by 
which this is achieved including changes in contractility due to changes in ventricular 
filling, i.e. the Frank-Starling relationship, as well as the varying input of the autonomic 
nervous system and circulating hormones (elaborated upon in later chapters). 
 
1.3.2 Cardiac Contraction 
The cardiomyocyte contracts when the sarcomeres shorten through the interaction of 
myosin and actin, in response to membrane depolarisation and subsequent elevated 
cellular Ca2+ concentration. This process is known as excitation-contraction (EC) 
coupling. When the membrane of a cardiomyocyte is depolarised by changes in ion 
gradients in the adjacent sarcolemma, the voltage-gated Na+ channels open, depolarising 
the sarcolemma further, leading to the opening of L-type voltage-gated Ca2+ channels. 
This occurs both in the sarcolemma proper, as well as in the T-tubules. The entering Ca2+ 
binds to ryanodine receptors (RYR2 is the cardiac isoform) present on the adjacent SR, 
which then triggers the opening of their associated channel. This leads to Ca2+ release 
from the SR thus elevating the myofibrillar Ca2+ concentration, so-called Ca2+-induced 
Ca2+ release (CICR). Myofibrillar Ca2+ then binds to troponin C, which forms part of a 
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heterotrimer with troponins T and I (Fig. 1.9). This troponin complex is attached to the 
polymerised actin within the sarcomere, and to the associated tropomyosin. When Ca2+ is 
absent, tropomyosin covers the myosin-binding site on actin, preventing cross-bridge 
formation and force generation. However, when Ca2+ binds to troponin C, a 
conformational change occurs in the troponin complex that causes tropomyosin to move 
away from the myosin-binding site, allowing myosin to bind, leading to force production 
via the cross-bridge cycle.  
 
 
Figure 1.9: Diagram illustrating the components of the thick and thin filaments involved in EC coupling 
and cross-bridge cycling, and the direction of movement of the two filaments relative to each other. Image 
taken from Kamisago, M. et al. (2000). 
 
Myosin, in its non-contractile state, has adenosine diphosphate (ADP) and inorganic 
phosphate (Pi) bound to it. This is stage 2 of the 4 stage cross-bridge cycle (Fig. 1.10). At 
this stage, the myosin head is primed, and if the myosin-binding site on the adjacent actin 
polymer is exposed, it will bind (stage 3) and Pi will be released. Subsequently, myosin 
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changes conformation such that the head is flexed at the neck of the complex (stage 4), 
resulting in the pulling of the thin filament towards the M-line, shortening of the 
sarcomere, and force generation. In the transition to stage 1 from stage 4, ATP binds to 
the myosin head and the myosin complex detaches from the thin filament. The ATP is 
then hydrolysed resulting in myosin resuming its primed conformation with ADP and Pi 
attached (stage 2), and its availability to bind any available exposed myosin-binding sites 
on actin. This cross-bridge cycle is repeated by the thick and thin filaments as long as 
Ca2+ is available to bind to troponin C, and the force generated at each cross-bridge 
summates to generate the total force that results in atrial and ventricular contraction 
during the cardiac cycle. 
 Cross-bridge cycling and force generation does not continue indefinitely. Once 
the atria or ventricles have ejected the requisite amount of blood necessary, they must 
relax and allow filling to occur. This occurs via a reduction of the myofibrillar Ca2+ 
concentration by the reuptake of Ca2+ by the SR through sarco/endoplasmic reticulum 
Ca2+-ATPase (SERCA). Myofibrillar Ca2+ concentration is also decreased to a lesser 
extent by efflux through the sarcolemmal Na+-Ca2+ exchanger (which utilises the 
favourable Na+ electrochemical gradient to drive Ca2+ out of the cell), as well as by the 
Ca2+-ATPase present on the sarcolemma, and uptake into the mitochondria.  
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Figure 1.10: Schematic diagram showing the 4 stages of the cross-bridge cycle. Image taken from Cooke, 
R. (2004). 
 
  23
1.3.3 Regulation of Contraction 
1.3.3.1 Intrinsic Regulation 
A ventricle can modify the magnitude of contraction, i.e. the total amount of force 
generated to decrease the volume of the chamber, depending on the extent to which it is 
filled at the end of diastole. Increasing end-diastolic volumes (EDV) lead to a more rapid 
increase in ventricular pressure, a higher peak pressure, and a more rapid rate of 
relaxation. Thus, a ventricle filled with more blood at the end of diastole, will pump more 
blood out during systole. This is known as the Frank-Starling relationship, also referred to 
as length-dependent activation. There are a number of proposed mechanisms (reviewed in 
Opie, L. H. 2004). One is that stretching of the cardiomyocyte with constant volume, 
results in decreased distance between thick and thin filaments (with titin and myosin 
binding protein C possibly playing a role), increasing the probability of cross-bridge 
cycling at any particular Ca2+ concentration. The second is that cross-bridge formation 
may result in neighbouring actin and myosin molecules being brought into greater 
vicinity, increasing the likelihood of cross-bridge cycling at those sites. Additionally, 
myosin ATPase activity increases in response to stretch, and through as yet uncertain 
mechanisms, stretch seems to increase the opening of Ca2+ channels on the sarcolemma 
leading to greater CICR. Finally, any increase in heart rate (HR), whether mediated by 
enhanced sympathetic stimulation (see below) or otherwise, leads to an increase in 
contractility via accumulation of Ca2+ in the SR, with greater Ca2+ release and cross-
bridge formation in successive heart beats. This is known as the Bowditch phenomenon 
or Treppe effect (Opie, L. H. 2004). 
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1.3.3.2 Regulation by the Autonomic Nervous System 
Both the sympathetic and parasympathetic divisions innervate the heart, and branches 
from both of these systems form cardiac plexuses. The deep cardiac plexus is located 
anterior to the carina of the trachea, and the superficial cardiac plexus is located inferior 
to the aortic arch. Pre-ganglionic parasympathetic fibres arising from the vagus nerve 
synapse onto post-ganglionic fibres either in these plexuses, or pass through the plexuses 
to synapse in the walls of the atria. Activation of these fibres results in a decrease in SA 
node pacemaker activity and thus, a decrease in HR.  
 Pre-ganglionic sympathetic nerves arising from T1 to T5, pass into the 
sympathetic trunk and synapse in cervical and upper thoracic sympathetic ganglia.  The 
post-ganglionic fibres pass to the plexuses and mix with the parasympathetic fibres to 
form nerves that innervate the SA node, as well as the entire atrial and ventricular 
musculature. Activation of these fibres leads to increases in HR (positive chronotropic 
effect), contractility (positive inotropic effect), as well as an increase in the rate of 
relaxation (positive lusitropic effect). This positive lusitropic effect ensures that 
ventricular filling during diastole does not become limiting at elevated heart rates. 
 The sympathetic nervous system primarily acts through β1-adrenergic receptors 
located on the sarcolemma (reviewed in Opie, L. H. 2004). They are activated by 
norepinephrine released at sympathetic nerve terminals, as well as epinephrine (released 
from the adrenal medulla in response to sympathetic stimulation). Activation of this G-
protein coupled receptor leads to activation of adenylyl cyclase which increases cyclic  
adenosine monophosphate (cAMP) levels within the cardiomyocyte. cAMP binds to and 
activates protein kinase A, which then phosphorylates multiple cellular targets. These 
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include the L-type Ca2+ channel that leads to greater Ca2+ entry and the RYR2, leading to 
increased CICR. These changes are responsible for the positive inotropic effect of 
adrenergic signalling. The positive lusitropic effect is mediated partly by phosphorylation 
of proteins of the thin filament that leads to reduced Ca2+ sensitivity (i.e. probability of 
cross-bridge formation at any particular Ca2+ concentration), as well as by 
phosphorylation (causing inhibition) of phospholamban, a protein that normally inhibits 
SERCA. The net result is faster Ca2+ reuptake and thus enhanced relaxation. 
 
1.4 Heart Failure 
1.4.1 Pathophysiology 
Heart failure (HF) can be defined as the inability of the heart to generate adequate blood 
flow to supply the needs of the tissues of the body (Opie, L. H. 2004). Depending on the 
degree of HF, CO may be adequate at rest, but under conditions of increased demand, 
such as exercise, the heart cannot increase its CO to match, i.e. there exists decreased 
cardiovascular reserve with HF. In patients with end-stage HF, CO is inadequate even at 
rest, and the patient has intractable symptoms of dyspnoea, fatigue and drowsiness.  
 The defects of cardiac contraction can be separated into two interrelated concepts: 
1) systolic dysfunction, i.e. inadequate force generation, and 2) diastolic dysfunction, i.e. 
inability of the ventricles to relax to allow adequate ventricular filling. The various 
clinical entities that patients are diagnosed with have features of both systolic and 
diastolic dysfunction. 
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With systolic dysfunction, there is a decrease in the rate of increase of ventricular 
pressure and a decrease in peak ventricular pressure. Stroke volume (SV) is defined as the 
volume of blood pumped out of the ventricle during systole. One measure used to 
quantify the extent of systolic dysfunction is the ejection fraction (EF), defined as the 
SV/EDV. With a decreased EF, the LV EDV increases, and this results in greater 
contractility via Frank-Starling mechanisms. This somewhat compensates for the 
otherwise decreased contractility, maintaining the stroke volume, which assists in 
maintaining CO. However, the consequence is a reduction in the scope for further 
increases in contractility in response to increased venous return to the LV in times of 
increased CO requirement. In addition, a more dilated LV has increased wall stress during 
systole as defined by the LaPlace Law: Wall Stress = (Pressure * Ventricle Radius) / (2 * 
Ventricle wall thickness) (Opie, L. H. 2004). This is a measure of the tension within the 
ventricle wall that must be overcome by the opposing tension generated by cycling cross-
bridges in order to pump blood out of the ventricle. Pressure in the wall stress equation 
refers to the blood pressure in the ventricular cavity and aorta during systole, when the 
aortic semi-lunar valve is open (also referred to as afterload). Wall stress is a major 
determinant of oxygen and nutrient consumption per unit mass of the ventricle wall. The 
response to increased wall stress is LV hypertrophy (LVH), in an attempt to normalise 
wall stress. LVH as a reaction to systolic dysfunction occurs via an increase in the size of 
individual cardiomyocytes (cell hypertrophy), as well as by an increase in the number of 
cardiomyocytes (hyperplasia) (Quaini, F. et al. 1994; Kajstura, J. et al. 1998). However, 
such hypertrophy is not perfectly compensatory, with inadequate angiogenesis having 
been suggested to contribute to mild ischaemia and dysfunction of the greater 
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cardiomyocyte population (Rakusan, K. et al. 1992). Regardless of the underlying 
mechanisms, there are absolute reductions in phospho-creatine, ATP and the ratio of 
phospho-creatine/ATP, as well as flux through the creatine kinase pathway in 
myocardium from patients with end-stage HF, demonstrating a state of energy deficiency 
(Ten Hove, M. and Neubauer, S. 2007). Note that the levels of phospho-creatine, ATP and 
the ratio of phospho-creatine/ATP, as well as flux through the creatine kinase pathway in 
non-failing (NF) LV myocardium do not change with age (Bottomley, P. A. et al. 2009). 
Additionally, the rate of apoptosis is increased in the failing heart (Olivetti, G. et al. 
1997), with higher rates in males than females (Guerra, S. et al. 1999). Furthermore, 
apoptotic rate has been demonstrated to correlate with the rate of disease progression in 
HF (Saraste, A. et al., 1999). Necrosis is also increased in HF (Guerra, S. et al. 1999), 
also with higher rates in males than females. Loss of cardiomyocytes by apoptosis and 
necrosis increases the load on the remainder, promoting a vicious cycle of haemodynamic 
overload.  
 Diastolic dysfunction is promoted by LVH via several mechanisms, including 
increased interstitial tissue deposition (mainly collagen), as well as decreased energy 
availability which impairs ATP-dependent reuptake of Ca2+ back into the SR by SERCA. 
This in turn, decreases EDV, which as a result, decreases stroke volume and hence, CO. 
 Taken together, these defects in cardiac function lead to impairment of LV 
emptying, leading to increased hydrostatic pressure within the pulmonary circulation and 
pulmonary oedema. The result is decreased oxygen diffusion, as well as increased lung 
stiffness leading to the symptoms of dyspnoea, and at end-stage, cyanosis. Back pressure 
from the failure of the LV and RV, leads to increased pressure in the venae cavae, 
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resulting in hepatic congestion and dysfunction. Decreased CO (and hypoxia in end-stage 
HF) leads to abnormalities of cerebral, renal and skeletal muscle perfusion, leading to 
encephalopathy, renal impairment, and increased fatiguability, respectively.  
 Compensatory neurohumoral mechanisms that attempt to maintain adequate 
perfusion of the heart and brain act by increasing systemic arterial pressure through 
actions on the heart and vasculature. These include increased sympathetic nervous system 
stimulation of the heart itself via the cardiac nerves to increase contractility, HR, and rate 
of relaxation, thus increasing CO. Sympathetic stimulation also leads to peripheral 
arteriolar vasoconstriction in viscera, skeletal muscle, and skin, thereby increasing 
systemic vascular resistance, and hence, systemic arterial pressure. Sympathetic 
stimulation of the kidneys leads to increased Na+ and water reabsorption and decreased 
urine formation via afferent arteriolar vasoconstriction and activation of the renin-
angiotensin-aldosterone system. This results in an increase in total blood volume and 
venous return to the LV to increase CO, albeit at the risk of exacerbating pulmonary 
oedema. However, these compensatory mechanisms also increase afterload, and thus 
increase wall stress. This raises the energetic demands on the cardiomyocytes, promoting 
dysfunction and cell death, with progressive worsening of HF chronically. 
 End-stage HF eventually results in death via either progressive HF and circulatory 
shock with multi-organ failure, sudden death from cardiac arrhythmia, or stroke due to 
embolism of thrombi formed on the wall of the dilated LA or LV.  
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1.4.2 Ischaemic Cardiomyopathy 
Myocardial infarction (MI) is the most common cause of HF in the Western world. The 
aetiology of HF due to ischaemic cardiomyopathy (ISCM) is the loss of contractile 
ventricular tissue from the infarcted site itself, as well as more generalised loss of 
cardiomyocytes with replacement fibrosis, as a result of atherosclerotic arterial occlusion 
across the LV (Beltrami, C. A. et al. 1994). The remaining cardiomyocytes display 
compensatory hypertrophy. This results in systolic dysfunction, with superadded 
impairment of energy-dependent relaxation due to ischaemia (diastolic dysfunction), 
playing an additional perhaps more minor role. The result is an increase in LV EDV, a 
dilated heart, with increased wall stress partially compensated by LVH. 
 
1.4.3 Idiopathic Dilated Cardiomyopathy 
Idiopathic Dilated Cardiomyopathy (IDCM) can be considered as a phenotypic group that 
encompasses patients with HF from a variety of different aetiologies including mutations 
in cytoskeletal and sarcomeric genes as well as previous subclinical myocarditis and 
other occult causes (Opie, L. H. 2004). All these various pathologies lead to a similar 
phenotype characterised by predominantly systolic dysfunction, with a dilated LV and 
varying levels of LVH. 
 
1.4.4 Hypertrophic Cardiomyopathy  
Hypertrophic cardiomyopathy (HCM) is another LV myocardial pathology that 
predisposes to the development of HF. It is characterised by gross LVH with markedly 
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reduced LV chamber volume, diastolic dysfunction, and relatively preserved systolic 
function. For the majority of HCM patients, an underlying genetic cause is found, and 
these include mutations in a variety of sarcomeric proteins (Opie, L. H. 2004). The 
common underlying pathophysiology behind HCM may be a deficit in force generation 
and increased Ca2+ sensitivity (Hoskins, A. C. et al. 2010), leading to systolic and 
diastolic dysfunction, respectively. This initial defect then leads to compensatory, but 
ultimately excessive LVH (and associated ischaemia), that exacerbates the diastolic 
dysfunction, and finally results in the development of end-stage HF.  
 
1.4.5 Recovery with LV Assist Device Implantation 
A Left Ventricular Assist Device (LVAD) is a mechanical device implanted into patients 
with LV failure that receives blood from the LV, and then pumps the blood into the 
ascending aorta, thereby unloading the LV and maintaining adequate CO within the 
patient. In several trials, LVAD insertion has been shown to improve survival and 
symptoms in patients with end-stage HF, whether it is being used as a bridge to 
transplantation or as long-term therapy (reviewed in Birks, E. J. 2010). In a minority of 
patients, recovery of LV function has been such that the patient no longer required LVAD 
assistance, nor heart transplantation. In these instances, the patient's hearts seem to have 
undergone a partial, or almost complete reversal of the defects associated with their HF 
phenotype. 
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1.5 The Effects of Age and Gender on the Human Heart 
1.5.1 Introduction  
The changes in the human heart due to the ageing process are often accompanied by 
changes recognised as due to the development of pathologies, such as narrowing of the 
coronary arteries and microcirculation due to atherosclerosis, superimposition of valvular 
defects associated with older ages, such as calcific aortic stenosis, and progressive 
systemic arterial hypertension. Different investigators have attempted to separate the 
effects of the development of pathology from the unremitting ageing process by 
analysing patients without clinically apparent pathology, however this does not eliminate 
the effects of sub-clinical pathology. On the other hand, one could argue that these sub-
clinical pathologies form part of the ageing process of the heart. I think that the study of 
the hearts of ageing patients, both with and without overt cardiovascular pathology, have 
merit. An analysis of the latter population may more properly represent the ageing 
phenotype, and an analysis of the former population, is more representative of the 
average patient found in the clinic, who will have an aged heart that has also been 
subjected to the myriad pathologies associated with older ages. 
 
1.5.2 Structural Changes with Age and Gender 
1.5.2.1 Macroscopic Changes with Age and Gender 
In the Baltimore Longitudinal Study of Ageing cohort, male and female participants were 
selected who had no chest wall abnormalities, coronary heart disease (asymptomatic and 
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with negative stress tests), valve dysfunction, or hypertension. Assessed by 
echocardiography, it was found that from the ages of 25 to 85 there was an increase in 
posterior LV wall thickness by ~ 50 % (Gerstenblith, G. et al. 1977). In the Framingham 
cohort, a similar increase with age of LV mass was observed in both men and women 
(Savage, D. D. et al. 1990). However, in a subset of patients without cardiopulmonary 
disease, hypertension or obesity, LV mass did not increase in men, and the increase in 
women was highly attenuated (Dannenberg, A. L. et al. 1989). Echoing these latter 
findings, Olivetti, G. et al. (1995) showed that in a similar population of healthy 
individuals that there was no change in wall thickness with age in both the LV and RV of 
both genders. In fact, it was found that the weight of the myocardium decreases in males 
with age (0.78 g per year in LV, 0.16 g per year in RV) while remaining constant in 
females.  
 Thus, in the absence of pathology, myocardial mass may remain the same with 
age, but in response to the superimposition of age-related pathology, there may be 
varying amounts of compensatory LVH. 
 
1.5.2.2 Cardiomyocyte Compartment Changes with Age and Gender 
In studies of human hearts that were grossly normal, as well as hearts with eccentric and 
concentric hypertrophy due to valvular defects, hypertension, chronic pulmonary diseases 
and congenital abnormalities, no change in cardiomyocyte numbers in either the RV or 
LV were detected with age (Arai, S. and Machida, A. 1972; Tadokoro, M. and Arai, S. 
1972). In contrast, in a group of hearts from patients without significant cardiac related 
pathology, cardiomyocyte loss has been shown to occur with age (Olivetti, G. et al. 1995; 
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Olivetti, G. et al. 1991). According to Olivetti, G. et al. (1995), in males, there is a loss of 
approximately 45 million cardiomyocytes per year in the LV and 19 million 
cardiomyocytes per year in the RV, corresponding to a decrease of ~ 1 % of the total 
number of cardiomyocytes per year. In 20 year old males, the LV contains approximately 
5.8 x 109 myocytes of which 5.4 x 109 are mononucleated and 0.4 x 109 are binucleated. 
Due to the decrease in cardiomyocytes with age, in 70 year old males, the LV contains 
approximately 3.6 x 109 cardiomyocytes of which 2.9 x 109 are mononucleated and 0.7 x 
109 are binucleated. Note that in addition to the decrease in overall cardiomyocyte 
numbers in the LV and RV, there is an increase in the proportion of binucleated 
cardiomyocytes. This loss of LV cardiomyocytes with age in males may account for the 
decrease in myocardial weight observed. The female LV, on the other hand, contains on 
average 4.31 x 109 cardiomyocytes of which 3.6 x109 are mononucleated and 0.67 x 109 
are binucleated, and there was no change with age (Olivetti, G. et al. 1995). Similarly, 
there were no changes in cardiomyocyte numbers in the RV. The mean cardiomyocyte 
volume per nucleus was ~ 20,000 μm3 in both men and women at 20 years, and 
simultaneous with the loss of cardiomyocytes with age in the male heart, mean 
cardiomyocyte cell volume increased by 158 μm3 per year in the LV and 167 μm3 per 
year in the RV (Olivetti, G. et al. 1995). There was no change in mean cardiomyocyte cell 
volume in the female heart. Taken together, it seems that loss of cardiomyocytes in the 
ageing male heart is associated with hypertrophy of the remaining to cope with an 
unchanged haemodynamic load, whereas this does not seem to occur in women. In 
contrast, in the presence of pathology, the number of cardiomyocytes does not tend to 
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decrease implying a compensatory hyperplastic response to cope with changes in load as 
a result of superimposition of pathology.  
 
1.5.2.3 Non-Cardiomyocyte Compartment Changes with Age 
Collagen content can be used as a surrogate marker for fibroblast abundance and activity. 
Wegelius, O. and Von, K. (1964) analysed macroscopically normal hearts and did not find 
a change in collagen content with ageing in either ventricle. Caspari, P. G. et al. (1977) 
analysed hearts that did not show valvular abnormalities or evidence of ischaemic heart 
disease at autopsy and also found no relationship between collagen content and age. 
Furthermore, in a subset of hearts exhibiting hypertrophy, collagen concentration in the 
LV remained the same. Similarly, Mollova, M. et al. (2013) did not observe a change in 
fibrotic tissue with age. Olivetti, G. et al. (1991) however, found that rarely, areas of 
replacement fibrosis and interstitial and perivascular fibrosis are observed in the aged 
heart.  
 Little is known about the changes in the microvascular compartment that are 
associated with age in the human heart. In a study by Rakusan, K. et al. (1992) of hearts 
from patients who died of non-cardiac causes, with no evidence of coronary disease, 
mitral regurgitation or aortic valve dysfunction, capillary density decreased from child 
hood (9 to14 years) to adolescence and early adulthood (15 to 30 years). However, 
changes with more advanced age are currently unknown. 
 It is clear that more work needs to be done to describe adequately the remodelling 
of the non-cardiomyocyte compartment that occurs during the ageing process in humans. 
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1.5.3 Functional Changes with Age and Gender 
There are a number of age-related changes in human cardiac function that have been 
described, both at rest, and during times of increased haemodynamic requirement. 
 CI at rest declines slightly in women but not in men, with age (Fleg, J. L. et al. 
1995; Rodeheffer, R. J. et al. 1986). There is a small increase in LV EDV index (LV EDV 
normalised for body surface area, LV EDVI), LV end systolic volume index (LV ESVI), 
and stroke volume index (SVI) in men, but not in women (Fleg, J. L. et al. 1995). 
However, Rodeheffer, R. J. et al. (1986) did not confirm increases in cardiac volumes at 
rest in men at older ages. These possible increases in cardiac volumes in the male along 
with an increased SVI, are opposed by a larger decline in HR at rest with age, as 
compared to women who experience a smaller decline in resting HR with age. With 
higher EDVI in males, and higher systolic blood pressure in both sexes, there is an 
increase in afterload. LV EF at rest, which is consistently higher in females, in 
accordance with the above findings, does not decline with age (Fleg, J. L. et al. 1995). LV 
early diastolic filling rate however, does decrease with age in both males and females 
(Schulman, S. P. et al. 1992; Benjamin, E. J. et al. 1992; Swinne, C. J. et al. 1992). This 
decrease is countered by an enhanced late filling rate due to more vigorous atrial 
contraction that maintains diastolic filling (Swinne, C. J. et al. 1992). This decrease in 
early diastolic filling may represent an increase in stiffness due to changes in the 
interstitial tissues of the heart, or defects in relaxation at the level of the myofibrils, due 
to residual Ca2+ from the previous systole. In any case, these results imply a maintenance 
of almost normal cardiac function at rest at older ages, in both males and females.  
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At maximal exercise, peak CI is reduced in both males and females at older ages (Fleg, J. 
L. et al. 1995). Maximal HR declines with age in both men and women, and is thought to 
be primarily responsible for the decrease in maximal CI. EDVI increases in older men 
during maximal exercise compared to younger men, who do not experience an increase 
(Fleg, J. L. et al. 1995). This age-related change in EDVI during peak exercise occurs to a 
lesser extent in women. EF at maximal exercise decreases with age in both sexes, but to a 
lesser extent in women (Fleg, J. L. et al. 1995). However, coupled with a greater EDVI 
during exercise, especially in older men, SVI is preserved in both sexes at peak exercise 
compared to younger people. These results imply that there is a greater reliance on Frank-
Starling mechanisms to maintain SVI at older ages, and also, that during maximal 
exercise, to achieve the same SVI, a higher EDVI is required in men, implying decreased 
contractility in male hearts compared to female hearts (Fleg, J. L. et al. 1995). As a 
further piece of evidence of decreased contractility, the same study found that during 
maximal exercise, LV end systolic pressure/ESV (a marker of LV contractility) decreases 
with age in both males and females, with the decrease being possibly steeper in males. 
 There are a variety of possible mechanisms that may explain the change in human 
LV function with age, at both the microscopic and macroscopic levels. Given the 
decreased maximal HR, a decrease in contractility would be expected, due to decreased 
Ca2+ accumulation in the SR secondary to the Bowditch phenomenon (Lakatta, E. G. and 
Levy, D. 2003). In addition, there is decreased post-synaptic adrenergic responsiveness in 
the older heart which manifests as lower contractility, impaired diastolic filling, as well as 
lower HR (Opie, L. H. 2004). It was earlier described that in the absence of 
cardiovascular pathology, there is an age-related loss of cardiomyocytes (with 
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compensatory cellular hypertrophy) in males, and this may partially contribute to the 
greater decrease in systolic function with age in males, at least during states of increased 
haemodynamic requirement. However, in the presence of increasing afterload and/or the 
development of other cardiovascular pathology with age, LVH occurs as a response in 
both sexes (Savage, D. D. et al. 1990; Gerstenblith, G. et al. 1977). This 
hypertrophy/hyperplasia of cardiomyocytes may not be coupled with a corresponding 
increase in blood vessels (Rakusan, K. et al. 1992), which may lead to impaired oxygen 
and nutrient delivery to cardiomyocytes and a combination of systolic and diastolic 
dysfunction (Schulz, R. et al. 2001). This would be exacerbated by the presence of age-
related sub-clinical atherosclerotic narrowing of the macro- and micro-circulation.  
 
1.5.4 The Ageing Cell 
Another major factor that determines how the human heart changes with age is the ageing 
of the cardiomyocytes themselves, and how that ageing impacts on their ability to 
generate force, repair and renew themselves. 
 All cells are subject to the damaging and cumulative effects of oxidative stress, 
and the cardiomyocyte may be particularly vulnerable. Reactive oxygen species (ROS) 
are a natural byproduct of cellular respiration, and these in turn can oxidatively modify 
deoxyribonucleic acid (DNA), proteins and lipids, and lead to a derangement in their 
function. The mitochondrion is the major source of ROS in the cardiomyocyte, and is 
also the most affected. Mitochondrial DNA (mtDNA) mutations accumulate with age as a 
result of oxidative damage, and these in turn result in accumulating mitochondrial deficits 
in functioning, including decreased oxidative phosphorylation, as well as increased ROS 
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formation and further mtDNA damage (Judge and Leeuwenburgh, 2007). As an example 
of the ageing related defects in mitochondrial function, decreased activities and/or levels 
of complexes I, III, IV and V have been demonstrated in older hearts in a variety of 
animals (Judge and Leeuwenburgh, 2007). 
 Autophagy is a process whereby cellular components, including mitochondria, are 
entrapped into double-membrane vacuolar structures called phagosomes. These 
phagosomes fuse with lysosomes, and the cellular components within are digested. This 
is a mechanism for eliminating damaged organelles and other intracellular structures. 
Autophagy decreases with age, and this is at least partly due to accumulation of 
indigestible material (lipofuscin, an aggregate of protein and lipid) within lysosomes that 
disrupts their function (Terman and Brunk, 2005). This then causes an age-related 
accumulation of damaged mitochondria which would otherwise be targeted for 
destruction, and thus further increased ROS production. In addition, one would expect the 
accumulation of other damaged organelles and cellular structures to decrease cellular 
functioning with age. 
 Despite these mechanisms for decreased cardiomyocyte function, there is no 
increase in the rate of apoptosis with age in humans without cardiovascular disease 
(Mallat, Z. et al. 2001). However, this does not preclude a difference in susceptibility to 
apoptosis with the imposition of pathology. In addition, rates of apoptosis are higher in 
men than women, which may partly account for the maintenance of cardiomyocyte 
numbers in aged female hearts described above.  
 Alongside the degradation in the structure and function of cardiomyocytes with 
age, and their elimination by apoptosis (and necrosis), there also occurs a beneficial 
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replacement of such cells from either resident stem cells and/or division of differentiated 
cardiomyocytes. Bergmann, O. et al. (2009) demonstrated that cardiomyocyte renewal 
occurs in the human heart, and that it is negatively correlated with age. At age 25, the rate 
of renewal is ~1 % per year, compared to at 75 years, when the rate of renewal is ~ 0.45 
%. The data also suggest that the probability of turnover is similar among all the 
cardiomyocytes. Kajstura, J. et al. (2012) report complementary findings, demonstrating 
that the number of phosphorylated histone H3 (marker of mitosis) positive 
cardiomyocytes declines with age (from 0.01% at 1-10 years, to 0.006% above 40 years 
of age). Similar findings are presented by Mollova, M. et al. (2013), i.e. decreased 
phosphorylated histone H3 positive cardiomyocytes with age, however, they could not 
demonstrate contractile rings (required for cytokinesis) in cardiomyocytes from patients > 
20 years of age. Therefore, mitosis among cardiomyocytes may be decreasing with age, 
and the probability that each mitotic event is accompanied by cytokinesis decreases as 
well, which could account for the increase in the proportion of polyploid, polynucleated 
cardiomyocytes with age, as was mentioned earlier. 
Additionally, Bergmann O. et al. (2009) found the rate of turnover of non-
cardiomyocyte cells to be ~ 18 % per year, and this rate did not appear to change with 
age.  
Therefore, there appears to be replacement of damaged and dying cardiomyocytes 
in the human heart, however this replacement proceeds at a reduced rate at older ages, 
which would result in the accumulation of less functional cardiomyocytes in the older 
heart. Decreased renewal can partly explain why the number of cardiomyocytes can 
decrease with age in males, even if rates of apoptosis remain steady. This decreased 
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renewal may be due to the accumulation of damage within cardiac stem cells themselves 
decreasing their proliferative capacities, or to decreased division of differentiated 
cardiomyocytes. Furthermore, from the cells that continue to proliferate (differentiated 
cardiomyocyte or stem cell), will arise cardiomyocytes that inherit the accumulated 
damage of their parent cells. Thus, with age, there are changes in the structure of the 
heart, at the tissue, cellular, and subcellular levels, and these changes in turn, lead to 
changes in the function of the heart. 
 
1.5.5 The Risk of HF as Modified by Age and Gender 
There is an increase in coronary heart disease (angina pectoris and MI) with age, as well 
as an increase in HF with age (National Heart, Lung and Blood Institute, 2006). In a large 
post MI cohort, ~ 1% developed HF per year (risk of HF plus all-cause mortality was ~ 
2% per year) (Lewis, E. F. et al. 2003). In the above study, age was the most powerful 
predictor of HF, with each 1 year increase in age at time of MI associated with a 7 % 
increase in risk of HF. The second most powerful predictor of development of HF was 
baseline LV EF post MI. With respect to MI treated with emergent revascularisation, 
Brodie, B. R. et al. (2006) found that patients over 70 years of age had a greater risk of 
late mortality with a median follow up of 7 years. Similarly, Parodi, G. et al. (2007) found 
that age was a significant independent predictor of 5 year mortality. Note that HF is one 
of several causes of late mortality. With respect to HF only, Terkelsen, C. J. et al. (2011) 
found that each additional decade in age increased the risk of presenting with HF, with a 
follow up of up to 7 years, post MI treated with emergent revascularisation. Thus it seems 
that the heart of an older person does not cope as well with the superimposition of 
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pathology such as a MI. This decreased coping ability may extend to other cardiac insults 
as well. In the presence of diagnosed HF, the risk of death is increased with age, and 
interestingly, the survival advantage of HF with preserved EF is diminished as well with 
increasing age (MAGGIC et al. 2012).  
 With respect to gender, all-cause mortality in patients with HF is greater in men 
than in women, adjusted for age (Martinez-Selles, M. et al. 2012). There are many 
proposed mechanisms for such a difference in risk, some of which derive from the data in 
this thesis, and will be presented later. As mentioned earlier, female LV maintain 
cardiomyocyte numbers with age, thus with the onset of HF there are a greater number of 
cardiomyocytes to share the load, and they are less likely to undergo apoptosis/necrosis. 
The cardiomyocytes in ageing males will be larger, which may affect diffusion of 
nutrients and waste products. In addition, for as yet unclear reasons, females show lower 
rates of RV dysfunction (measured as low RV EF or large RV EDV) for the same degree 
of LV systolic dysfunction (Martinez-Selles, M. et al. 2006). Looking at a different aspect 
of the gender divide in terms of cardiovascular disease, Brodie, B. R. et al. (2006) found 
no difference in the risk of late mortality during 10 years of follow up post MI treated 
with emergent revascularisation. However, Parodi, G. et al. (2007) found that female 
gender was independently associated with recovery of LV EF post MI treated with 
emergent revascularisation, though this was not observed in a similar study by Van 'T 
Hof, A. W. et al. (1998). In the same context, Lewis, E. F. et al. (2003) found that gender 
was not related to HF risk post MI, despite what one might expect from the increased 
likelihood of LV EF recovery observed by Parodi, G. et al. (2007). However, there are 
many factors that affect likelihood of HF development including recurrent MI, 
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differences in treatment among men and women, and others that would obscure the effect 
of greater LV EF recovery.   
  
1.6 Focus of Thesis 
The major purpose of this thesis is to describe the changes that occur in the ageing human 
heart with respect to gene expression, and then to relate these changes to what occurs in 
the patient with end-stage HF. I surmise that this approach will shed light on why an older 
heart will succumb more easily to HF as a consequence of the superimposition of 
pathology such as a MI or other cardiac insults. With this knowledge we may discover 
pathways to target for intervention, to reduce the probability and/or rate of development 
of HF in older patients. Similarly, an understanding of how females seem to have a better 
prognosis in HF may also assist in the discovery of future therapeutic interventions that 
can be applied to both genders. 
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Chapter 2: General Methods 
 
2.1 Collection of Human Heart Tissue 
2.1.1 Human Research Ethics Committee Approval 
Prior to collection of human heart samples, the Human Research Ethics Committee of the 
University of Sydney (#09-2009-12146), St. Vincent's Hospital (H91/048/1a), and the 
Australian Red Cross Blood Service approved the project. Patients undergoing 
transplantation gave informed consent prior to the collection of end-stage HF heart 
samples, and the families of heart donors gave informed consent prior to the collection of 
NF heart samples for research. 
 
2.1.2 Collection of Human Heart Tissue  
Collection of all heart tissue was undertaken at St. Vincent's Hospital. NF hearts were 
obtained from donors who had died from non-cardiac causes but whose organs were 
maintained by life support until permission was obtained from donor’s next-of-kin. Only 
donor hearts that were not suitable for cardiac transplantation were used for research. 
Donor hearts were rejected for transplantation for a range of reasons, but a common 
cause for rejection was the unavailability of a tissue-compatible recipient. All donor 
hearts were excised from patients while the donors were on life support, immediately 
flushed with chilled cardioplegic solution, and transported to Sydney on ice within four 
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hours of loss of coronary blood flow. Transmural blocks of LV (weighing approximately 
1 g) were frozen in de-identified coded cryovials, stored and maintained in liquid 
nitrogen. With respect to end-stage HF hearts, these were excised from patients 
undergoing transplantation within 30-40 minutes of aortic cross-clamping, and samples 
were immediately dissected and stored as described for NF hearts.  
 
2.2 mRNA Expression Analysis 
2.2.1 RNA Extraction 
Extraction of total RNA was carried out using Trizol reagent (Invitrogen) essentially as 
described in the manufacturer's protocol. All the following steps were carried out at room 
temperature unless otherwise stated. Approximately 250 mg of LV tissue was 
homogenised using a rotor stator homogeniser (PRO200, PRO Scientific, Oxford, CI, 
UK), in 1 mL of ice-cold Trizol. Specifically, samples were homogenised for 30 seconds 
at maximum speed and cooled on ice for 1 minute, and this was repeated 2 further times 
to ensure complete homogenisation while maintaining the temperature of the sample near 
zero. This was done to ensure minimal RNase-mediated destruction of sample RNA prior 
to full homogenisation and denaturation of RNase enzymes present in sample. The 
homogenates were then stored at –80 C. The homogenates were thawed and centrifuged 
at 12,000 x g at 4 C for 10 minutes and the pellet containing insoluble material (i.e. high 
molecular weight DNA, extracellular matrix, polysaccharides) was discarded. 0.2 mL of 
chloroform was added to each supernatant and the mixture was vigorously shaken for 30 
seconds. The samples were left to incubate for 2 to 3 minutes and then centrifuged at 
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12,000 x g at 4 C for 15 minutes. During this step, the mixture separated out into an 
upper aqueous layer (approximately 60% of volume, containing the total RNA), a milky 
white interphase (containing DNA), and a lower, pink organic layer (containing protein). 
400 µL (approximately 2/3 of the volume) of the aqueous layer was carefully removed 
and mixed with 0.1 mL of ice-cold isopropanol, and the RNA was left to precipitate for 
10 minutes on ice. To pellet the RNA, the mixture was then centrifuged at 12,000 x g at 
4 C for 10 minutes. The supernatant was discarded and the pellet washed with excess 
ice-cold 70% ethanol (EtOH) twice, vortexing for 10 seconds, and centrifugation at 7,500 
x g at 4 C for 5 minutes. Finally, the supernatant was completely removed and the pellet 
left to air-dry. The RNA was resuspended in nuclease-free water, incubating at 55 C for 
10 minutes and the resuspended RNA was then treated with Amplification-grade DNase I 
(Invitrogen) to remove residual genomic DNA contamination. For each LV sample, 20 µg 
total RNA was incubated with 20 U of DNase I in DNase I reaction buffer (20 mM Tris-
HCl, 2 mM MgCl2, 50 mM KCl) for 15 minutes. To halt the reaction, 20 µL of 25 mM 
EDTA was added and the mixture was heated to 65 C for 10 minutes. Post DNase 
treatment, the mixture was purified using a GenElute Mammalian Total RNA Isolation 
Kit (Sigma) according to manufacturer's instructions. Total RNA was quantified and 
assayed for purity (260/280 nm and 260/230 nm ratios) using the NanoDrop 1000 
(Thermo Scientific) and all RNA samples used for further experiments exhibited 
A260/A280 ratios > 1.7 and < 2, and A260/A230 ratios > 2. RNA integrity was analysed 
using the 2100 BioAnalyser (Agilent) and only samples with an RNA integrity number > 
6 were used for gene expression experiments (Fig. 2.1). The RNA integrity number is a 
ranking from 0 (completely degraded mRNA) to 10 (completely intact mRNA) generated 
  46
by an algorithm that analyses the electropherogram from the 2100 Bioanalyser for 
specific features including the sizes of the 28s and 18s peaks and their relation to the total 
signal, plus the sizes of the downstream regions reflecting the presence of smaller 
fragments of degraded RNA (Schroeder, A. et al. 2006).  
 
Figure 2.1: Bioanalyser 2100 (Agilent) electropherogram demonstrating RNA integrity.  ‘FU’ stands for 
fluorescent units, and ‘s’ for seconds. 
 
Note, for RNA samples that were to be used for real-time PCR, DNase treatment and 
column purification were not performed. Given there is no PCR-like amplification step in 
the preparation of RNA for microarray analysis, contaminating genomic DNA might 
make up a significant proportion of total nucleic acid, that might interfere with 
hybridisation of labelled cDNA to targets on the glass slides, hence the desirability of 
prior DNase treatment. This was followed by column purification to remove residual 
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DNA fragments, salts and DNase enzyme. With respect to real-time PCR, given the 
primers were designed to cross exon-exon boundaries, there would be no amplification of 
corresponding r-protein DNA. Pseudogenes present in contaminating genomic DNA may 
be amplified, however, the number of pseudogene copies to mRNA copies for a particular 
r-protein is likely at least several orders of magnitude lower, therefore, the effect on Ct 
values would be insignificant. Instead, an additional RNA precipitation step was used to 
further purify the RNA samples to maximise the efficiency of downstream enzymatic 
reactions. To perform this RNA precipitation step, Na acetate, pH 5.2 was added to a final 
concentration of 0.3 M plus 3 volumes of absolute EtOH, and the samples were incubated 
overnight at -20 C. The samples were centrifuged at 12,000 x g for 10 minutes at 4 C, 
and then washed with 70% EtOH, recentrifuged at 7,500 x g for 5 minutes, and then 
allowed to dry. RNA was resuspended as above and then analysed for purity and integrity 
as above. 
 
2.2.2 Microarray Analyses 
See Sections 3.2 and 4.2 
 
2.2.3 Real-Time Polymerase Chain Reaction Analysis 
950 ng of total RNA extracted from each human LV sample was mixed with 50 ng of 
yeast total RNA (kindly supplied by Dr. Grace Wei, Victor Chang Cardiac Research 
Institute). The addition of yeast total RNA was carried out so that Scr1, a highly abundant 
yeast transcript, could be used as a spike-in control to normalise the real-time PCR results 
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to control for reverse transcription (RT) and polymerase chain reaction (PCR) efficiency 
differences between RNA samples (Kubista, M. et al. 2006). RT was carried out using the 
SuperScript® III First-Strand Synthesis System for RT-PCR (Invitrogen). Each RNA 
sample was made up to 11 µL with nuclease-free H20, and 2 µL of a master mix 
(containing 1 µL of dNTP (10 mM) and 1 µL of random hexamers (50 ng/µL) per RT 
reaction) was added. This mixture was incubated at 65° C for 5 minutes, and the samples 
were returned to ice. 7 µL of a second mastermix (containing 1 µL DTT (0.1M), 1 µL 
RNAseOUT (40 Units/µL), 1 µL Superscript III (50 Units/µL), and 4 µL 5 x first strand 
buffer) was then added. The mixture was incubated at 50 degrees C for 2 hours, then 
75°C for 15 minutes. RT products were stored at -80° C until PCR was carried out. 
 
Table 2.1: Primer sequences for all genes analysed with real-time PCR. Note: primer sequences for Scr1 
were taken from Miller, A. et al. (2008), and primers for 45s rRNA were taken from Uemura, M et al. 
(2012). RHEB, Ras homolog enriched in brain and MTOR, Mammalian target of rapamycin. 
Gene Forward Primer (5' to 3') Backward Primer (5' to 3') 
SCR1 CGCGGCTAGACACGGATT GCACGGTGCGGAATAGAGAA 
45s rRNA GAACGGTGGTGTGTCGTT GCGTCTCGTCTCGTCTCACT 
MTOR AGCTGTGCTACACTACAAAC GGTTTTGGACAGATCCTCAG 
RHEB TTCAACTTGTAGACACAGCC TCCAACAATTTGCCATGGAT 
RPL23A CCAAATATCCTCGGAAGAGC ATGCCTTCTTCTCTCCATCA 
RPL26 TAAAGGTCAGCAAATTGGCA AGTTGTGCCATTAGCCTTTT 
RPL34 GTGTGCTAAATGTGTTCGTG CTTTCTGACTCTGTGCTTGT 
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Gene Forward Primer (5' to 3') Backward Primer (5' to 3') 
RPL37 GAACGTCATCGTTTGGAAAG TCGACTTCTGAAGGTGGTAG 
RPS7 CATGTCGTCTTTATCGCTCA ATCTAGTTTGACGCGGATTC 
RPS10 TGCCTGGAGACATTTCTACT GGGCAGATGAAGGTAATCAC 
RPS18 AGTTCCAGCATATTTTGCGA GTCAATGTCTGCTTTCCTCA 
RPS21 CGAGTTCGTGGACCTGTA CACGTTCATCTGGATGGATG 
 
Primers for the real-time PCR were designed using Primer-BLAST (Ye, J. et al. 2012) 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) which uses the Primer3 engine (Rozen, 
S. and Skaletsky, H. 2000). RNA nucleotide sequences transcribed from the various target 
genes that were used for primer design were derived from the ENSEMBL Genome 
Browser (http://asia.ensembl.org/index.html). The nucleotide sequences used were 
selected such that they fulfilled the criteria of being exonic sequences common to all the 
RNA transcripts deriving from the particular gene. Given that it is was unclear in many 
cases which was the predominant transcript transcribed from a particular gene (in terms 
of abundance and in terms of the transcript that would be translated), I decided on a 
strategy whereby all transcripts would be detected and quantified to ensure that 
biologically significant regulation would not be missed. This strategy would however, 
also result in contaminating signal generated by the amplification of non-translated RNA 
transcripts of unknown biological importance that might make it more difficult to detect 
the changes in mRNA expression that would result in changes in protein expression that I 
was interested in quantifying. In cases where there were no overlapping regions common 
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to all RNA transcripts, the RNA transcripts designated within ENSEMBL to be non-
protein coding were discarded. Additional primer design criteria: amplicon to be between 
70 and 150 base pairs (bp) (RNA integrity has been shown to have negligible effects on 
PCR efficiency if amplicons are < 250 bp (Fleige, S. and Pfaffl, M. W. 2006), Tm 57 to 
62° C, species is homo sapiens, and the algorithm must use the 'nr' database to look for 
non-specific amplification. Primers generated by Primer-BLAST which were deemed to 
not amplify non-specific sequences (except for pseudogenes) were then entered into 
DNACalc (Sigma Genosys) (http://www.sigma-genosys.com/calc/DNACalc.asp) to 
characterise their physico-chemical properties in terms of secondary structure (only 
primers with 'moderate' or less tendency were used), primer dimer (only primers that 
were deemed to not form primer dimers), and a requirement was set that Tm for each 
primer within a pair did not differ by more than 4° C. See Table 2.1 for primer sequences 
used. 
 For the real-time PCR, 3 µL of RT products (diluted 1:60 in nuclease-free water) 
were mixed with 1 µl of forward and reverse primers (250 µM) and 5 µL of Lightcycler 
480 SYBR Green I Master Mix (Roche). This was done using an epMotion 5075 LH 
(Eppendorf) liquid handling robot in 384 well plates (Roche). After pipetting, the plates 
were centrifuged at 800 x g for 2 minutes. Real-time PCR running conditions were as 
follows unless otherwise specified: 10 minutes at 95° C to heat-activate the Taq 
polymerase, and then 35 cycles of 1) Binding: 30 seconds at 60°C for Taq polymerase 
and primer binding to DNA template, 2) Elongation: 72°C for 30 seconds for elongation 
of DNA strand and acquisition of fluorescence, and 3) Denaturing: 5 seconds at 95°C to 
denature the double-stranded DNA products. For certain primer pairs that formed non-
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specific PCR products as determined from melting curves run post PCR, a modified 
'Touchdown' PCR strategy was used: 35 cycles were run as above, but the binding step 
was modified such that the temperature at which it was carried out was 64°C for the first 
cycle, and then with each subsequent cycle, the temperature was lowered by 0.25°C. This 
was done to minimise non-specific binding of PCR primers to non-target template, under 
the assumption that binding to non-target template would be with a lower affinity than 
binding to target template, thus, a higher temperature would promote the latter relative to 
the former. However, there would be an overall decreased amount of binding at a higher 
temperature resulting in a lower PCR efficiency. With each subsequent cycle, the amount 
of target template (original copy deoxyribonucleic acid (cDNA) plus newly synthesised 
amplicons) increases relative to non-target template which promotes primer binding to 
target template and reduces the requirement for the binding step to be carried out at as 
high a temperature to ensure intended target amplification. 'Touchdown' PCR was carried 
out for the genes RPS21 and RPL26. 
 Melting curves were analysed post real-time PCR run and all primers led to 
amplification of a single PCR product in the runs used for analysis. This was further 
confirmed with DNA electrophoresis of the PCR products using a 1% agarose gel. 
 Pooled cDNA was used at dilutions 1:20, 1:60, and 1:180 to create a relative 
standard curve. Using these standard curves, Ct values from each PCR reaction were 
converted into values representing a relative measure of mRNA expression. Each cDNA 
sample representing a particular LV samples was PCR amplified in triplicate, and the 
mean of the 3 values obtained was used for statistical analysis. For details of statistical 
analysis of real-time PCR results, see Sections 3.2 and 4.2. 
  52
 
2.3 Protein Expression Analysis 
2.3.1 Protein Extraction 
From transmural sections of human LV tissue frozen and stored in liquid nitrogen, 50 to 
100 mg was homogenised using a rotor stator homogeniser in 1 ml of ice-cold RIPA 
buffer (50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 
(NP-40), 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) (Sigma) plus 
Protease Inhibitor Cocktail (Sigma) (AEBSF 1.04 mM, aprotinin, 0.8 μM, bestatin 40 
μM, E-64 14 μM, leupeptin 20 μM, pepstatin A 15 μM). As was done for the RNA 
extractions (see above), samples were homogenised for 30 sec at maximum speed and 
cooled on ice for 1 minute, and this was repeated 2 further times to ensure complete 
homogenisation. The homogenates were immediately centrifuged at 14,000 x g at 4°C for 
10 minutes. The supernatant was collected and stored at -80°C. 
 
2.3.2 Determination of Protein Extract Concentration 
The protein concentrations of the LV protein samples were determined using the BCA 
method described in Smith, P. K. et al. (1985) with the Micro BCA Protein Assay Kit 
(Thermo Scientific) essentially according to the manufacturer’s instructions. The samples 
were diluted 1:500 to be within the linear detection range of the assay (i.e. 2 to 40 
µg/mL). A Bovine serum albumin standard curve was constructed, with protein 
concentrations 0.5, 1, 2.5, 5, 10, 20, 40, and 200 μg/mL. 50 µL of freshly made-up 
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working reagent was mixed with 50 μL of sample in a 96-well polypropylene microtitre 
plate. This mixture was incubated at 37°C for 2 hours. The plate was then cooled to room 
temperature, and the PolarStar Galaxy Plate Reader (BMG) was used to quantify 
absorbance at 562 nm of the standards and the unknown samples. A standard curve of 
concentration versus absorbance was constructed in Excel (Microsoft) to calculate the 
concentration of protein in the LV protein samples. 
2.3.3 SDS-PAGE and Western Blotting 
LV protein samples (40 ng) were prepared for sodium dodecyl sulfate – polyacrylamide 
gel electrophoresis (SDS-PAGE) by mixing with DTT (0.05 M) and 2 x Laemmli sample 
buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue, 
0.125 M Tris HCl, pH 6.8) and then heating to 99°C to ensure protein denaturation. 
Protein mixtures were kept on ice post denaturation. Protein samples were loaded onto 
nUView 4-20% gradient Tris-glycine gels (Nusep) and run at 250V for 35 minutes in 
Mini-PROTEAN II electrophoresis cells (Bio-Rad) with SDS running buffer (25 mM 
Tris, 192 mM glycine, 0.1% SDS). Dual color Precision Plus Protein Prestained 
Standards (Bio-Rad) were used to monitor electrophoresis progression and blotting 
efficiency. At the completion of SDS-PAGE, gels were visualised using the ChemiDoc 
MP Imaging System (Bio-Rad). As per the 'Stain-free gel' imaging protocol, the gels were 
UV irradiated for 1 minute prior to UV-induced fluorescence image acquisition. The 
nUView gels used contain a trihalo compound that covalently binds to tryptophan 
residues upon UV irradiation. This compound fluoresces under UV light allowing one to 
visualise the proteins loaded in each well, and thus confirm equal loading per well, 
similar to using a housekeeping gene as a loading control, except that the former does not 
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require assumptions regarding the stability of expression of the housekeeping gene used. 
A drawback is that given the covalent modification that occurs at tryptophan residues, 
there is a risk of altering the epitopes to which antibodies will subsequently bind, 
resulting in a lowering of affinity or even failure to bind, thus affecting the sensitivity of 
the assay.  
Immediately after imaging, proteins were transferred to nitrocellulose using the Trans-
Blot Turbo Transfer System (Bio-Rad) using the “Low MW” protocol (2.5 A for 5 
minutes), a protocol optimised for the transfer of proteins less than 30 kD. Nitrocellulose 
membranes were then air-dried overnight to maximise protein binding given the low 
molecular weight of the proteins blotted. 
 For antibody staining and visualisation, dried nitrocellulose blots were first 
blocked with Odyssey Blocking Buffer (Li-Cor Biosciences) for 1 hour at room 
temperature. All subsequent steps were also carried out at room temperature. Blots were 
incubated in primary antibody (1:200 for rabbit anti-human RPS18) for 1 hour. Primary 
antibodies were kindly provided by Dr. Jacob Odeberg, KTH Royal Institute of 
Technology, Sweden. Blots were agitated in phosphate buffered saline (PBS) plus 0.1% 
Tween 20 for 5 minutes three times to remove any unbound primary antibody. Blots were 
then incubated in secondary antibody (1:10000 IRDye800 donkey anti-rabbit IgG (Li-Cor 
Biosciences)) for 30 minutes in the dark. Blots were washed as above and then stored in 
PBS for immediate imaging.  
 Blots were imaged and quantified using the Odyssey Clx Imaging System (Li-Cor 
Biosciences). Integrated intensity (IInt) was calculated as a measure of protein 
expression, IInt = a(ƩIi – Pixels * B) where a = (resolution*10-3)2, ƩIi is the sum of the 
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intensity of all pixels within the rectangular area drawn manually around the protein 
bands, P is the number of pixels within the rectangular area, and B is the mean 
background intensity. For details of statistical analysis, see Sections 3.2.4 and 4.2.4. 
 
 
Chapter 3: Age and Sex-related Changes 
in Human NF LV 
 
3.1 Introduction 
Age is the principal risk factor for cardiovascular disease, as has been discussed above. 
The human heart undergoes many changes with age, both structural and functional, and 
they underlie the increased susceptibility to cardiac pathology with age. These changes 
were described in Section 1.4. The changes that the human heart undergoes must at some 
level be represented at the level of gene expression. Gene expression changes can be the 
causal mechanisms behind the age-related changes, or be compensatory responses that 
attempt to limit the decline in function from age-related derangements in cardiac 
physiology and/or anatomic structure. Therefore, an analysis of the changes in the 
transcriptome (and proteome) of the ageing human LV was undertaken. 
 Gender has an influence on the age-related changes in the structure and function 
of the human heart as discussed in Sections 1.4.2 and 1.4.3, as well as susceptibility to 
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the development of cardiac pathology as discussed in Section 1.4.5. Therefore, an 
analysis was also carried out to discover sex-related differences in the transcriptome (and 
proteome) of the human LV.  
 
3.2 Methods 
3.2.1 RNA extraction for Microarray and Real-time PCR Analysis 
For details regarding RNA extraction for microarray analysis and real-time PCR see 
Section 2.2.1. 
 
3.2.2 Microarray Analysis of NF LV to Discover Age- and Sex-related Changes 
3.2.2.1 RNA labelling for microarray analysis, hybridisation and scanning  
Microarray analysis was carried out on 57 NF LV samples (age range: 4 to 65 years, 27 
females: mean age: 44.6, years and 30 males: mean age: 38.3 years) to determine changes 
in gene expression associated with age or sex in the cardiac transcriptome. 
 Microarrays were created in-house at INSERM (Université de Nantes, Nantes, 
France). The Ocimum Biosciences 30K Oligo Set A (19968 unique probes) was used for 
construction, and these probes were spotted onto epoxysilane-coated glass slides using 
the Lucidea Array Spotter (Amersham). These microarrays were constructed and kindly 
provided to me by Catherine Chevalier of INSERM. 
 Total RNA samples were transcribed into cDNA and labelled with dye using the 
CyScribe First-Strand cDNA Labeling Kit (Amersham) as described in the manufacturer's 
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protocol. RT of total RNA to aminoacyl-cDNA was verified by analysis with the 
Bioanalyser 2100 (Agilent) (Fig. 3.1). Total RNA from each NF LV sample analysed was 
labelled with Cy3 and hybridised against a Cy5-labelled reference RNA pool consisting 
of a mixture of RNA from all NF LV RNA samples. Utilising a competitive hybridisation 
strategy against a common reference pool is useful as it controls for heterogeneity in 
spotting. Specifically, some spots on a microarray may have more or less oligonucleotide 
bound due to imprecision in the microarray creation process, and this will be reflected in 
the amount of both Cy3-labelled sample cDNA and Cy5 labelled reference pool cDNA 
bound. Taking the ratio of Cy3 and Cy5 signal intensity for each spot (which corresponds 
to a different mRNA and therefore, gene) will control for this heterogeneity in spotting.  
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Figure 3.1: Bioanalyser 2100 (Agilent) electropherogram showing the population of aminoacyl-cDNA 
derived from total RNA using CyScribe First-Strand cDNA Labeling Kit (Amersham). 
Microarrays were pre-hybridized for 1 hour at 42° C (in 10 % BSA, 20 x saline-sodium 
citrate buffer (SSC), 10 % SDS). 0.5 μg of labelled sample cDNA was mixed with 0.5 μg 
of labelled reference cDNA in 40 μL of hybridization mix (50 x Denhardt's solution, 20 x 
SSC, 10 μg/μL polyA RNA, 10 μg/μL yeast tRNA, 10 % SDS, 50 % formamide) and 
hybridized to the microarrays overnight at 42° C in a humidified chamber. Finally, slides 
were washed in 1 x SSC + 0.05 % SDS, then twice in 0.06 SSC, and then dried by 
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centrifugation. Microarrays were scanned by fluorescence confocal microscopy 
(Scanarray 4000XL, GSI-Lumonics) (Fig. 3.2). Fluorescence measurements were 
obtained separately for Cy3- and Cy5-labelled cDNA at 10 µm/pixel resolution. 
 
Figure 3.2: An example of a microarray captured using fluorescence confocal microscopy (Scanarray 
4000XL, GSI-Lumonics) and processed in GenePix Pro 5.0 (Axon). Two images, for Cy3-labelled cDNA 
acquired at 570nm and Cy5-labelled cDNA acquired at 650nm were superimposed. Each spot contains a 
different oligonucleotide attached to the surface bearing the sequence of a different gene, with variable 
amounts of bound complementary Cy3- and Cy5-labelled cDNA representing the level of expression in the 
LV of individual patients and the common reference RNA pool, respectively. Yellow spots indicate the 
abundance of a particular RNA species in the LV patient samples and the reference RNA pool are equal, 
green spots indicate the abundance of RNA in the LV patient sample is higher, and conversely for red spots. 
3.2.2.2 Analysis of Microarray Data 
Microarray images were analyzed with GenePix Pro 5.0 (Axon). The spots to which 
GenePix assigned a value less than zero to the 'flag' variable (indicating the spots were 
missing) were given a weight of zero for subsequent analysis and particular mRNA 
probes weighted zero on more than 75% of the microarrays were removed from 
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subsequent analysis. The raw Cy3 and Cy5 expression data were analysed in R using the 
LIMMA statistical module (Smyth, G. K. 2005) (Appendix B). Print-tip LOESS and scale 
normalisation was used for intra-array and inter-array normalisation, respectively (Smyth, 
G. K. and Speed, T. 2003). Genes that exhibit differential expression (DE) with respect to 
age were determined using a linear model, where we regressed the normalized log-ratio 
data (log2 Cy3/Cy5) against covariates age and sex (Smyth, G. K. 2004). The 
corresponding False Discovery Rate (FDR) was also computed for each gene (Benjamini, 
Y. and Hochberg, Y. 1995). The FDR refers to the proportion of genes called as DE that 
will be false-positives in the list of genes with an FDR less than or equal to the FDR cut-
off used. More explicitly, if one has a list of genes ordered by likelihood of being truly 
DE with age in the human heart (i.e. ordered by p-value), and if one selects an FDR of 
0.05 as a cut-off, as was done here, then out of all the genes with a FDR < 0.05, 5% will 
be false-positives.   
 To gain further insight into biological processes affected by age and gender, we 
also carried out a separate analysis looking for coordinated DE of entire sets of genes, so-
called gene set analysis. There are several reasons for such an analysis. The first is 
biological. Many genes are coordinately regulated, i.e. all the genes that subserve a 
particular pathway such as oxidative phosphorylation, are switched on or off at the same 
time by master regulators in response to cellular conditions. Therefore, it is 
physiologically apt to consider genes in sets. The second is pragmatic. A small change in 
mRNA expression, perhaps 20%, in a particular direction of all the genes in a particular 
pathway, whilst being physiologically significant, may be missed by single gene 
approaches such as the one used above, as the difference in expression is small relative to 
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the noise of the microarray platform (Subramanian, A. et al. 2005). Therefore, by 
combining genes into sets, one can discover physiologically significant gene regulation 
that would be otherwise missed. We utilized the gene set enrichment analysis (GSEA) 
method as detailed in Subramanian, A. et al. (2005). The summary statistics used for the 
GSEA procedure were the t-statistics derived from the linear model measuring the 
association between gene expression and age or sex. These t-statistics were inputted into 
the GSEA v2.0 applet (http://www.broadinstitute.org/gsea/software/gsea2_1024mb.jnlp) 
and the analysis was carried out using the 'GseaPreranked' module. The gene sets used 
were based on the KEGG knowledgebase from the Molecular Signatures Database 
(MSigDB, http://www.broad.mit.edu/gsea/msigdb/index.jsp). GSEA calculates an 
enrichment score (ES) that is a measure of the extent to which the genes in the particular 
gene set are overrepresented at the extreme ends (top or bottom) of the ranked (by t-
statistic in this case) list of genes (Subramanian, A. et al. 2005). An FDR q-value < 0.05 
was set as a threshold for determining significantly regulated gene sets against the advice 
of  Subramanian, A. et al. (2005) who suggested FDR q-value < 0.25. Unfortunately, a 
major caveat of this analysis is that the stated FDR q-values may be significant 
underestimations of the true likelihood of observing these results if the null hypothesis is 
true. This is due to the underlying assumption behind the methodology that each gene is 
independent, which cannot be true (Goeman, J. J. and Buhlmann, P. 2007). Therefore, a 
more stringent FDR q-value was selected. The FDR q-value, in this context, represents 
the probability that a particular gene set is a false positive, i.e. that the null hypothesis 
cannot be rejected. In the context of competitive gene set testing of which our analysis is 
a variant, the null hypothesis is that the ranks of genes within this gene set (ranked 
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according to strength of association with phenotype, in this case by t-statistic) are not 
unevenly distributed towards the extreme ends amongst the ranks of all genes on the 
microarray. That is, that genes within the particular gene set are no more likely to be DE 
than genes not in the gene set (Goeman, J. J. and Buhlmann, P. 2007).  
 
3.2.3 Real-Time PCR Analysis of Ribosome-related Genes in NF LV 
Real-time PCR was carried out on 38 NF LV samples (20 younger NF subjects: mean 
age: 20.1, standard deviation (SD): 7.5 years, 6 women and 14 men; and 18 older NF 
subjects: mean age: 57.3, SD: 4.2 years, 9 females and 9 males) to validate the changes in 
expression of r-protein mRNA observed to be DE with age and sex by microarray 
analysis. For details of the experimental protocol see Section 2.2.3. As discussed above, a 
mean relative measure of expression was computed from triplicate PCR reactions for 
each NF LV sample. Multiple linear regression was performed with age and sex as the 
independent variables, and mean relative expression for each gene as the dependent 
variable in order to test for an effect of age or sex on the expression of r-protein mRNA. 
In addition, Pearson's correlation coefficients were computed from the mean relative 
expression measure from the real-time PCR and the corresponding measure (log2 
Cy3/Cy5) from the microarrays as an alternative method of validating the microarray 
analysis. For all statistical tests, p-values < 0.05 were regarded as significant. 
 
  63
3.2.4 Western Blotting Analysis of RPS18 in NF LV 
Protein expression analysis was carried out on 6 NF LV samples (older group: 65 and 63 
year old males and 55 year old female; younger group: 4, 8 and 19 year old males) to 
determine change in expression of RPS18 associated with age. For details regarding 
protein extraction, see Section 2.3.1. For details regarding protein quantification, see 
Section 2.3.2. For details regarding SDS-PAGE and western blotting, see Section 2.3.3. 
IInt measures for LV samples in older and younger NF groups were compared by 
unpaired two-tailed t-tests to assess for DE of RPS18 with age. A p-value < 0.05 was 
considered significant.   
 
3.3 Results 
3.3.1 Microarray Analysis of NF LV to Discover Age- and Sex-related Changes 
Of the 19968 probes represented on the microarray platform based on the Ocimum 
Biosciences Oligo Set A probe set, 18725 passed the filtering criteria and were considered 
suitable for assessment for DE with age and sex. With respect to age, 109 probes were 
DE in NF LV (FDR q-value < 0.05), and these could be mapped to 94 unique genes using 
Entrez IDs (Table 3.1). Of these 109 DE probes, 39 probes (38 unique genes) were 
upregulated, and 70 probes (57 unique genes) were downregulated with age. Using the 
coefficients derived from the statistical model applied to calculate the expected change in 
expression over a 50 year period, the majority of genes exhibit changes that amount to 
less than a 2-fold change in expression. Specifically, only 5 probes (out of 18725) exhibit 
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a greater than 2-fold increase in expression, and only 2 probes exhibit a greater than 2-
fold decrease in expression, over a 50 year period. 
 
Table 3.1: 109 probes were DE with age in NF human LV found using the microarray platform containing 
the probes from the Ocimum Biosciences 30K Oligo Set A. 'Log(2) FC' represents the change in mRNA 
expression per year on a log2 scale, e.g. log(2) FC = 1 corresponds to a doubling of mRNA expression, and 
– 1 corresponds to a halving of mRNA expression. 'Mean Expression' represents an arbitrary linear scale of 
mRNA abundance. 'FDR', for the meaning of which, see Section 3.2.2.2. 
GenBank 
Accession 
Symbol Entrez ID Log(2) FC Mean 
Expression 
FDR 
AC099849 - - -0.00797 9.10329 0.001 
D26309 LIMK1 3984 0.00864 7.90425 0.005 
NM_005493 RANBP9 10048 -0.00648 8.35893 0.005 
NM_016258 YTHDF2 51441 -0.0076 10.30782 0.005 
NM_152729 NT5DC1 221294 0.01297 6.80619 0.011 
NM_004861 GAL3ST1 9514 0.00539 9.20474 0.011 
NM_005990 STK10 6793 -0.00773 10.68771 0.011 
AL591049 - - -0.00592 9.82693 0.013 
AJ697971 SYNM 23336 0.01226 7.93921 0.013 
NM_006068 TLR6 10333 -0.00853 7.17515 0.013 
NM_006639 CYSLTR1 10800 -0.00687 8.00557 0.013 
NM_001014
797 
KCNMA1 3778 -0.00814 10.47064 0.013 
NM_002775 HTRA1 5654 0.00708 8.43547 0.013 
BC065563 VPS11 55823 -0.01161 6.89523 0.013 
BC001405 UPP1 7378 0.01036 10.71248 0.013 
NM_015443 KIAA1267 284058 -0.0061 10.90064 0.013 
NM_000086 CLN3 1201 -0.00551 10.60348 0.013 
NM_138778 WDR85 92715 -0.00636 9.40951 0.013 
NM_003802 MYH13 8735 0.01002 11.66331 0.013 
BC003065 CDK2 1017 0.0094 9.70848 0.013 
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GenBank 
Accession 
Symbol Entrez ID Log(2) FC Mean 
Expression 
FDR 
AC011498 - - -0.0079 9.55644 0.014 
NM_022486 SUSD1 64420 -0.00593 9.26826 0.015 
NM_005281 GPR3 2827 -0.00508 11.89351 0.015 
NM_138796 SPATA17 128153 -0.01473 6.75389 0.017 
NM_000284 PDHA1 5160 0.00524 10.24394 0.017 
AB016898 C6orf124 653483 -0.00493 8.44071 0.018 
NM_005622 ACSM3 6296 -0.00962 6.62112 0.02 
NM_014463 LSM3 27258 -0.00897 8.5315 0.02 
NM_025191 EDEM3 80267 0.01053 6.87895 0.02 
BC002427 CASP2 835 -0.00813 7.19251 0.021 
NM_021184 C6orf47 57827 -0.00635 12.04333 0.028 
NM_025170 PREX2 80243 -0.00729 9.06905 0.028 
NM_004870 MPDU1 9526 -0.00741 9.475 0.028 
NM_005197 FOXN3 1112 -0.00675 7.94658 0.028 
NM_015106 RAD54L2 23132 0.0066 8.36483 0.029 
BC004343 C21orf122 728039 0.01788 6.49715 0.029 
BC092476 RBPMS 11030 -0.00507 12.0179 0.033 
NM_080862 SPSB4 92369 0.00565 13.08059 0.033 
NM_002117 HLA-C 3107 -0.00999 11.27382 0.036 
NM_017481 UBQLN3 50613 -0.00649 11.43234 0.036 
NM_020212 WDR93 56964 -0.00689 8.41272 0.036 
NM_052864 TIFA 92610 -0.00765 7.23797 0.036 
BC014144 ELAVL3 1995 0.00918 9.71658 0.036 
NM_017553 INO80 54617 -0.00511 11.19678 0.036 
AK022468 SORBS1 10580 -0.00531 10.78696 0.037 
NM_020659 TTYH1 57348 0.00536 11.40098 0.037 
NM_002215 ITIH1 3697 0.00932 10.29121 0.037 
AY256821 WWOX 51741 0.00493 11.51324 0.037 
AK027437 - - -0.01095 11.631 0.037 
NM_058004 PI4KA 5297 -0.00566 8.35115 0.037 
NM_005284 GPR6 2830 -0.00651 11.72877 0.037 
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GenBank 
Accession 
Symbol Entrez ID Log(2) FC Mean 
Expression 
FDR 
BC000979 DDX49 54555 -0.00654 10.0822 0.037 
NM_022481 ARAP3 64411 -0.00425 12.11319 0.037 
BC022307 ATM 472 -0.008 7.22298 0.037 
XM_374983 - - 0.00796 8.58884 0.037 
NM_021140 KDM6A 7403 -0.00758 7.21303 0.037 
BC101301 PAX3 5077 0.00743 11.14169 0.037 
NM_022092 CHTF18 63922 -0.00591 10.41938 0.037 
NM_001184 ATR 545 0.01196 6.83698 0.037 
NM_012103 - - -0.00802 10.66867 0.037 
NM_013354 CNOT7 29883 -0.00706 8.049 0.037 
NM_213636 PDLIM7 9260 0.00871 9.29493 0.037 
NM_006542 SPHAR 10638 0.02515 6.49186 0.037 
AC078860 - - -0.00638 8.29991 0.037 
Z95114 - - -0.00883 6.8725 0.038 
NM_015139 SLC35D1 23169 0.00787 8.16734 0.038 
NM_006225 PLCD1 5333 0.00546 11.17581 0.038 
NM_006392 NOP56 10528 -0.00707 7.82859 0.038 
AL590106 - - -0.01178 12.75166 0.038 
NM_000272 NPHP1 4867 0.008 7.22654 0.038 
NM_020064 BARHL1 56751 -0.00523 8.92242 0.038 
BC012993 RBMS1 5937 0.0067 11.09068 0.038 
AC122129 - - -0.0078 9.99833 0.038 
NM_031297 RNF208 727800 -0.00455 11.40265 0.039 
BC108917 KIR2DS2 100132285 -0.01234 6.76435 0.041 
NM_024122 APOO 79135 -0.00581 8.78299 0.042 
NM_014068 PSORS1C1 170679 -0.00575 11.1356 0.042 
NM_005514 HLA-B 3106 -0.00881 7.8735 0.042 
NM_018976 SLC38A2 54407 -0.01155 9.291 0.042 
NM_014701 SECISBP2L 9728 0.00773 7.90408 0.043 
NM_021095 SLC5A6 8884 -0.00638 12.16871 0.043 
AF288738 - - 0.00549 10.57222 0.043 
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GenBank 
Accession 
Symbol Entrez ID Log(2) FC Mean 
Expression 
FDR 
J03639 MCF2 4168 -0.00643 11.86421 0.043 
NM_033052 - - -0.00551 9.76119 0.043 
BC069810 - - -0.00569 10.44001 0.043 
NM_014555 TRPM5 29850 -0.00774 11.61154 0.043 
NM_003095 SNRPF 6636 0.01074 9.39458 0.044 
BC053585 CSF3R 1441 -0.00511 11.83018 0.044 
NM_000098 CPT2 1376 0.0078 7.02202 0.044 
NM_015853 UBXN1 51035 0.00756 8.81844 0.044 
AL122043 C20orf112 140688 0.00771 7.32908 0.044 
NM_006332 IFI30 10437 0.00613 10.83373 0.044 
BC040034 CORT 1325 -0.00615 10.87187 0.045 
NM_024293 FAM134A 79137 -0.00698 10.75081 0.045 
NM_003579 RAD54L 8438 -0.00621 10.62869 0.045 
NM_017709 FAM46C 54855 0.00517 12.63892 0.045 
BC106009 RPL34 6164 -0.00969 10.34143 0.045 
AL354898 - - -0.00621 11.29974 0.046 
NM_003750 - - -0.00562 10.27669 0.046 
NM_017980 LIMS2 55679 -0.00533 12.00008 0.047 
NM_133468 BMPER 168667 -0.00729 7.92808 0.047 
NM_020374 C12orf4 57102 0.00709 10.16234 0.047 
NM_006500 MCAM 4162 0.0053 10.62599 0.047 
AK074957 KCNQ4 9132 0.00384 11.57865 0.047 
NM_012309 SHANK2 22941 0.0075 8.94692 0.047 
AF213465 DUOX1 53905 -0.00646 12.97164 0.047 
NM_014703 VPRBP 9730 0.00709 8.35103 0.048 
NM_002037 FYN 2534 -0.00634 8.97312 0.048 
NM_014341 MTCH1 23787 -0.00544 9.63417 0.049 
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With respect to gender, 5 probes corresponding to 5 unique genes were DE in NF LV 
(FDR q-value < 0.05). Three genes were upregulated in male, and 2 in female LV (Table 
3.2) 
 
Table 3.2: Five probes were DE with gender in NF human LV using the microarray platform containing the 
probes from the Ocimum Biosciences 30K Oligo Set A. 'Log(2) FC' represents the change in mRNA 
expression as a function of gender on a log2 scale, e.g. log(2) FC = 1 corresponds to mRNA expression in a 
male being twice that of a female, and – 1 corresponds mRNA expression in a male being half that of a 
female. 'Mean Expression' represents an arbitrary linear scale of mRNA abundance. 'FDR' represents the 
FDR q-value, the meaning of which is explained in Section 3.2.2.2. 
Genbank 
Accession 
Symbol Entrez ID Log(2) FC Mean 
Expression 
FDR 
NM_004653   KDM5D     8284 0.49637 7.28068 <0.001 
NM_032490 C14orf142   84520 0.55457 6.47439 0.007 
NM_004555   NFATC3      4775 0.27737 7.33425 0.011 
NM_001007   RPS4X     6191 -0.40798 10.53845 0.015 
NM_016509   CLEC1B     51266 -0.81863 6.29678 0.039 
 
The Genbank Accession numbers for each of the 18725 filtered probes of the microarray 
platform based on the Ocimum 30K Oligo Set A were entered into the GSEA software, 
along with the two t-statistics describing the relationship between gene expression in 
human LV and age and sex, respectively. Of those 18725 probes, the software collapsed 
the list to 16112 unique Genbank accession numbers, then collapsed this list to a 
corresponding list of 9954 unique genes as defined by Entrez ID (taking the mean of the 
t-statistics for all the probes that corresponded to the same unique gene). This collapsed 
gene list was used in the analysis. The GSEA analysis found 3 KEGG pathway gene sets 
to be significantly downregulated with age in human LV (KEGG_RIBOSOME, 54 
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probes, ES = -0.71, FDR q-value < 0.005 (Fig. 3.3); 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION, 44 probes, ES = -0.51, 
FDR q-value = 0.049; and KEGG_DORSO_VENTRAL_AXIS_FORMATION, 18 
probes, ES = -0.63, FDR q-value = 0.037) and zero KEGG pathway gene sets to be 
significantly upregulated with age. The GSEA analysis found 2 KEGG pathway gene sets 
was expressed at a higher level in female LV (KEGG_RIBOSOME, 54 probes, ES = -
0.80, FDR q-value < 0.0005; KEGG_PROTEIN_EXPORT, 17 probes, ES = -0.64, FDR 
q-value = 0.05), and zero at lower levels in female LV, compared to male LV. 
 
                                       
Figure 3.3: Enrichment plot generated by the GSEA applet (v 2.0). for the KEGG_RIBOSOME gene set. 
Note that the red side of the bar indicates genes more upregulated with age and the violet side indicates 
genes more downregulated with age, and that r-protein coding genes, individually represented by vertical 
black lines, are concentrated towards the violet end. A similar pattern is seen for the comparison between 
female and male NF LV. 
  70
3.3.2 Real-Time PCR Analysis of Ribosome-related Genes in NF LV 
For confirmation of changes in mRNA expression discovered using microarray analysis, 
real-time PCR analysis was carried out on RNA samples extracted from the LV of 38 NF 
hearts. The GSEA results indicated that the genes contained within the KEGG Ribosome 
gene set, i.e. genes that code for proteins that comprise the subunits of the ribosome 
ribonucleoprotein complex, were downregulated with age and were also expressed at a 
higher abundance in females. To confirm, real-time PCR was used to quantify the 
expression of RPL23A, RPL26, RPL34, RPL37, RPS7, RPS10, RPS18, RPS21, 45s 
rRNA, MTOR, and RHEB. 
 
Table 3.3: The results of the multiple linear regression model with age and sex as independent and gene 
expression as the dependent variable, i.e. gene expression = y-intercept + β1 * age + β2 * sex (n = 38). “% 
Change / 50 years” was derived from β1 and refers to the difference in expression observed after 50 years of 
ageing, “% Change in Males” was derived from β2 and refers to the difference in expression in males 
versus females across all ages. 
Gene % Change / 50 
years 
P-value % Change in 
Males 
P-value 
45s rRNA -11.4 0.41 -21.2 0.06 
MTOR -15.9 0.06 3.1 0.63 
RHEB -21.5 0.09 -12.2 0.20 
RPL23A -8.5 0.40 -6.5 0.42 
RPL26 -15.7 0.13 -8.5 0.29 
RPL34 -15.5 0.15 -4.4 0.59 
RPL37 -24.3 0.015 -6.2 0.39 
RPS7 -17.4 0.23 -11.6 0.30 
RPS10 -18.9 0.046 -11.3 0.12 
RPS18 -28.8 0.006 -8.8 0.25 
RPS21 -14.0 0.14 -12.0 0.10 
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With respect to age, RPS10, RPS18, and RPL37 were statistically significantly 
downregulated with age (p-values = 0.046, 0.006, and 0.015, respectively) (Table 3.3). 
All other genes were not shown to be DE with age, although the fold-change estimates 
for all mRNA coding for r-proteins, as well as for 45s rRNA, were in the direction of 
downregulation. With respect to gender, no genes were shown to be DE, however, all 
fold-change estimates for mRNA coding for r-proteins, plus for 45s rRNA, were in the 
direction of decreased expression in males.  
 
Table 3.4: The results of the Pearson's correlation analyses to determine if the gene expression 
measurements derived from the microarrays are linearly related to the measurements from the real-time 
PCR experiments (n=18). 'Normalised' refers to calculations done with real-time PCR data normalised to 
the internal control gene, SCR1, and 'Raw' refers to the use of non-normalised real-time PCR data. Note, 
RPS10 has an additional probe represented on the array, for this probe: normalised to Scr1: Pearson's r = 
0.5006826, p-value = 0.01716; non-normalised: Pearson's r = 0.3152774, p-value = 0.1013. Similarly, 
RPS21 has an additional probe: normalised to Scr1: Pearson's r = 0.2403324, p-val = 0.1684; non-
normalised: Pearson's r = 0.1991245, p-val = 0.2141.  
Gene Pearson's r 
(Normalised) 
P-value Pearson's r 
(Raw) 
P-value 
RPL23A 0.06 0.41 0.09 0.36 
RPL26 0.66 0.001 0.68 0.001 
RPL34 0.64 0.002 0.58 0.01 
RPL37 0.21 0.20 0.03 0.46 
RPS7 0.66 0.001 0.65 0.002 
RPS10 0.71 0.0004 0.60 0.004 
RPS18 0.74 0.0002 0.67 0.001 
RPS21 0.52 0.01 0.48 0.02 
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With respect to the Pearson's correlation between the microarrays and real-time PCR 
experiments, the gene expression measurements for 6 out of 8 r-protein mRNA were 
significantly correlated, irrespective of normalisation of real-time PCR results to the 
internal control gene, Scr1 (Table 3.4). 
 
3.3.3 Western Blotting Analysis of RPS18 in NF LV 
The rabbit ant-human RPS18 antibody stained a band in the Western blot experiments at 
the correct migration point of ~17 kDa (Fig. 3.5 and Appendix A). Note equal loading of 
protein among all wells is observed (Fig. 3.4). However, no difference in expression 
between younger and older NF hearts was observed, mean IInt of 0.82 vs 0.79, 
respectively, p-value = 0.82 (Fig. 3.5).  
 
Figure 3.4: SDS-PAGE using a Nusep 4-20% gradient gel loaded with 40 μg LV total protein. The gel was 
UV irradiated for 1 minute prior to imaging to activate the Stain-free compound to visualise tryptophan-
containing proteins. Protein bands corresponding to size range 75 (top) to 25 kDa (bottom) are shown. 
Samples from left: alternating older NF, HCM, and younger NF LV samples. 
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Figure 3.5: Western blot with 1:500 rabbit anti-human RPS18 antibody and 1:10000 IRDye800 donkey 
anti-rabbit IgG (Li-Cor), see Figure 3.2 for details of the SDS-PAGE. Samples from left: alternating older 
NF, HCM, and younger NF LV samples. 
 
3.4 Discussion 
3.4.1 Technical Interpretation of Results 
The validity of the microarray analysis is supported by the statistically significant 
correlation of the real-time PCR results with that of the microarray results. Furthermore,   
3 mRNA coding for r-proteins were found to be significantly downregulated with age by 
real-time PCR. The other mRNA coding for r-proteins tested by real-time PCR were not 
shown to be DE with age or sex, despite the gene set analysis of the microarray data 
implying that all r-proteins might be downregulated. This was expected, as out of the 54 
r-proteins with corresponding mRNA represented on the microarrays, only RPL34 was 
found to be DE (downregulated) with age with a FDR q-value < 0.05 in the initial gene-
by-gene microarray analysis. Only with the gene set analysis was it possible to tease out 
the existence of an effect of age (and sex) on the coordinated expression of multiple r-
proteins. One can consider a gene-by-gene analysis of microarray data to lack sensitivity 
to discover DE genes, due to the large number of genes that are tested, and thus the need 
to control for multiplicity of testing. If one uses the raw p-value associated with each 
gene tested on a microarray to determine DE, one would expect 0.05 * (no. of genes on 
microarray) false positives. Therefore, one must use a correction such as the FDR 
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correction employed here to minimise the false positive rate (Benjamini, Y. and 
Hochberg, Y. 1995). However, this comes at the cost of significantly reducing the true 
positive rate of DE gene discovery.  
 I had hypothesised that a decrease in the expression with age (and male gender) of 
mRNA coding for r-proteins would be accompanied by a decrease in synthesis of the 45s 
rRNA that could be detected by real-time PCR. This was not detected, and there are a 
number of possible reasons for this. Note that the 45s rRNA amplicon in the real-time 
PCR was located in the 5' upstream region not present within the mature rRNA species. If 
we assume that there is in fact a true decrease in the rate of transcription of the 45s rRNA 
within LV tissue with age (and male gender), and it is coupled with an equal decrease in 
the rate of processing of the 45s rRNA into the mature 18s, 28s, and 5.8s rRNA species, 
then there would not be a change in abundance of the 45s rRNA. This would be despite 
there being a decrease in the rate of production of mature rRNA to be incorporated into 
newly-synthesised ribosomes. Another possibility is that per unit mass of tissue, there is a 
decrease in 45s rRNA abundance secondary to a decrease in the rate of transcription, and 
this leads to a corresponding decrease in the levels of mature rRNA per unit mass of 
tissue. Note that given that rRNA constitutes approximately 80% of total RNA, this 
would result in a decrease in extracted RNA per unit mass of tissue. Unfortunately, 
documenting yields of RNA per unit mass of tissue is complicated by various aspects of 
the RNA extraction process that are difficult to control for. These include: (1) differences 
in the amount of precipitated moisture present on LV tissue samples when they are 
removed from liquid nitrogen and being fragmented into a suitable size for extraction; (2) 
variable amounts of LV tissue per equal amounts of extraction reagent which may alter 
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the efficiency of RNA extraction; (3) variation in the efficiency with which tissue is 
homogenised in extraction reagent prior to the first centrifugation step; (4) variable loss 
of RNA at different stages of the extraction procedure; and (5) potentially other sources 
of variability. Thus, it was decided not to analyse RNA yield to assess for changes in 
RNA concentration with age or gender. Then, a constant amount of RNA was added to 
each RT reaction, the consequence of which was that one could only discover changes in 
particular RNA species relative to the overall RNA pool. If mature rRNA abundance 
decreases with age alongside the decrease in 45s rRNA, then the tissue from older ages 
will yield less RNA, and then to add the same amount of total RNA to each RT reaction, 
total RNA from a greater mass of tissue will have been added to the RT reactions of the 
older NF hearts. In this way, any detectable change in 45s rRNA between younger and 
older NF hearts would be attenuated, which would explain the inability to discover a 
statistically significant decrease in 45s rRNA with age (or male gender). 
 Regarding the Western blot results, we did not find that RPS18 protein levels 
were different in old and young NF hearts. There are several possible explanations. The 
first is that the change in mRNA expression of r-proteins is not associated with a 
corresponding change in r-protein abundance, i.e. while there may be a reduced 
abundance of r-protein mRNA transcripts, they may be more stable (longer half-life 
within the cytoplasm) and/or are translated at a higher rate at older ages, and thus the 
expression of r-proteins is maintained. The alternative is that the lack of appreciation of a 
true downregulation in RPS18 protein abundance is due to sampling error and/or 
technical variation. The sample size was quite small and there is massive variation among 
NF donors in terms of lifestyle, including nutrition and physical activity, subclinical 
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cardiac pathology, genetics, as well as cause of death, all of which may impact upon 
RPS18 protein expression/abundance. As an example, Luczak, E. D. et al. (2011) have 
shown that in rats, a casein-rich diet increases the expression of several r-proteins 
including RPS18. In addition, sampling error notwithstanding, the Western blot is a 
multi-step technique, each step of which introduces variability. This variability, coupled 
with the expectation of only a small change in protein abundance from the real-time PCR 
experiments, which demonstrated an approximate reduction of 30% in mRNA abundance 
over 50 years of ageing, makes it conceivable that the experiment would not allow 
appreciation of such a small change.  
 A significant technical limitation of the microarray analysis was the incomplete 
coverage of the genome (12087 unique Entrez IDs in the Ocimum 30K oligo set A), 
which prevented the discovery of all the transcriptomic changes associated with cardiac 
ageing and gender.  
 Another important limitation was that the location within the LV from which the 
biopsies were derived was unknown, thus regional variation in gene expression could not 
be appreciated. As an example, Heerdt, P. M. et al. (2000) found that SERCA2A mRNA 
is more highly expressed in LV apex versus free wall. Furthermore, this regional variation 
would have introduced biological variation not captured in the statistical model applied, 
therefore reducing the power to detect statistically significant changes in gene expression 
with age or gender common to all regions of LV myocardium.  
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3.4.2 Biological Interpretation of Results 
The KEGG_RIBOSOME gene set, which was significantly downregulated, contains the 
genes that code for the r-proteins, of which 79 were represented in the microarray 
platform. Note that these must be present in equimolar proportions, along with rRNA, in 
order to form functioning ribosomes (Hannan, R. D. et al. 2003). Therefore a decrease in 
any r-proteins would be reflected in a decrease in ribosome synthesis. This has been 
shown by Robledo, S. et al. (2008) who found that siRNA mediated knockout of any r-
protein led to a decrease in protein abundance of all other r-proteins comprising the same 
subunit, a reduction in abundance of the particular subunit, plus a reduction in abundance 
of the mature 80s ribosome. An increase in cardiomyocyte size, or number, requires 
increased protein synthesis. This can be achieved in several ways. One way is to increase 
the number of ribosomes within a cell, which will allow the number of mRNA molecules 
that can be translated in parallel to increase, assuming that ribosome abundance is 
limiting. Beltrami, A. P. et al. (2001) have demonstrated myocyte division in the border 
zone and in distant myocardium in the days following MI within the LV. This implies that 
the heart is attempting to compensate for the loss of contractile tissue by hyperplasia (and 
concomitant hypertrophy) of myocardial cells to replace infarcted tissue. With age, if 
there is a decrease in ribosome abundance or a decrease in the capacity to synthesise 
additional ribosomes (if decreased r-protein mRNA abundance with age is limiting for 
increasing the rate of ribosome synthesis), then this may interfere with this compensatory 
hyperplasia/hypertrophy. Without replacement of infarcted tissue, assuming similar 
haemodynamic demands post MI, the load on the remaining cardiomyocytes will have 
increased and thus, the probability of cardiomyocyte apoptosis and/or necrosis will also 
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increase, with further worsening of haemodynamic load on each remaining 
cardiomyocyte. As noted before, the likelihood of HF developing post MI is increased 
with the age at which the MI occurred (Lewis, E. F. et al. 2003; Terkelsen, C. J. et al. 
2011), and increased age also increases the risk of death in the context of established HF 
(MAGGIC et al. 2012). Decreased ribosome synthesis at older ages may contribute. In 
end-stage HF it has already been mentioned that there is ongoing increased hyperplasia 
(Quaini, F. et al. 1994; Kajstura, J. et al. 1998) of the cardiomyocytes relative to NF 
myocardium, reflecting inadequacy of contractile function of the cardiomyocytes with an 
attempt at compensation. A decreased abundance of ribosomes or inadequate capacity to 
upregulate the synthesis of ribosomes with age, in the end-stage HF state of increased 
need for protein synthesis, might represent a contributing factor to the inadequacy of 
hyperplasia. This inadequacy of hyperplasia in the aged heart is reflected in the findings 
of Bergmann, O. et al. (2009) of decreased cardiomyocyte renewal. Finally, the increased 
rate of apoptosis in end-stage HF (Olivetti, G. et al. 1997) may reflect in part the 
increased haemodynamic load on the available pool of cardiomyocytes that is not 
attenuated by cardiomyocyte hyperplasia to share the haemodynamic burden.  
 If the effects of male gender are similar to the effects of age on the capacity to 
synthesise ribosomes, then one would expect that the male heart would be less able to 
cope with the imposition of an MI, and would have an increased risk of HF, all other 
factors being equal. Parodi, G. et al. (2007) found greater recovery of LV EF post MI in 
females, and this may be related to greater ribosome synthesis affording greater 
hyperplasia/hypertrophy of the remaining viable myocardium in females. However, 
protection from development of HF in females was not demonstrated in a number of 
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studies mentioned above, the reasons for which are unclear. All-cause mortality in 
patients with HF is greater in men than in women, adjusted for age (Martinez-Selles, M. 
et al. 2012). This greater risk in males was found to be modified by aetiology of HF and 
diabetes. Specifically, in subgroup analyses, the association of female gender with greater 
survival appeared more marked in non-ischaemic aetiologies of HF, and separately, 
diabetes attenuated the protective effect of female gender in HF (Martinez-Selles, M. et 
al. 2012). It is possible that the advantage of female gender is to be found only prior to 
the development of ischaemia from coronary obstruction, either at the micro- or macro-
vascular level (which are features of diabetes and ISCM). Ribosome synthesis is 
energetically costly and in conditions of reduced blood flow it might be physiologically 
rational to reduce the synthesis of ribosomes to conserve ATP for use by the contractile 
machinery. If however, ischaemia due to atherosclerosis does not supervene in end-stage 
HF, then we might see that ribosome synthesis is greater in female hearts within the 
viable myocardium, and this confers an advantage in terms of greater capacity for 
hyperplasia/hypertrophy to compensate for the contractile deficit. This theory implies that 
blood flow is not limiting in end-stage HF, or at least during the evolution of HF, except 
in patients where coronary artery/arteriolar obstruction is the predominant cause of the 
HF phenotype. Perhaps the discrepancy between the results of Parodi, G. et al. (2007) and 
Van 'T Hof, A. W.  et al. (1998) lies in the higher rate of multi-vessel disease in the latter 
study, abrogating the advantage of female gender.  
 The effects of a proposed reduction in the capacity to synthesise ribosomes with 
age (and male gender) has been discussed, but what has so far not been addressed, is the 
underlying basis for this reduction. The expression of RHEB and MTOR were examined 
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by real-time PCR to discern whether they might be responsible for the decrease in 
expression of r-protein mRNA. RHEB is a GTP-binding protein with intrinsic GTPase 
activity, which in its active GTP-bound form, activates mTOR protein (Bai, X. et al. 
2007). MTOR in turn, is a well-established promoter of cardiac hypertrophy through a 
number of mechanisms including the stimulation of ribosome biogenesis (Mayer, C. and 
Grummt, I. 2006). However, neither RHEB nor MTOR mRNA expression were shown to 
be differentially expressed with age, though the direction of change was of possible 
downregulation. This does not preclude changes in protein abundance and activity as 
potential explanations for decreased r-protein mRNA expression with age (and in males), 
and further studies to investigate this possibility would be useful. Another potential 
mechanism for decreased ribosome synthesis with age was demonstrated by Strehler, B. 
L. et al. (1979) who reported decreased hybridisation of labelled rat rRNA to human 
myocardial DNA in older versus younger males. This may represent either loss via 
deletion of rRNA gene segments with age, or some other modification such as 
accumulation of point mutations or covalent cross-linking which would interfere with 
such complementary binding. A reduced number of structurally intact rRNA genes which 
can be transcribed simultaneously may lead to a decreased rate of production of 45s 
rRNA. It has been proposed that this may feedback negatively to pathways responsible 
for r-protein synthesis (Hannan, R. D. et al. 2003) resulting in the reduction of r-protein 
mRNA abundance found with age. A future analysis to see if such a modification of 45s 
rRNA genes also occurs in female LV with age, and at what rate, should be undertaken, 
which may or may not be able to explain the increased r-protein mRNA expression in 
females. Finally, depletion of ATP and decreased flux through the creatine kinase 
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pathway has not been shown to occur with age (Bottomley, P. A. et al. 2008), therefore 
energy depletion does not seem to be the explanation for decreased ribosome synthesis in 
aged NF LV myocardium.   
 Another DE gene set with age was the 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION gene set, which was 
downregulated with age. The most highly ranked DE genes within the gene set include 
the various haplotypes of the Major histocompatibility complex Class I and II genes, 
beta-2-microglobulin, cathepsin S, interferon alpha 6 and 10, and transporter 1, ATP-
binding cassette, sub-family B. These proteins are involved in cell-mediated immunity 
against intracellular microbes. Decrease in expression of the various components of the 
immune response to intracellular microbes may lead to increased susceptibility to 
myocarditis with age. Future studies looking at changes in the protein expression of the 
above genes should be undertaken.  
The genes discovered by the initial, gene-by-gene analysis include several with 
known cardiovascular roles in humans. The mRNA coding for Potassium (K) large 
conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1), a K+ 
channel responsive to voltage and Ca2+ in human coronary artery smooth muscle cells, 
was shown to decrease in expression with age (Fig. 3.6). Activation of this channel is 
associated with relaxation of coronary arterioles (Lu, R. et al. 2006), and thus, a 
reduction in expression with age may increase susceptibility to myocardial ischaemia. 
Incidentally, expression of KCNMA1 has also been detected in human cardiac fibroblasts 
(Wang, Y. J. et al. 2006), the functional implications of which are currently unknown. 
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LIM domain kinase 1 (LIMK1) was the most highly ranked gene shown to be 
upregulated with age in our dataset (Fig. 3.7). It is a kinase that phosphorylates and 
thereby inactivates cofilin proteins (Scott, R. W. and Olson, M. F. 2007). Cofilin proteins 
are F-actin depolymerising enzymes, suggesting that an increased abundance of LIMK1 
might lead to a decrease in F-actin disassembly. Although this is highly speculative, 
decreased F-actin disassembly might have several effects on ageing cardiomyocytes. The 
first is to prevent the disassembly of sarcomeres which would be required in order to 
allow cardiomyocytes to undergo cytokinesis and hence, hyperplasia, in response to 
increased haemodynamic demands. Note, as mentioned earlier, that cardiomyocyte 
renewal decreases with age in the human heart (Bergmann, O. et al. 2009), though it is at 
present unknown whether this renewal is from cardiomyocyte division or from cardiac 
stem cell differentiation. The second is a reduction in turnover of F-actin, leading to the 
accumulation within sarcomeres of post-translationally modified actin (e.g oxidised) 
which would decrease the sarcomere's ability to generate force. An alternate effect might 
be to reduce the breakdown of F-actin and thus preserve myofibril mass in light of 
increasing haemodynamic demands with age.  
 Another gene that was shown to be upregulated with age was cyclin-dependent 
kinase 2 (CDK2), a kinase that complexes with cyclin proteins to control the cell cycle 
(Fig. 3.8). In rat cardiomyocyte cultures, activation of cyclin E-CDK2 is involved in 
angiotensin II-induced hypertrophy as well as serum- and angiotensin II-induced nuclear 
replication (Hinrichsen, R. et al. 2008). Given the decreased cardiomyocyte turnover that 
seems to occur with age as described earlier, this increase in CDK2 mRNA might be the 
opposite of what one would expect. However, cardiomyocyte cell turnover in the aged 
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heart is possibly frustrated by a bottleneck at another stage of cell division, and this 
increased CDK2 expression reflects the increasing need for hypertrophy/hyperplasia with 
age (particularly in the male heart with the observed loss of cardiomyocytes with age). 
Figure 3.6: mRNA expression of KCNMA1 from the microarray analysis. The line represents the least-
squares regression line for the effect of age on the expression of KCNMA1 in LV NF myocardium (FDR q-
value = 0.01). Red spots denote female and blue spots denote male subjects.  
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Figure 3.7: mRNA expression of LIMK1 from the microarray analysis. The line represents the least-
squares regression line for the effect of age on the expression of LIMK1 in LV NF myocardium (FDR q-
value = 0.005). Red spots denote female and blue spots denote male subjects.  
 
Toll-like receptors, found both on the plasma membrane and on endosomes 
intracellularly, can bind to conserved structures present on microbes and are involved in 
activation of the innate immune system. Toll-like receptor 6 (TLR6), as well as others of 
this class, is expressed on cardiomyocytes (Frantz, S. et al. 2007) and polymorphisms of 
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TLR6 have been linked to propensity to develop LV wall thickening in response to 
systolic hypertension in women (Sales, M. L. et al. 2010). Specifically, the authors found 
that the TLR6 polymorphism associated with reduced activation in response to the 
agonist zymosan, was associated with reduced LV wall thickness in the context of 
systolic hypertension. TLR6 mRNA was found to be downregulated with age in the 
microarray experiments (Fig. 3.9), and this downregulation might inhibit LV 
hypertrophy/hyperplasia in response to the increased haemodynamic loads in the LV, 
adversely affecting CO at older ages. As to why TLR6 polymorphisms only affect LV 
wall thickness in women, and the relation to the functioning of the innate immune system 
in the heart, is unclear. 
 Nuclear factor of activated T-cells (NF-AT) is a transcription factor that is 
involved in promotion of hypertrophy in response to increased haemodynamic load in 
cardiomyocytes, as well as being involved in the inhibition of apoptosis (Vega, R. B. et 
al. 2003). NF-AT translocates to the nucleus after it is dephosphorylated by calcineurin, 
which is a phosphatase activated by binding to the Ca2+-calmodulin complex (Vega, R. B. 
et al. 2003). In this way, NF-AT transcriptional activity is stimulated by increased 
cytoplasmic Ca2+, which reflects contractile activity and is chronically elevated in states 
of increased haemodynamic load. The mRNA coding for nuclear factor of activated T-
cells, cytoplasmic, calcineurin-dependent 3 (NFATC3), the isoform of NF-AT found in 
cardiomyocytes, was found to be more highly expressed in males than in female LV in 
our study (Fig. 3.10). This may represent an upstream actor in the mechanism of 
hypertrophy of cardiomyocytes in the male LV with age, to compensate for the 
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simultaneous decrease in abundance of cardiomyocytes with age, which does not occur 
(or at least occurs to a lesser extent) in female LV.  
Figure 3.8: mRNA expression of CDK2 from the microarray analysis. The line represents the least-squares 
regression line for the effect of age on the expression of CDK2 in LV NF myocardium (FDR q-value = 
0.01). Red spots denote female and blue spots denote male subjects.  
 
In conclusion, the transcriptome of human LV undergoes substantial change with age 
(and is modified to a lesser extent by gender) and close examination of such changes will 
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allow discovery of age- and sex-related mechanisms that are related to the anatomical and 
functional changes that the heart undergoes as described above. More importantly, 
understanding the changes in the LV transcriptome will shed light on the effect of age and 
gender on the evolution of various cardiovascular pathologies, including MI, valvular 
disorders, and HF of a variety of aetiologies. 
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Figure 3.9: mRNA expression of TLR6 from the microarray analysis. The line represents the least-squares 
regression line for the effect of age on the expression of TLR6 in LV NF myocardium (FDR q-value = 
0.01). Red spots denote female and blue spots denote male subjects.  
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Figure 3.10: mRNA expression of NFATC3 from the microarray analysis indicating the difference in 
expression between female and male LV NF myocardium (FDR q-value = 0.01). The limits of the boxes 
represent the interquartile range for the values, whiskers are 1.5 * inter-quartile range distant from the 
median (middle line in the boxes).  
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Chapter 4: Ribosomal Gene Expression in 
End-Stage HF and LVAD Support 
 
 
4.1 Introduction 
As described in Chapter 3, with ageing of the LV myocardium, ribosome synthesis seems 
to decrease. In addition, it was also shown that ribosome synthesis may be lower in male 
LV compared to female LV. This may affect the susceptibility of the aged (and male) 
heart to the development of HF in response to the superimposition of pathologies like MI 
and valvular dysfunction. To extend this work, I examined the expression of ribosome 
coding genes in end-stage HF, and what effect LVAD support may have. It was postulated 
earlier that the reduced energy status of the failing heart (Ten Hove, M. and Neubauer, S. 
2007) may lead to a rational decrease in the synthesis of ribosomes to divert scarce ATP 
to the myofibrils to maintain contractility. One might expect that mechanical unloading of 
the LV via LVAD implantation might lead to normalisation of the energy status of the 
cardiomyocyte, and thus, the expression of ribosome genes was also examined in failing 
hearts pre- and post-LVAD implantation to further test the above postulate. 
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4.2 Methods 
4.2.1 RNA extraction for Real-time PCR Analysis 
For details regarding RNA extraction for real-time PCR see Section 2.2.1. 
 
4.2.2 Ribosome Gene Set Expression in End-Stage HF and LVAD Support 
To analyse gene expression changes related to r-protein mRNA associated with HF, two 
different types of microarray datasets were downloaded from the microarray dataset 
repository, Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/). The first kind were 
of comparisons of LV samples from patients with end-stage HF versus NF LV samples 
(GSE1145, GSE1869, GSE3585, GSE3586, GSE5406, and GSE21610), and the second 
were of comparisons of LV samples from patients with end-stage HF at LVAD 
implantation versus LV samples from the same patients at LVAD explantation 
(GSE21610, GSE974, and GSE430). For patient demographics see Table 4.1. 
 
Table 4.1: Patient demographics for the various end-stage HF versus NF LV and end-stage HF pre- and 
post-LVAD support datasets. *Summary statistics only were available, 'na' means data was not available. 
GEO Dataset Reference Phenotype Mean Age (SD) Gender 
GSE430 Chen, Y. et al. 
(2003) 
IDCM (n=7) 47.4 (8.6) 2 females,  
5 males 
GSE974 Hall, J. L. et al. 
(2004) 
IDCM (n=8) 44.0 (7.0) 4 females,  
4 males 
  ISCM (n=5) 58.8 (6.1) 0 females,  
5 males 
  MI (n=6) 53.2 (6.4) 0 females,  
6 males 
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GEO Dataset Reference Phenotype Mean Age (SD) Gender 
GSE1145 Tsubakihara, M. 
et al. (2006) 
NF (n=11) 61.4 (6.7) 2 females,  
9 males 
  IDCM (n=15) 53.7 (18.1) 7 females,  
8 males 
  ISCM (n=11) 54.1 (13.8) 4 females,  
7 males 
GSE1869 Kittleson, M. M. 
et al. (2005) 
NF (n=6) 43.0 (13.1) 1 female,  
5 males 
  IDCM (n=21) 45.6 (11.0) 6 females,  
15 males 
  ISCM (n=10) 55.8 (na) * 0 females,  
10 males 
GSE3585 Barth, A. S. et 
al. (2006) 
NF (n=5) 48.8 (9.4) 4 females,  
1 male 
  IDCM (n=7) 37.0 (14.1) 3 females,  
4 males 
GSE3586 Barth, A. S. et 
al. (2006) 
NF (n=15) 53.7 (4.1) 4 females,  
11 males 
  IDCM (n=13) 44.3 (17.5) 5 females,  
8 males 
GSE5406 Hannenhalli, S. 
et al. (2006) 
NF (n=16) 54 (12) * na 
  HF (n=194) 57 (12) * na 
GSE21610 Schwientek, P. 
et al. (2010) 
NF (n=8) 29.0 (17.4) 2 females,  
6 males 
  IDCM (n=21) 48.6 (13.4) 2 females,  
19 males 
  ISCM (n=10) 57.6 (8.9) 0 females,  
9 males 
 
Raw CEL file image data was used if available, otherwise pre-normalised data were 
analysed. Normalisation of Affymetrix CEL data was done using Robust multi-array 
average (Irizarry, R. A. et al. 2003) implemented in Bioconductor's affy package. 
Analyses carried out are detailed further in Appendix C. For the end-stage HF versus NF 
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datasets, t-statistics for each gene were first generated in R using a linear model for each 
probe set, where we regressed the normalized expression values against phenotype 
(Smyth, G. K.  2004). T-statistics were similarly generated for each gene in the 
comparisons of pre- and post-LVAD implantation HF samples. These t-statistics were 
then inputted into GSEA to calculate the ES and statistical significance of the association 
of ribosome gene set expression with phenotype, essentially as described in Section 
3.2.2.2. However, given that we were only testing one gene set, we relied on the p-value 
to decide significance, with a p-value < 0.05 regarded as significant. 
 To assess the similarity of the datasets analysed, specifically, of the Affymetrix 
datasets comparing end-stage IDCM (GSE1145, GSE1869, GSE3585, GSE5406, and 
GSE21610) and ISCM (GSE1145, GSE1869, GSE5406, and GSE21610) with NF LV, we 
undertook two different, complementary analyses. The first was an analysis of the 
overlap of the lists of ranked DE genes between the various datasets comparing the same 
phenotype of HF. This was done by computing the number of genes in common between 
the top 2000 most highly DE genes in each dataset. To estimate the likelihood of the 
particular number of overlapping genes occurring by chance, i.e. the p-value, for the null 
hypothesis of no relation between the various datasets comparing HF LV with NF LV of a 
particular aetiology, a frequency distribution of number of overlapping genes was 
computed by randomly sampling 2000 genes from each dataset and computing the 
overlap for each random sample. A p-value < 0.05 was considered to indicate a 
statistically significant relationship between the datasets. Note that the above analysis 
does not take into account that genes show correlated expression patterns. Thus, the 
frequency distribution generated would be narrower than it otherwise would be, and thus, 
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the resultant p-values may be underestimations of the probability of observing a 
particular level of overlap or greater, were the null hypothesis true. The second analysis 
was more descriptive in nature, and involved the construction of intersection plots 
illustrating the level of overlap of DE genes among the various datasets comparing end-
stage HF LV with NF LV of a particular aetiology. The GSE3586 dataset was not 
included in these two analyses as it was carried out on a different platform to the others, 
with probes against different sections of the nucleic acid strands of each particular gene, 
as well as coverage of fewer genes, making comparison difficult. The GSE21610 and 
GSE1145 datasets derive from the Affymetrix H133 plus 2 platform which carries 54675 
probes, which includes the 22283 probes represented on the Affymetrix H133A platform 
from which the other datasets derive, and only the subset of probes common to both 
platforms was analysed.  
 
4.2.3 Real-time PCR Analysis of Ribosome-related Genes in End-Stage HF 
Real-time PCR was carried out on LV from 18 NF patients (mean age: 57.3, SD: 4.2 
years, 9 females and 9 males), 19 ISCM (mean age: 58.8, SD: 4.1 years, 2 females and 17 
males), 10 IDCM (mean age: 57.1, SD: 4.0 years, 2 females and 8 males), and 4 HCM 
(mean age: 61.5, SD: 3.4, 2 females and 2 males) patients with end-stage HF.  This was to 
validate the changes in expression of r-protein mRNA discovered to be DE with end-
stage HF by the microarray analysis. For details of the experimental protocol see Section 
2.2.3. As discussed above, a mean relative measure of expression was computed from 
triplicate PCR reactions for each LV sample. Unpaired two-tailed t-tests were used to 
compare mRNA expression between NF LV samples and LV samples from patients with 
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end-stage HF due to the above aetiologies. For all statistical tests, p-values < 0.05 were 
regarded as significant. 
4.2.4 Western Blotting Analysis of RPS18 in End-Stage HF 
Protein expression analysis was carried out on LV from 5 NF subjects (55 year old 
females and 65, 63, 61 and 55 year old males), 4 IDCM (59, 56, and two 52 year old 
males) and 4 ISCM (65, 59, 58, and 56 year old males) patients with end-stage HF, and 
separately on 3 NF subjects (55 year old female, 65 and 63 year old males) and 3 HCM 
(57 year old female, 61 and 26 year old males) patients with end-stage HF to determine 
changes in expression of RPS18. For details regarding protein extraction, see Section 
2.3.1. For details regarding protein quantification, see Section 2.3.2. For details regarding 
SDS-PAGE and Western blotting, see Section 2.3.3. Mean IInt for LV samples from each 
phenotype group were compared by unpaired two-tailed t-tests to assess for DE. For all 
statistical tests, p-values < 0.05 were considered significant.   
 
4.3 Results 
4.3.1 Ribosome Gene Set Expression in End-Stage HF and LVAD Support 
In two microarray studies comparing end-stage IDCM with NF LV, the ribosome gene set 
was highly significantly downregulated (GSE5406 and GSE1145), with an additional 
study showing borderline significance for downregulation with IDCM (GSE21610), and 
another showing insignificant downregulation (GSE3586) (Table 4.2). Note that the final 
study had the lowest representation of probes targeting r-protein mRNA species, and thus 
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the sensitivity to detect significant downregulation would have been reduced as compared 
with the other studies. However, in two additional studies (GSE1869 and GSE3585), the 
ribosome gene set was significantly upregulated in end-stage IDCM.  
In three microarray studies comparing end-stage ISCM with NF LV, the ribosome gene 
set was highly significantly downregulated (GSE5406, GSE1145, and GSE21610), and in 
one dataset it was found to be significantly upregulated (GSE1869). Interestingly, this last 
dataset was a subset of the same microarray dataset in which was discovered an 
upregulation in ribosome gene set expression with end-stage IDCM.  
 
Table 4.2: Ribosome gene set (HSA03010_RIBOSOME) expression in various datasets comparing end-
stage HF due to IDCM and ISCM with NF LV. Within the 'Study design' column one finds the phenotype 
comparisons carried out with the sample sizes for each group in parentheses. 'Size' refers to how many 
nucleic acid targets are present on each platform that bind to mRNA coding for r-proteins. 'ES' is 
enrichment score, explained in Section 3.2.2.2, however, in this context, a negative 'ES' means that the 
ribosome gene set is downregulated in the end-stage HF or pre-LVAD groups. The studies are ordered in 
descending sample size. 
GEO 
Dataset 
Reference Study design Platform Size ES P-value 
GSE5406 Hannenhalli
, S. et al. 
(2006) 
IDCM 
(n=108) vs 
NF (n=16) 
HG-U133A 78 -0.4 0.004 
GSE5406 Hannenhalli
, S. et al. 
(2006) 
ISCM (n=86) 
vs NF (n=16) 
HG-U133A 78 -0.43 < 0.001 
GSE21610 Schwientek, 
P. et al. 
(2010) 
IDCM (n=21) 
vs NF (n=8) 
HG-
U133_Plus_2 
79 -0.29 0.057 
GSE3586 Barth, A. S. 
et al. (2006) 
IDCM (n=13) 
vs NF (n=15) 
Unigene3.1 
cDNA Array 
37.5K v1.0  
53 -0.21 0.78 
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GEO 
Dataset 
Reference Study design Platform Size ES P-value 
GSE1869 Kittleson, 
M. M. et al. 
(2005) 
IDCM (n=21) 
vs NF (n=6) 
HG-U133A 78 0.66 < 0.001 
GSE1145 Tsubakihara
, M. et al. 
(2005) 
IDCM (n=15) 
vs NF (n=11) 
HG-
U133_Plus_2 
79 -0.54 < 0.001 
GSE1145 Tsubakihara
, M. et al. 
(2005) 
ISCM (n=11) 
vs NF (n=11) 
HG-
U133_Plus_2 
79 -0.45 0.001 
GSE21610 Schwientek, 
P. et al. 
(2010) 
ISCM (n=9) 
vs NF (n=8) 
HG-
U133_Plus_2 
79 -0.71 < 0.001 
GSE1869 Kittleson, 
M. M. et al. 
(2005) 
ISCM (n=10) 
vs NF (n=6) 
HG-U133A 78 0.61 < 0.001 
GSE3585 Barth, A. S. 
et al. (2006) 
IDCM (n=7) 
vs NF (n=5) 
HG-U133A 78 0.77 < 0.001 
GSE21610 Schwientek, 
P. et al. 
(2010) 
Paired IDCM 
post- vs pre-
LVAD (n=21)
HG-
U133_Plus_2 
79 0.32 0.05 
GSE21610 Schwientek, 
P. et al. 
(2010) 
Paired ISCM 
post- vs pre-
LVAD (n=9) 
HG-
U133_Plus_2 
79 0.81 < 0.001 
GSE974 Hall, J. L. et 
al. (2004) 
Paired IDCM 
post- vs pre-
LVAD (n=8) 
HG-U133A 78 0.49 < 0.001 
GSE430 Chen, Y. et 
al. (2003) 
Paired IDCM 
post- vs pre-
LVAD (n=7) 
HG-U133A 78 0.72 < 0.001 
GSE974 Hall, J. L. et 
al. (2004) 
Paired ISCM 
post- vs pre-
LVAD (n=5) 
HG-U133A 78 0.5 < 0.001 
GSE974 Hall, J. L. et 
al. (2004) 
Paired AMI 
post- vs pre-
LVAD (n=6) 
HG-U133A 78 -0.62 < 0.001 
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In order to understand the above discrepancies in results, I undertook to explore how 
similar the various datasets were to each other. Almost all the Affymetrix datasets showed 
more overlap of genes ranked as DE than would be expected by chance, however certain 
studies showed little overlap with each other. For studies comparing end-stage IDCM 
with NF LV, out of the top 2000 genes in order of strength of DE by p-value, only 141 
genes were found in common to GSE1145 and GSE21610, an amount of overlap that 
would be expected by chance (p-value = 0.99), and similarly, only 77 in common 
between GSE1145 and GSE3585 (p-value = 0.59). For studies comparing end-stage 
ISCM LV with NF LV, all studies showed significant overlap in terms of the number of 
genes in common ranked in the top 2000 most highly DE genes. To illustrate the level of 
overlap between datasets in a more intuitive way, see Figs. 4.1 to 4.8. Note firstly, the 
relatively low proportion of highly ranked DE Affymetrix probes that overlap amongst 
the various datasets for both IDCM and ISCM comparisons (Figs. 4.1 to 4.4). Despite this 
lack of substantial overlap, a few key observations can be made. The first is that it 
appears that the datasets most concordant with each other with respect to IDCM are 
GSE21610 and GSE5406, which happen to also be the two largest datasets in terms of 
sample size. Note that the analysis of both these datasets found a downregulation of the 
ribosome gene set with end-stage IDCM. With respect to ISCM, GSE5406 and GSE1145 
are the most concordant with each other, and these two datasets also have the largest 
sample sizes for the ISCM LV versus NF LV comparison, and in both was a significant 
downregulation of the ribosome gene set observed in end-stage ISCM. 
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Figure 4.1: Intersection plot showing the proportion of overlapping Affymetrix probes ranked by strength 
of evidence of DE (i.e. p-value) among the datasets comparing end-stage IDCM LV and NF LV. Black 
represents the overlap between GSE21610 and GSE3585, blue represents the overlap between GSE5406 
and GSE1869, brown represents the overlap between GSE21610 and GSE5406, cyan represents the overlap 
between GSE21610 and GSE1145, green represents the overlap between GSE1145 and GSE5406, grey 
represents the overlap between GSE1145 and GSE3585, orange represents the overlap between GSE5406 
and GSE3585, purple represents the overlap between GSE21610 and GSE1869, red represents the overlap 
between GSE1145 and GSE1869, and yellow represents the overlap between GSE3585 and GSE1869. 
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Figure 4.2: Intersection plot showing the proportion of overlapping Affymetrix probes ranked by strength 
of evidence of DE (i.e. p-value) among the datasets comparing end-stage IDCM LV and NF LV for the top 
2000 most highly ranked Affymetrix probes in each dataset. Black represents the overlap between 
GSE21610 and GSE3585, blue represents the overlap between GSE5406 and GSE1869, brown represents 
the overlap between GSE21610 and GSE5406, cyan represents the overlap between GSE21610 and 
GSE1145, green represents the overlap between GSE1145 and GSE5406, grey represents the overlap 
between GSE1145 and GSE3585, orange represents the overlap between GSE5406 and GSE3585, purple 
represents the overlap between GSE21610 and GSE1869, red represents the overlap between GSE1145 and 
GSE1869, and yellow represents the overlap between GSE3585 and GSE1869. 
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Figure 4.3: Intersection plot showing the proportion of overlapping Affymetrix probes ranked by strength 
of evidence of DE (i.e. p-value) among the datasets comparing end-stage ISCM LV and NF LV. Blue 
represents the overlap between GSE5406 and GSE1869, brown represents the overlap between GSE21610 
and GSE5406, cyan represents the overlap between GSE21610 and GSE1145, green represents the overlap 
between GSE1145 and GSE5406, purple represents the overlap between GSE21610 and GSE1869, red 
represents the overlap between GSE1145 and GSE1869. 
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Figure 4.4: Intersection plot showing the proportion of overlapping Affymetrix probes ranked by strength 
of evidence of DE (i.e. p-value) among the datasets comparing end-stage ISCM LV and NF LV for the top 
2000 most highly ranked Affymetrix probes in each dataset . Blue represents the overlap between GSE5406 
and GSE1869, brown represents the overlap between GSE21610 and GSE5406, cyan represents the overlap 
between GSE21610 and GSE1145, green represents the overlap between GSE1145 and GSE5406, purple 
represents the overlap between GSE21610 and GSE1869, red represents the overlap between GSE1145 and 
GSE1869. 
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If we separate the most highly ranked DE Affymetrix probes according to direction of 
expression change with HF, we can observe more clearly the similarities between the 
various datasets (Figs. 4.5 to 4.8). For both IDCM and ISCM comparisons, GSE1145 and 
GSE5406 are more highly concordant with respect to the other datasets. In addition, the 
concordance between GSE5406 and GSE21610 for both IDCM and ISCM comparisons 
is also high with respect to the other datasets. By contrast, the concordance between 
GSE1145 and GSE1869 is particularly low, especially for the IDCM comparison. To 
conclude, it appears that the most highly concordant datasets for both IDCM and ISCM, 
seem to be the datasets with the highest sample sizes, and it is these datasets that also 
consistently show a downregulation of ribosome gene set expression with end-stage HF 
related to IDCM and ISCM. The reverse effect is seen when comparing studies with 
lower sample sizes. Note GSE3583 and GSE1869 analysing end-stage IDCM, where we 
observe a moderately low concordance, and GSE3585 and GSE1145 also analysing end-
stage IDCM, where we observe a similarly low level of concordance.   
 With regards to the studies examining the effect of LVAD support in patients with 
end-stage ISCM, both GSE21610 and GSE974 showed a highly significant upregulation 
of the ribosome gene set (Table 4.2). Similarly for end-stage IDCM, GSE974 and 
GSE430 showed a highly significant upregulation of the ribosome gene set, with 
GSE21610 also showing upregulation, but only with borderline statistical significance 
(Table 4.2). In a subset of the study (GSE21610) by Hall, J. L. et al. (2004), LV tissue 
sampled at the time of LVAD insertion, within 10 days of an MI significant enough to 
cause acute HF, was analysed. This tissue was compared to LV tissue from the same 
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patients at the time of LVAD removal and heart transplantation. In this comparison, there 
was observed a decrease in ribosome gene set expression post LVAD support.  
Figure 4.5: Intersection plot showing the proportion of overlapping Affymetrix probes that are upregulated 
ranked by strength of evidence of DE (i.e. p-value) among the datasets comparing end-stage IDCM LV and 
NF LV for the top 2000 most highly ranked Affymetrix probes in each dataset. Black represents the overlap 
between GSE21610 and GSE3585, blue represents the overlap between GSE5406 and GSE1869, brown 
represents the overlap between GSE21610 and GSE5406, cyan represents the overlap between GSE21610 
and GSE1145, green represents the overlap between GSE1145 and GSE5406, grey represents the overlap 
between GSE1145 and GSE3585, orange represents the overlap between GSE5406 and GSE3585, purple 
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represents the overlap between GSE21610 and GSE1869, red represents the overlap between GSE1145 and 
GSE1869, and yellow represents the overlap between GSE3585 and GSE1869. 
Figure 4.6: Intersection plot showing the proportion of overlapping Affymetrix probes that are 
downregulated ranked by strength of evidence of DE (i.e. p-value) among the datasets comparing end-stage 
IDCM LV and NF LV for the top 2000 most highly ranked Affymetrix probes in each dataset. Black 
represents the overlap between GSE21610 and GSE3585, blue represents the overlap between GSE5406 
and GSE1869, brown represents the overlap between GSE21610 and GSE5406, cyan represents the overlap 
between GSE21610 and GSE1145, green represents the overlap between GSE1145 and GSE5406, grey 
represents the overlap between GSE1145 and GSE3585, orange represents the overlap between GSE5406 
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and GSE3585, purple represents the overlap between GSE21610 and GSE1869, red represents the overlap 
between GSE1145 and GSE1869, and yellow represents the overlap between GSE3585 and GSE1869. 
Figure 4.7: Intersection plot showing the proportion of overlapping Affymetrix probes that are upregulated 
ranked by strength of evidence of DE (i.e. p-value) among the datasets comparing end-stage ISCM LV and 
NF LV for the top 2000 most highly ranked Affymetrix probes in each dataset. Blue represents the overlap 
between GSE5406 and GSE1869, brown represents the overlap between GSE21610 and GSE5406, cyan 
represents the overlap between GSE21610 and GSE1145, green represents the overlap between GSE1145 
and GSE5406, purple represents the overlap between GSE21610 and GSE1869, red represents the overlap 
between GSE1145 and GSE1869. 
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Figure 4.8: Intersection plot showing the proportion of overlapping Affymetrix probes that are 
downregulated ranked by strength of evidence of DE (i.e. p-value) among the datasets comparing end-stage 
ISCM LV and NF LV for the top 2000 most highly ranked Affymetrix probes in each dataset. Blue 
represents the overlap between GSE5406 and GSE1869, brown represents the overlap between GSE21610 
and GSE5406, cyan represents the overlap between GSE21610 and GSE1145, green represents the overlap 
between GSE1145 and GSE5406, purple represents the overlap between GSE21610 and GSE1869, red 
represents the overlap between GSE1145 and GSE1869. 
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4.3.2 Real-time PCR Analysis of Ribosome-related Genes in End-Stage HF 
To confirm the above findings, real-time PCR was carried out on samples of LV from 
patients with end-stage HF due to IDCM, ISCM, as well as HCM, and compared to NF 
LV (Table 4.3). With respect to ISCM, 4 out of 8 r-protein mRNA tested were confirmed 
to be downregulated in end-stage HF. With respect to IDCM, 5 out of 8 r-protein mRNA 
were confirmed to be downregulated. And finally, in HCM, 4 out of the 8 r-protein 
mRNA tested were found to be downregulated. Note that even for the r-protein mRNA 
found not to be statistically significantly DE, the direction of DE for all were towards 
downregulation in end-stage HF. In end-stage HF from IDCM, ISCM and HCM, 45s 
rRNA was found to be statistically significantly downregulated (Table 4.3). Finally, 
RHEB mRNA was found to be downregulated only in end-stage HF due to HCM. 
 
Table 4.3: Real-time PCR results comparing mRNA expression of various genes in end-stage HF versus NF 
hearts. Results are presented as percentage change from NF LV (n=8) with associated p-values in parentheses. 
Sample size is in parentheses beside each phenotype group label, with 'End-stage HF' being a composite group of 
all HF patients. Real-time PCR results normalised to Scr1. 
 End-stage HF 
(n=33) 
ISCM (n=19) IDCM (n=10) HCM (n=4) 
45s rRNA -28.8 (0.009) -24.7 (0.03) -34.2 (0.005) -37.7 (0.006) 
RPS10 -16.1 (0.03) -16.1 (0.04) -11.0 (0.25) -34.7 (0.07) 
RPS21 -20.3 (0.007) -18.7 (0.02) -19.5 (0.01) -30.9 (0.006) 
RPL26 -19.4 (0.01) -15.5 (0.04) -20.2 (0.02) -31.8 (0.04) 
RPL37 -14.5 (0.09) -10.0 (0.30) -18.2 (0.04) -29.1 (0.09) 
RPS7 -29.1 (0.01) -28.4 (0.01) -27.7 (0.02) -37.6 (0.046) 
RPS18 -9.4 (0.30) -11.1 (0.25) -2.6 (0.82) -18.8 (0.25) 
RPL23A -11.6 (0.16) -10.7 (0.25) -13.4 (0.11) -13.4 (0.47) 
RPL34 -4.8 (0.52) -1.6 (0.81) -3.2 (0.73) -20.6 (0.21) 
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 End-stage HF 
(n=33) 
ISCM (n=19) IDCM (n=10) HCM (n=4) 
RHEB -17.2 (0.09) -12.5 (0.26) -19.5 (0.09) -37.5 (0.008) 
MTOR 7.5 (0.41) 11.8 (0.32) 3.2 (0.70) -4.3 (0.04) 
 
4.3.3 Western Blotting Analysis of RPS18 in End-Stage HF 
The rabbit anti-human RPS18 antibody stained a band in the Western blot experiments at 
the correct migration point of ~17 kDa (Fig. 4.10 and Appendix A). Note similar loading 
of protein among all wells is observed (Fig. 4.9). However, no difference in expression 
between end-stage IDCM and ISCM LV versus NF LV were observed (mean IInt of 0.73 
and 0.75 versus 0.70 with associated p-values = 0.77 and 0.62, respectively) (Fig. 4.10). 
Similarly, no difference in RPS18 protein expression was observed between end-stage 
HCM and NF LV (mean IInt 1.03 and 0.79, respectively, p-value = 0.19) (Figs. 3.4 and 
3.5).  
 
Figure 4.9: SDS-PAGE using a Nusep 4-20% gradient gel loaded with 40 μg LV total protein. The gel was 
UV irradiated for 1 minute prior to imaging to activate the Stain-free compound to visualise tryptophan-
containing proteins. Protein bands corresponding to size range 75 (top) to 25 kDa (bottom) are shown. 
Samples from left: alternating NF, IDCM, and ISCM LV samples. 
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Figure 4.10: Western blot with 1:500 rabbit anti-human RPS18 antibody and 1:10000 
IRDye800 donkey anti-rabbit IgG (Li-Cor). Samples from left: alternating NF, IDCM, 
and ISCM LV samples. 
 
4.4 Discussion 
4.4.1 Technical Interpretation of Results 
It has been demonstrated among several microarray datasets comparing NF LV with LV 
from patients with end-stage HF due to IDCM and ISCM, that there is a decrease in 
expression of ribosome subunit coding mRNA. More precisely, mRNA coding for r-
proteins are more likely to be downregulated than the average mRNA transcript. 
However, there were discrepancies in the results of the analyses of the microarray studies 
above, as already mentioned. Not all microarray studies comparing end-stage IDCM and 
ISCM with NF LV found a decrease in r-protein expression, and in fact, analysis of the 
datasets from Kittleson, M. M. et al. (2005) and Barth, A. S. et al. (2006) demonstrated 
the reverse. These studies had smaller sample sizes, making them more susceptible to 
idiosyncrasies in the biology of the particular patients involved, which would be 
unrelated to HF pathology. This would explain the relatively low concordance of ranked 
DE genes in end-stage IDCM among the lower sample size datasets derived from 
Kittleson, M. M. et al. (2005), Barth, A. S. et al. (2006), and Tsubakihara, M. et al. 
(2005). It is also possible that there may have been confounding by age and gender. As 
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demonstrated in Chapter 3, there is evidence to suggest that increasing age and male 
gender is associated with lower expression of r-protein mRNA. These factors were not 
incorporated into the analyses as age and/or gender information was not available for all 
the datasets. For the datasets for which age and/or gender data was available, matching 
the human subjects in each phenotype group according to said factors would have 
dramatically reduced the sample sizes of the groups. The assumption was thus made that 
the effect on the transcriptome of end-stage HF would far outweigh the effects of age and 
gender. The strength of the findings above rests on the validity of this assumption. As 
discussed in Chapter 3, the particular gene set testing strategy used may underestimate 
the p-values for the association between the expression of the r-protein gene set and the 
phenotype in question (Goeman, v J. J. and Buhlmann, P. 2007). However, given that 
multiple microarray datasets have been analysed, which constitutes a form of biological 
replication, the results can be accepted with more confidence. 
 Downregulation of particular r-protein mRNA in end-stage HF due to IDCM and 
ISCM, and additionally in HCM, has also been confirmed using real-time PCR. This 
lends support to the results of the microarray experiments, as well as extending them to 
the particular aetiology of HCM. Note that 45s rRNA expression was also shown to be 
downregulated in all forms of end-stage HF, and this lends support to the idea of a 
coordinated downregulation of mRNA coding for ribosomal subunits. Given the 
argument put forth explaining the inability to demonstrate a decrease of 45s rRNA 
expression with age or sex in Section 3.4.1, the demonstration of such a downregulation 
in end-stage HF due to ISCM, IDCM, and HCM increases our confidence that this is a 
true feature of end-stage HF. 
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 We did not observe a difference in protein expression of RPS18 in end-stage HF 
due to ISCM, IDCM and HCM, despite the differences in mRNA expression observed for 
many other ribosomal subunit coding genes. Whilst we did not observe a statistically 
significant downregulation of RPS18 mRNA in any end-stage HF group in our real-time 
PCR experiments, we would expect the protein abundance of RPS18 to be downregulated 
in the context of decreased expression of mRNA coding for other r-proteins that make up 
the same subunit (40s or 60s) (Robledo, S. et al. 2008). It has been explained above in 
Section 3.4.1 how such a difference may not be appreciable using conventional protein 
quantification methods employed here. In addition, the sample size particularly in these 
experiments was severely limiting, and a larger study should be contemplated to properly 
address this question.  
 
4.4.2 Biological Interpretation of Results 
The above experiments demonstrate a decrease in the synthesis of components that make 
up the ribosome in end-stage HF of a variety of aetiologies. This would result in a 
decrease in ribosome abundance within cardiomyocytes in end-stage HF, leading to a 
decrease in the capacity for protein synthesis, turnover, hypertrophy, and hyperplasia.  
 Pagani, E. D. et al. (1988) have found that myofibrillar protein content per unit 
wet weight of LV myocardium is decreased in end-stage IDCM and ISCM hearts when 
compared to NF hearts. Scholz, D. et al. (1994) have demonstrated that the myofibrillar 
volume density of LV cardiomyocytes from patients with end-stage IDCM is reduced. 
These findings could be explained by a decrease in myofibril content in cardiomyocytes, 
as well as by the replacement of cardiomyocytes with non-muscle cells. Extending the 
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above findings, Hein, S. et al. (1994) have demonstrated reduced expression of actin, 
myosin, troponin T, tropomyosin and titin in end-stage IDCM hearts using 
immunofluorescence, with marked heterogeneity of loss of expression between and 
within, individual cardiomyocytes. Furthermore, Hammond, E. H. et al. (1987) found that 
myofibril loss in IDCM as assessed by EM is predictive of worse prognosis, similar to 
findings from a study by Figulla, H. R. et al. (1985) in ISCM. Decreased ribosome 
abundance may lead to decreased production of myofibrillar proteins within 
cardiomyocytes in end-stage HF. Under conditions of decreased capacity for protein 
turnover, it is also possible that the loss of appreciable myofibrillar proteins may 
represent an increase in deleterious post-translational modifications, leading to alterations 
in tertiary structure and breakdown of myofibrils, with the accumulation of misfolded 
proteins in the cytosol that are not detected by the various techniques for quantifying 
myofibrils used in the above studies. Supporting the latter proposal, Pagani, E. D. et al. 
(1988) found that the Mg-ATPase activity of myofibrils extracted from end-stage IDCM 
and ISCM LV is reduced compared to NF LV, and this could be due to reduced protein 
turnover leading to the accumulation of actin and myosin filaments with increased 
deleterious post-translational modifications resulting in reduced enzymatic activity. 
Similar decreases in myofibril ATPase activity in LV tissue from patients with end-stage 
HF was demonstrated by Peters, T. J. et al. (1977). However, in this study myofibril 
ATPase activity was expressed as a function of total extracted protein, and thus reduced 
synthesis of actin/myosin or other myofibril proteins that modulate ATPase activity may 
account for the findings. Pagani, E. D. et al. (1998) also found that Mg-ATPase activity 
was depressed in LV papillary muscle from patients undergoing mitral valve replacement 
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for severe mitral regurgitation. These hearts were not in end-stage HF at the time of 
surgery, and this group was not found to have reduced myofibril proteins per unit wet 
weight of myocardial tissue. It is possible that pre-end-stage HF hearts such as these with 
severe mitral regurgitation are suffering an energy deficit that is not as profound as that 
found in end-stage HF, such that there is a decrease in protein turnover, but the rate of 
synthesis is not depressed to such an extent that there is a net loss of myofibrils. 
Therefore, a decrease in Mg-ATPase activity is found due to accumulation of myofibril 
proteins with accumulated deleterious post-translational modifications. Evidence for this 
proposed mechanism comes from a study by Gubdjarnason, S. et al. (1964), who 
measured protein turnover/synthesis by radioactive glycine accumulation in rabbit LV 
myocardium. It was found that the induction of aortic stenosis led to increased protein 
synthesis 2 days post surgery, and protein turnover was mildly increased 1-6 months post 
operation, as compared with sham operated rabbits. However, for the rabbits that 
developed acute HF post operation, protein synthesis was increased, but not to the extent 
of the group who did not develop acute HF, and finally, in the rabbits who developed 
chronic HF 1-6 months post operation, protein turnover was found to be lower compared 
to all other groups. 
 In the microarray datasets analysed above, LVAD implantation into hearts with 
end-stage HF due to IDCM or ISCM was shown to lead to an upregulation of ribosome 
gene set expression. Furthermore, in their own analysis, Schwientek, P. et al. (2010) 
found that LVAD implantation corrected the downregulation in end-stage HF of 
elongation factor, RNA polymerase II, 2, which is a protein that is believed to increase 
the overall rate of mRNA transcription (Shilatifard, A. et al. 1997). The analysis of 
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ribosome gene set expression with LVAD support is consistent with the general 
contention of this thesis that energy deficits drive downregulation of ribosome 
production, by demonstrating that reducing myocardial energy expenditure by 
mechanical unloading leads to an increase in r-protein coding mRNA expression. My 
results also concur with Razeghi, P. et al. (2006) who found increased RPS10 mRNA and 
18s rRNA expression post LVAD implantation in end-stage HF due to IDCM and ISCM. 
Similarly, Matkovich, S. J. et al. (2009) found that RPL17 is downregulated in end-stage 
HF, and that this decrease was attenuated by LVAD support. At the same time, LVAD 
support leads to increased mRNA expression of multiple sarcomeric and non-sarcomeric 
genes including β-myosin heavy chain (Rodrigue-way, A. et al. 2005). LVAD support has 
also been demonstrated to ameliorate, though incompletely, the distorted myofibrillar 
structure within cardiomyocytes from patients with end-stage HF (de Jonge, N. et al. 
2002). These findings are consistent with a normalising of myocardial energy status 
leading to a resumption of protein synthesis/repair of cellular structures, assisted by an 
increase in ribosome synthesis. LVAD support appears to cause reduced cardiomyocyte 
volume, length and width in conditions with pathological hypertrophy associated with 
end-stage HF (Ambardekar, A. V. and Buttrick, P. M. 2011), but the effect on the total 
volume of the myofibrillar compartment is unclear, and prolonged unloading may be 
leading to cardiomyocyte atrophy which might be harmful (more on this later). LV 
cardiomyocytes from patients with end-stage HF exhibit decreased rates of shortening, 
magnitude of shortening and rates of relaxation, alongside decreased peak cytosolic Ca2+ 
and rate of Ca2+ uptake, and LVAD support has been demonstrated to reverse these 
deficits (Dipla, K. et al. 1998). Similarly, LVAD support has been shown to reverse, albeit 
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incompletely, the decreased maximal force able to be generated by myofibrils from 
patients with end-stage IDCM (Ambardekar, A. V. et al. 2001). It is suggested here that 
an increase in r-protein mRNA represents an increase in ribosome synthesis that then 
leads to increased protein turnover, which reverses the accumulation of proteins with 
deleterious post-translational modifications which contributes to the aforementioned 
defects. Muscle ring finger proteins are ubiquitin ligases that have been demonstrated to 
target multiple proteins (including myosin and troponin I) in the cardiac sarcomere for 
proteasome-dependent destruction, and knockout mice display impaired cardiac muscle 
performance, cardiac hypertrophy and early-onset HF (Willis, M. S. et al. 2009). While it 
has been argued that net accumulation of particular sarcomeric proteins leads to the 
myofibrillar disarray and hypertrophy associated with these phenotypes, it is also possible 
that decreased turnover of damaged sarcomeric proteins leads to impairment of force 
generation that results in cardiac hypertrophy via enhanced neurohumoral signalling in 
the context of haemodynamic insufficiency. In humans, bortezomid (a proteasome 
inhibitor) administration for cancer has been observed to lead to HF (Enrico, O. et al. 
2007), and the mechanism may be decreased turnover of cardiomyocyte proteins, echoing 
the effect of ribosome deficiency. As a potential strategy for the testing of the conjecture 
of reduced protein turnover in end-stage HF, and its reversal with LVAD implantation, 
one could use the context of 'bridge to transplant' LVAD implantation/explantation. 
Specifically, patients with end-stage HF scheduled for LVAD insertion could be injected 
with radioactive amino acids just prior, and then at LVAD implantation, apical tissue 
removed could be analysed for incorporated radioactivity, as a measure of protein 
turnover in end-stage HF. At LVAD explantation and heart transplantation, one could 
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carry out the same injection just prior, and then analyse the explanted heart tissue for 
incorporation, as a measure of protein turnover post mechanical unloading. 
 As mentioned earlier, end-stage HF is associated with increased mitosis and 
cardiomyocyte division (Quaini, F. et al. 1994; Kajstura, J. et al. 1998; Kajstura, J. et al. 
2012), presumably in an attempt to compensate for the deficit in contractility. However, 
clearly this attempt at compensation is inadequate. Wohlschlaeger, J. et al. (2010) have 
observed a decrease in mean cardiomyocyte DNA content and an increase and decrease 
in diploid and polyploid cardiomyocytes, respectively, post LVAD support in end-stage 
HF due to a variety of aetiologies. They hypothesise that this is due to increased 
cardiomyocyte division post LVAD support. It is possible that this represents an 
augmentation of the pre LVAD inadequate hyperplastic response in end-stage HF. An 
increase in ribosome synthesis post LVAD implantation would be in accordance with the 
aims of cardiomyocyte hyperplasia (and associated hypertrophy). The findings from 
Wohlschlaeger, J. et al. (2010) can also explain the observation that LVAD support 
appears to reverse the increased volume, length, and width of cardiomyocytes in LV from 
patients with end-stage HF (Ambardekar, A. V. and Buttrick, P. M. 2011). This may be 
due to an increase in cardiomyocyte division, with smaller daughter cells, rather than due 
solely to atrophy of cardiomyocytes.  
RHEB mRNA expression was shown to be decreased in end-stage HF due to 
HCM. Notwithstanding that RHEB protein expression has not yet been shown to be 
decreased in end-stage HCM, I think this result must be accepted cautiously as only 4 
patients were present in this group. Also, the fact that such a downregulation was not seen 
in IDCM and ISCM, highlights that even if such an effect is true, it does not represent a 
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feature of end-stage HF in general, but rather a peculiarity of HCM itself, which is not the 
focus of my thesis.  
 Analysing the dataset from Hall, J. L. et al. (2004), in patients in whom LVAD 
insertion was performed who were < 10 days post MI severe enough to cause acute HF, r-
protein mRNA expression was lower post LVAD explantation. This can be explained by 
the observation that hypertrophy/hyperplasia is markedly increased in the remaining 
viable myocardial tissue immediately after an MI occurs (Beltrami, A. P. et al. 2001). 
This process, which would require increased ribosome synthesis, would diminish over 
time as the deficit in contractile tissue is reduced. Thus at LVAD explantation, ribosome 
synthesis would be at a lower level compared to immediately post MI during which a 
burst of increased protein synthesis was occurring. This is despite ribosome synthesis at 
LVAD explantation being higher than it otherwise would be, had the LVAD not been 
inserted. 
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Chapter 5: The Effect of Age, Sex and 
End-Stage HF on Nucleolar 
Remodelling 
 
5.1 Introduction 
The nucleolus, the site of ribosome synthesis (Section 1.2.5.5), is a roughly spherical 
structure of approximately 1 μm in diameter. It is subdivided into three distinct regions: 
1) the fibrillar centre (FC) containing ribosomal deoxyribonucleic acid (rDNA) and RNA 
polymerase I subunits, 2) the dense fibrillar component (DFC), and 3) the granular 
component (GC) (Fig. 5.1 and 5.2). The nucleolus is the exclusive site of ribosome 
synthesis, but it performs a number of other functions, including regulation of mitosis, 
cell cycle arrest, and apoptosis in response to cellular stress via actions of nucleolar 
proteins on the levels of p53 (reviewed in Boisvert, F. M. et al. 2007). The nucleolus 
contains nucleolar organising regions (NOR) that are composed of clusters of rDNA 
repeat units. In man, there are approximately 400 copies of 43 kb repeat units distributed 
along chromosomes 13, 14, 15, 21, 22). Active NORs are a subset of NORs that are being 
actively transcribed, and are bound to the RNA pol I complex within the FC and the 
border zone between the FC and the DFC. RNA pol I, along with nucleolin and a number 
of other proteins that are localised to the FC and the DFC stain avidly with silver ions, 
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and the stained nucleoprotein complexes are known as AgNORs (Derenzini, M. 2000). 
The AgNOR area within nuclei is directly related to the size/abundance of nucleoli and 
the level of ribosome synthesis (Derenzini, M. 2000). 
 
Figure 5.1: This figure depicts the various sections of the nucleolus and associated molecular species. 
Within the FC or at the border between the FC and the DFC, rDNA is transcribed by the RNA pol I 
complex. The 45s rRNA then migrates to the DFC and then to the GC where various accessory proteins and 
enzymes process the rRNA precursor into the various mature rRNA species, and r-proteins bind, to form the 
  121
complete 40s and 60s ribosomal subunits.  These exit the nucleolus and form the complete ribosome in the 
cytoplasm where the process of protein translation occurs. Adapted from Boisvert, F. M. et al. (2007).  
 
Figure 5.2: Images of the nucleolus. 'a' is a differential interference contrast (DIC) image of a HeLa cell 
showing prominent nucleoli (indicated by arrows) within the nucleus. 'c' is another DIC image showing 
nucleoli purified from HeLa cells (inset is a scanning electron microscopy (EM) image of same). 'd' is a 
transmission EM image of a uranyl-acetate-stained cell section showing a nucleus with a nucleolus inside 
(labelled 'Nu'). 'e' is an electron spectroscopic image with phosphate enrichment showing nucleoplasm with 
a nucleolus with its distinct sections indicated: FC, DFC and GC. Adapted from Boisvert, F. M. et al. 
(2007).  
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As discussed in previous chapters, if the haemodynamic load increases, LV 
cardiomyocytes engage in hypertrophy/hyperplasia to increase the available contractile 
tissue, to meet the increased load. A paradigmatic example of this is the 
hypertrophy/hyperplasia that occurs after the loss of LV mass during an MI (Beltrami, A. 
P. et al. 2001). However, during end-stage HF of any particular aetiology, given the 
decrease in 45s rRNA and r-protein expression (at least at the mRNA level) that was 
observed in this study (Chapter 4), I hypothesised that the LV myocardium makes the 
compromise of diverting all available ATP to contraction and deprioritises ribosome 
synthesis which is energetically costly, as a strategy to maximise cardiac output in the 
short-term. If this is correct, one might expect to see a decrease in abundance of nucleoli 
in the LV cardiomyocyte nuclei of patients with end-stage HF, regardless of aetiology. 
This was assessed by quantifying the area of silver-stained AgNORs in LV samples from 
patients with end-stage HF of various aetiologies and comparing with LV samples from 
NF hearts.  
 With age, it has already been demonstrated that r-protein mRNA synthesis is 
decreased with age, and there is lower r-protein mRNA synthesis in males versus females. 
However, 45s rRNA synthesis was not found to decrease with age, nor differ by sex. 
Neither were protein levels of RPS18 shown to decrease with age or differ by sex. 
Regardless, the effect of age and gender on AgNOR staining area in NF LV was also 
assessed. 
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5.2 Methods 
5.2.1 Patient Demographics 
In the first part of this study, AgNO3 staining (for AgNOR area) was carried out on LV 
samples from 34 NF subjects, age range: 2 months to 66 years, to determine if abundance 
of nucleoli was altered with age or sex. Of these 33, there were 15 females, mean age: 
37.3, SD: 14.1 years and 18 males, mean age: 35.5, SD: 17.6 years.  In the second part of 
this study, AgNO3 staining was carried out on LV samples from 8 NF subjects (mean age: 
38.3, SD: 13.4 years, 6 females and 2 males), and 19 IDCM (mean age: 43.6, SD: 14.1 
years, 4 females and 15 males), 3 HCM (mean age: 45.7, SD: 4.2 years, 3 females), and 
11 ISCM (mean age: 54, SD: 6.6 years, 11 males) patients with end-stage HF to 
determine if abundance of nucleoli was altered in different forms of end-stage HF. For 
details regarding the collection of human heart tissue see Section 2.1.  
 
5.2.2 Tissue Microarray Construction 
To construct the tissue microarrays (TMA), samples of human LV stored in liquid 
nitrogen were slowly thawed to reduce damage from ice crystal formation. This was done 
by removing the samples in cryotubes from liquid nitrogen storage and placing them 
immediately onto dry ice, making sure that the cryotubes were completely covered. After 
45 minutes of dry ice incubation, the cryotubes were transferred to wet ice, and incubated 
for a further 30 minutes. The tissue was then removed from the cryotubes and cut into 1 
cm cubed pieces and incubated in 5% phosphate buffered formaldehyde for 24 to 36 
hours. The fixed tissue samples were then embedded in paraffin and 1 mm diameter cores 
  124
were taken and embedded in a separate paraffin block in a regular grid pattern. 4 μm 
thick sections were cut from these blocks of assembled cores and affixed to a glass slide. 
These sections were stained as described below within 48 hours of sectioning.  
 
5.2.3 AgNO3 Staining 
All the following steps were carried out at room temperature in a chemical fume hood 
unless otherwise stated. TMA staining with AgNO3 was carried out as described in Trere, 
D. (2000) with some modifications. The slides were dewaxed and hydrated as follows: 2 
x 5 minutes in histolene, 2 x 2 minutes in 100% EtOH, 1 x 2 minutes in 90% EtOH, 1 x 5 
minutes in 70% EtOH, 2 minutes in 50% EtOH, 2 x 2 minutes in reverse osmosis (RO) 
water. An antigen retrieval step was then performed, with the slides immersed in 0.01 M 
sodium-citrate monohydrate, pH 6.0 and incubated at 120° C for 20 minutes in a wet 
autoclave. The slides were allowed to return to room temperature and then rinsed 3 times 
in RO water for 1 minute. Immediately before use, 2 parts of 50% AgNO3 solution was 
mixed with 1 part of 2% gelatin plus 1% formic acid solution. Both solutions were at 25° 
C. The slides were then incubated in this solution for 15 minutes at 25° C in a dark, 
humidified chamber. After this incubation, slides were washed three times in RO water, 
agitating for 1 minute in each wash. To improve stain specificity, the slides were then 
incubated for 5 minutes in 5% sodium-thiosulfate, after which they were washed three 
times in RO water as above (Lindner, L. E. 1993). The slides were then dehydrated and 
cleared as follows: 1 x 5 minutes in 70% EtOH, 1 x 2 min in 90% EtOH, 2 x 2 min in 
100% EtOH, and 2 x 10 minutes in histolene. The slides were mounted in DPX and 
stored at room temperature in the dark and imaged within 48 hours. 
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5.2.4 Imaging and Quantification of AgNO3 Staining 
The AgNO3 stained LV samples were imaged using a DMRBE Microscope (Leica) 
controlled by Microscope and Stereo Investigator V8 (MBF Biosciences). The procedure 
was as follows: at 5 x magnification, contours were drawn around each LV section 
present on the TMA and labelled with a serial number that permitted blinding of the 
observer to the clinical details of the section. Then at 63 x magnification, five randomly 
located images were taken from each section (Figs. 5.3 and 5.5). If an image contained 
greater than ~ 20% empty space due to a split or missing section, or large blood vessel, a 
new random location was imaged. All sections to be analysed together were imaged on 
the same day with the same microscope settings to ensure similar overall intensity of 
images, and thus comparability in quantification and analysis. 
 Each image, five per tissue section, was analysed in Metamorph V7.6 (Molecular 
Devices). Given that AgNO3 is not a specific stain, and that some extracellular staining is 
common (Fig. 5.3), it was necessary to ensure that only AgNO3 stained regions within 
nuclei were included in the quantification. Nuclei were identified by their pale diffuse 
beige staining (Fig. 5.3), and regions were manually drawn around each nucleus 
identified. A threshold was set for all images, and pixels darker than said threshold were 
defined as being occupied by the argyrophilic proteins that stain with AgNO3 and that 
make up the AgNOR (Trere, D. 2000).  
 For each image, for each identified nucleus, the nuclear area (μm2) and AgNOR 
area (μm2) were recorded. The values for each nucleus were summated to give a total 
nuclear and total AgNOR area (in μm2) for each image. The mean nuclear area and 
AgNOR area among the five images for a particular LV section (i.e. a particular LV 
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sample) were computed. AgNOR area is thus a quantitative measure of the amount of 
AgNOR present per unit volume of heart tissue. These two values for each particular LV 
section were also used to compute AgNOR area / nuclear area to give a value that 
represents the proportion of nuclear area occupied by AgNOR material for each LV 
section. This was done in order to gain a quantitative measure of AgNOR area that was 
not affected by the area of nucleus present on each different section thus reducing 
sampling error introduced by taking random tissue sections from each LV samples with 
varying amounts of nuclei present. This measure would also represent the amount of 
AgNOR present per nucleus, rather than per unit volume of tissue. 
 
5.2.5 Statistical Analysis 
In order to investigate changes in AgNOR and nuclear area with age and sex, a linear 
model was applied with the dependent variables: AgNOR area, nuclear area, AgNOR area 
/ nuclear area, and covariates: age and sex. To investigate changes in AgNOR and nuclear 
area with end-stage HF, the mean and SD of AgNOR area, nuclear area, AgNOR area / 
nuclear area, were calculated for each group of patients (IDCM, HCM and ISCM) and 
compared with NF hearts using a two-tailed, unpaired Student's t-test assuming 
homogeneity of variance between groups. For all statistical tests, a p-value of < 0.05 was 
considered significant.  
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5.3 Results 
5.3.1 Effects of Age and Gender on AgNOR Abundance 
Across all NF subjects, mean AgNOR area was 6672.0 μm2 (SD: 8960.2), mean nuclear 
area was 67487.6 μm2 (SD: 34169.6 μm2), and mean AgNOR area / nuclear area was 
0.082 (SD: 0.065) (Fig. 5.3).  
 Regarding the effects of age on AgNOR area, there was a statistically significant 
decrease in AgNOR area with increasing age (-223.9 μm2 per year, p-value = 0.01, Fig. 
5.4). However, excluding subjects < 20 years old, there was no significant change in 
AgNOR area with age (79.7 μm2 per year, p-value = 0.10). There was a decrease in 
nuclear area with age (-767.6 μm2 per year, p-value = 0.02) (Appendix D, Fig. D.1). 
However, again, once NF subjects < 20 years old were excluded, there was no decrease in 
nuclear area with age (-4.0 μm2 per year, p-value = 0.99). Finally, there was no change in 
AgNOR area / nuclear area with age in NF subjects (-0.001 per year, p-value = 0.10), and 
in the subset of NF subjects greater than 20 years old (0.001 per year, p-value = 0.12) 
(Appendix D, Fig. D.2). 
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Figure 5.3: AgNO3 stained images of NF LV samples. Clockwise from upper left: 25 year old female, 55 
year old female, 65 year old male, and 19 year old male. Note the darkly staining nucleoli present within 
lightly staining, beige nuclei. 
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Figure 5.4: Plot illustrating mean AgNOR area (in μm2) versus age (in years) in NF hearts (n = 33). LV 
samples from females in red, males in blue. The least-squares regression lines for relationship between age 
and mean AgNOR for all NF hearts (yellow), and for subset of NF subjects >= 20 years old (green) are 
depicted. Asterisk indicates p-value < 0.05 for linear relationship between age and mean AgNOR area 
(controlled for gender). Nil statistically significant changes of mean AgNOR area with age (in subset of NF 
subjects >= 20 years) and gender were observed (p-values > 0.05 for both analyses). 
 
Gender had no effect on AgNOR area (3249 μm2 higher in females, p-value = 0.27), 
controlling for age (Fig. 5.4). This lack of effect was similar in the subset of NF subjects 
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greater than 20 years old (2032.1 μm2 higher in females, p-value = 0.07). Gender had no 
effect on nuclear area (18382.3 μm2 higher in females, p-value = 0.10), and neither did 
gender have an effect in the subset of NF subjects greater than 20 years old (18316.0 μm2 
higher in females, p-value = 0.08) (Appendix D, Fig. D.1). Finally, there was no change 
in AgNOR area / nuclear area with gender in NF subjects (0.011 higher in females, p-
value = 0.63), nor with subset of NF subjects greater than 20 years old (0.016 higher in 
females, p-value = 0.36) (Appendix D, Fig. D.2). 
 
5.3.2 Effect of End-Stage HF on AgNOR Abundance 
There was no difference between IDCM samples and NF samples with respect to mean 
AgNOR area (4126.3 versus 3436.6 μm2, p-value = 0.56, Fig. 5.6), mean nuclear area 
(77618.7 versus 75171.7 μm2, p-value = 0.86), and mean AgNOR area / nuclear area 
(0.051 versus 0.046, p-value = 0.71). 
 Mean AgNOR area was lower in ISCM samples compared with NF samples 
(1487.5 versus 3436.6 μm2, p-value = 0.02, Fig. 5.6), and similarly, mean AgNOR area / 
nuclear area was lower in ISCM samples compared with NF samples (0.022 versus 0.046, 
p-value = 0.04). There was no difference in mean nuclear area between ISCM and NF 
samples (62025.1 versus 75171.7 μm2, p-value = 0.37). 
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Figure 5.5: AgNO3 stained images of LV samples. Clockwise from upper left: 33 year old male NF donor, 
29 year old male IDCM, 41 year old female HCM, and 59 year old male ISCM. Note the darkly staining 
nucleoli present within lightly staining, beige nuclei. 
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Figure 5.6: Plot illustrating mean AgNOR area (in μm2) in the LV from patients with end-stage HF (ISCM, 
n = 11; HCM, n = 3; IDCM, n = 19) versus NF subjects (n = 8). Asterisks indicate statistically significant 
decreases (p-value < 0.05) for comparison with NF patients.  
 
Mean AgNOR area was lower in HCM samples compared with NF samples (1104.267 
versus 3436.6 μm2, p-value = 0.03, Fig. 5.6), however, mean AgNOR area / nuclear area 
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was not different between HCM and NF samples (0.021 versus 0.046, p-value = 0.21). 
There was no difference in nuclear area in HCM samples compared to NF samples 
(40338.7 versus 75171.7 μm2, p-value = 0.09). 
 
5.4 Discussion 
The AgNOR quantification method did not distinguish between the various cell types 
within the LV myocardium, however, given that cardiomyocytes make up the vast 
majority of myocardial tissue in terms of volume, it will be henceforth assumed that the 
changes in AgNOR abundance are occurring in the cardiomyocyte compartment for the 
purpose of interpretation of results. 
 We observed an effect of age on the abundance of AgNOR in NF hearts, however, 
this effect was not observed within the subset of NF patients greater than 20 years old. If 
AgNOR abundance can be taken as an indicator of nucleolar abundance, and more 
importantly, an indicator of rate of ribosome synthesis, then no histological evidence was 
obtained of a change in ribosome synthesis with age in adulthood. Neither was there any 
effect of gender observed on AgNOR area, nucleolar abundance, and by inference, 
ribosome synthesis. However, this does not preclude there being a difference in the 
potential to increase ribosome synthesis via increasing nucleolar capacity at different 
ages, and in males versus females, when haemodynamic load is increased.  
 Given the absence of a demonstrable effect of age or gender on the AgNOR area 
in NF hearts, it was deemed unnecessary to age and gender match the comparisons of NF 
hearts with end-stage HF hearts of IDCM, HCM, and ISCM aetiologies. 
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In end-stage ISCM, a statistically significant decrease in AgNOR abundance per unit 
volume of LV tissue was observed. This finding accords with Mamaev N. N. et al. (1998) 
who found lower AgNOR numbers in patients with more severe ISCM, as compared with 
NF hearts. With respect to end-stage HF in HCM patients, there also seems to be a 
decrease in AgNOR abundance per unit volume of heart tissue. Note that there was no 
difference in AgNOR volume per volume of nucleus in end-stage HCM LV versus LV 
from NF hearts. However, given the reduced volume of nuclei per unit volume of LV 
tissue, there was a reduced amount of nucleoli for the amount of LV contractile tissue that 
must be maintained. These data accord with the results of Chapter 4 which demonstrated 
the decreased synthesis of r-protein mRNA and 45s rRNA in end-stage HF from ISCM, 
IDCM, and HCM. However, in these experiments, end-stage IDCM does not seem to be 
associated with a decrease in AgNOR abundance compared to NF LV, the reasons for 
which are unclear.  
 There are several limitations to these studies. The first is the AgNOR staining 
technique, and subsequent quantification, did not distinguish between AgNOR located 
within cardiomyocytes, fibroblasts, endothelial cells, smooth muscle cells, or other cells 
present in the myocardium. To demonstrate that reduced AgNOR abundance is occurring 
in end-stage HF within the cardiomyocyte compartment would require the use of a 
staining protocol that allows for the positive identification of cardiomyocytes, such as 
using an antibody to cardiac actin or troponin, linked to a secondary antibody conjugated 
to a fluorophore or horseradish peroxidase, in order to direct the subsequent 
quantification to cardiomyocytes only. Another limitation relates to the location of 
samples of myocardial tissue within the LV in each patient. Within hearts from patients 
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with end-stage ISCM, there are commonly macroscopic regions of infarcted tissue, 
sampling of which, will yield mostly fibrotic tissue devoid of cardiomyocytes. A 
considerable effort was made to avoid sampling from macroscopically fibrotic regions of 
LV myocardium, which are clearly distinguishable from non-infarcted myocardium. 
However, it is more difficult to ensure that LV myocardial samples used for preparation 
of the TMAs do not contain smaller regions of fibrosis, too small to be appreciable by the 
naked eye, and that these minute fibrotic regions were not incorporated into the tissue 
sections used for AgNOR quantification. This methodological limitation is shared by the 
studies in Chapter 4, but is potentially more severe in this study, as the volume of LV 
myocardium sampled is much smaller, and thus, more likely to be affected by the 
incorporation of regions of fibrotic tissue which may in the worst case, make up the entire 
tissue section leading to the analysis being invalid for that sample. The use of a 
cardiomyocyte-specific stain to positively identify cardiomyocytes as suggested above 
would be expected to circumvent this, as one could then readily identify a tissue section 
containing only, or mostly fibrotic tissue, and exclude that section from the analysis.  
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Chapter 6: General Discussion and 
Future Work 
 
There remains a lot of additional experimental work that will be required in order to 
make solid the contention that ribosome synthesis is downregulated with age, and in the 
presence of end-stage HF, and that there is upregulation with mechanical unloading of the 
LV in patients with end-stage HF. The mRNA changes in r-protein expression have to be 
confirmed at the protein level, and this will require further Western blotting with 
antibodies targeted to multiple r-proteins, not just RPS18, which was focussed on in this 
thesis. In addition, an analysis of r-protein and 45s rRNA levels in LV samples from 
patients pre- and post-LVAD insertion will need to be carried out as well. The limitations 
imposed by protein extraction leading to the necessity of measuring the abundance of r-
protein levels relative to total protein, which similarly affects 45s rRNA quantitation, 
have been discussed previously in Section 3.4.1. Another approach would be to use 
immunofluorescence/immunohistochemistry with tissue sections from LV to quantify 
changes in r-protein levels with age, sex, HF, and pre- and post-LVAD support. This 
would also allow the quantitation of changes in r-proteins in particular cell types (with 
appropriate cell-specific antibodies), and thus allow us to confirm that changes in 
ribosome abundance occur in cardiomyocytes, rather than in other cell types. The 
quantity of fibrotic tissue (both diffuse and focally distributed) is increased in LV from 
patients with end-stage HF (De Leeuw, N. et al. 2001), and cardiac fibroblasts may have 
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reduced amounts of ribosome synthesis due to their particular roles in cardiac tissue. If 
this is the case, then the reduced ribosome synthesis demonstrated in the above 
experiments may have been partly due to a greater proportion of fibrotic tissue in LV 
samples from end-stage HF patients versus NF donors. This illustrates the importance of 
follow up experiments of a nature suggested above. The disadvantage of 
imunofluorescence and immunohistochemical analyses is however, that issues 
surrounding the sampling of minute amounts of myocardial tissue would then arise as 
discussed in Section 5.4. On another note, as r-proteins produced may not necessarily be 
incorporated into functional ribosomes, direct assessment of intact ribosome abundance 
per unit volume/weight of LV tissue should be carried out using a method similar to Earl, 
D. C. and Morgan, H. E. (1968). Nevertheless, this thesis has demonstrated evidence of a 
decrease in 45s rRNA abundance in ISCM, IDCM, and HCM suggesting that ribosome 
synthesis is decreased in end-stage HF. And this was supported indirectly by the 
demonstration of decreased nucleolar abundance, at least in end-stage ISCM and HCM. 
 The mechanistic basis for the changes in rRNA and r-protein mRNA in the 
various pathological states examined in this thesis is still unclear. It was mentioned earlier 
in Chapters 3 and 4 that changes in RHEB and mTOR activity may underlie these 
changes. The AMP activated protein kinase (AMPK) is an intracellular enzyme activated 
by energy depletion, manifested as an increase in AMP relative to ATP (Horman, S. et al. 
2012). HF, as has been discussed in this thesis, and reviewed in Ten Hove and Neubauer 
(2007), is a state that is associated with energy depletion within the cardiomyocyte. 
Specifically, there seems to be reduced concentrations of ATP and phospho-creatine 
within cardiomyocytes in end-stage HF, however, in less severe HF, ATP can be normal, 
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but there is decreased phospho-creatine and decreased flux through the creatine 
phosphate pathway (Weiss, R. G. et al. 2005; Smith, C. S. et al. 2006). Therefore, there is 
decreased ATP reaching the myofibrils leading to impaired contractility, and also 
presumably, decreased energy delivery to other cellular structures. AMPK can act to 
ameliorate cellular energy levels by inhibiting the action of mTOR and the downstream 
hypertrophic response (Horman, S. et al. 2012). One of the effects of mTOR inhibition is 
to decrease ribosome synthesis by interfering with mTOR-dependent transcription of 
rRNA and r-protein mRNA (Mayer, C. and Grummt, I. 2006). A decrease in mTOR 
mRNA was not detected in ageing nor in end-stage HF, but as mentioned in Section 3.4.2, 
this does not preclude a change in mTOR activity via changes in protein abundance or 
activation. mTOR is activated by the binding of RHEB-GTP, a binding which is 
antagonised by Tuberous Sclerosis Complex-1 (TSC1), a GTPase activating protein that 
acts on RHEB. Akt/Protein kinase B, a downstream effector of the insulin/Igf-1 
receptor/phosphoinositide 3-kinase pro-hypertrophy pathway, inhibits TSC1 GTPase 
activity, thereby increasing RHEB-GTP abundance, and mTOR activity. AMPK, on the 
other hand, disinhibits TSC1 GTPase activity, leading to repression of mTOR activity. 
The analysis of the protein abundance and activities of these various cellular mediators in 
ageing, between genders, and HF deserves further study. 
 A major limitation of the work presented in this thesis is the inability to 
distinguish cause from effect. Many changes at the transcriptomic, proteomic, and 
nuclear level have been described that are associated with end-stage HF. However, it is 
difficult to determine whether these changes are further upstream, that is, they were 
involved in the initiation of the evolution of HF, or further downstream. That is, that they 
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came after the HF phenotype began to be established, perhaps representing compensatory 
changes. The distinction is important, as the more upstream a change is, the more likely 
that intervention to reverse that change will lead to reversal of the HF phenotype. Or 
perhaps, the greater will be the magnitude of amelioration of the HF phenotype to be 
achieved. On the other hand, intervention to reverse phenotypic changes associated with 
HF that are in fact compensatory, would have the unintended effect of worsening the 
magnitude of the HF condition. It has been hypothesised in this thesis that ribosome 
synthesis is downregulated in the presence of end-stage HF, as a potentially 
compensatory mechanism designed to conserve energy, in order to keep available 
maximal amounts of ATP to be used for force production. And while this compensatory 
change is beneficial in the short term, over the long term, it might exacerbate the primary 
defect of decreased force production by leading to the net loss of myofibrils per unit mass 
of myocardial tissue and/or the accumulation of myofibrillar components with post-
translational modifications which renders them less able to efficiently generate force.  
Decreased turnover of cellular proteins would be expected of course to affect a myriad of 
cellular activities. Nevertheless, one can consider such a downregulation of ribosome 
synthesis as compensatory. Thus, if one were to intervene pharmacologically to increase 
ribosome synthesis, such as by designing a small molecule to decrease RHEB GTPase 
activity thus leading to increased mTOR activity, it might worsen the energy status of a 
cardiomyocyte and provoke acute LV failure and death from circulatory insufficiency or 
ventricular arrhythmia. With respect to female gender, it was hypothesised in Chapter 3 
that increased ribosome synthesis might improve HF via increased hypertrophy and 
hyperplasia, however, this contradicts the ribosome synthesis as detrimental argument put 
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forth here. It is possible that increased ribosome synthesis and associated 
hypertrophy/hyperplasia of cardiomyocytes is beneficial at earlier stages of the evolution 
of the HF phenotype, when the energetic status of the cardiomyocyte is more favourable. 
On the other side of the energy availability spectrum, viable LV myocardium in patients 
post MI in the absence of HF seems to exhibit nil deficits in ATP, phospho-creatine, and 
flux through the creatine kinase pathway (Bottomley, P. A. et al. 2009). Therefore, 
promotion of ribosome synthesis within cardiomyocytes in this clinical scenario may 
facilitate increased hypertrophy/hyperplasia, and thus a more complete replenishment of 
the deficit of contractile tissue, with a decrease in the probability of HF eventually 
supervening. 
 What has been missed from the analyses undertaken in this thesis is the changes 
in the RV that occur with age, gender, end-stage HF, and LVAD implantation. How the 
RV responds to the contractile dysfunction of the LV determines the clinical course of 
HF, and a repeat of the above studies in the RV would add much insight into the 
pathophysiology of HF, and how it is modified by age, sex, and LVAD implantation. As 
an example, it was noted earlier that female RV is more resistant to the effects of LV 
systolic dysfunction compared with male RV (Martinez-Selles, M. et al. 2006). Perhaps it 
is greater ribosome synthesis and associated greater capacity for hypertrophy/hyperplasia 
of the RV cardiomyocytes in the context of LV failure, that contributes to the better 
prognosis of HF in women.  
 To restate the overarching proposal of this thesis, in end-stage HF, ribosome 
synthesis is not pragmatic, and it is inhibited, whether through the AMPK pathway 
described above, or through another pathway that awaits description. However, in concert 
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with mechanical unloading of the LV with an LVAD, the promotion of ribosome synthesis 
becomes energetically feasible, and turnover of damaged myofibrillar components can be 
promoted, as well as the addition of more myofibrils. And thus, increasing the likelihood 
of recovery of LV myocardium and the ability to successfully wean the patient from 
mechanical support without recourse to transplantation. LVAD implantation however, 
does not usually lead to sufficient myocardial recovery to allow LVAD removal without 
subsequent transplantation (Birks, E. J. 2010), and this may be due to insufficient 
recovery such that the LV myocardium cannot “stand on its own”. It may also be related 
to the myocardial atrophy that occurs with prolonged unloading (Amebardekar and 
Buttrick, 2011). Hall, J. L. et al. (2007) describe a strategy of LVAD implantation 
combined with administration of Clenbuterol, a ß2-adrenergic agonist which promotes 
hypertrophy, and which resulted in the majority of patients achieving sufficient 
myocardial recovery to be weaned from LVAD support with sustained recovery. They 
report that among the many transcriptional changes associated with myocardial recovery 
was an increase in mRNA expression of Ribosomal protein 6 (Hall, J. L. et al. 2007), plus 
increased protein expression of myofibrillar proteins including sarcomeric actin and 
myosin heavy chain (Latif, N. et al. 2007). Clenbuterol has been shown to act through 
activation of mTOR (Kline, W. O. et al. 2007), thus one of its many actions may be to 
stimulate ribosome synthesis, with increased ribosome synthesis only being beneficial in 
the context of the favourable energy status of the unloaded cardiomyocyte.  
 This thesis has presented novel data on the effect of age and gender on the cardiac 
transcriptome, interpretation of which has only just begun. From my initial attempt at 
interpreting this trove of data, I was led to examine ribosome gene expression in HF. 
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From these studies has arisen my suggestion that the promotion of ribosome synthesis in 
LV myocardium post MI, or subject to other insults likely to lead to HF, may improve the 
clinical course, or perhaps even prevent the development of HF entirely. This is an 
avenue of research that I believe is worthy of further investigation, and will hopefully 
assist in the understanding and future treatment of this terrible illness. 
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Appendix A: Further Details of Western 
blot of RPS18 
 
Figure A.1: Full Western blot demonstrating the specificity of the rabbit anti-RPS18 (1:500) and IRDye800 
donkey anti-rabbit IgG (1:10000) (Li-Cor) used in the experiments described in Chapters 3 and 4. Note, the 
bright band at ~ 17kDa which represents the predominant splice form of RPS18 denoted as 
ENSP00000211372. There is also a faint band at ~ 10 kDa which may correspond to the smaller 
alternatively spliced forms ENST00000476288 and ENST00000477055 which weigh approximately 9.7 
kDa.  
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Appendix B: R code to Generate the 
Results of Chapter 3 
 
# Code to analyse the raw images of the microarrays analysing the effects of age and 
# sex on the human LV myocardium, 'morris' is the name of the dataset I used. #  
# signifies the beginning of a comment, and > signifies the beginning of output of the 
# R environment 
library(limma) 
morristargets <- readTargets() 
RG <- read.maimages(morristargets,source="genepix.median", columns=list(R='F532 
Median', G='F635 Median', Rb='B532 Median', Gb='B635 Median'), 
wt.fun=wtflags(weight=0,cutoff=-40) ) 
RG$genes <- readGAL('223272_low.gpr') 
RG$printer <- getLayout(RG$genes) 
RG <- backgroundCorrect(RG, method="normexp", offset=50) 
MA <- normalizeWithinArrays(RG) 
remove(RG) 
morrisnormaldata <- normalizeBetweenArrays(MA, method='scale') 
remove(MA) 
# To eliminate genes/probes with fewer than 13 arrays that were analysable 
vectorofweightsums<-c() 
for (count in 1:20160) { 
 vectorofweightsums[count]<-sum(morrisnormaldata[count,]$weights); 
} 
morrisnormaldata<-morrisnormaldata[vectorofweightsums>13,] 
ageofmorris <- c( 19, 48, 37, 8, 37, 31, 39, 55, 50, 19, 41, 39, 23, 39, 47, 52, 40, 8, 55, 
37, 53, 42, 23, 65, 44, 17, 4, 25, 26, 21, 36, 45, 50, 49, 49, 56, 24, 51, 52, 49, 52, 48, 53, 
50, 60, 49, 65, 52, 65, 34, 27, 23, 56, 52, 48, 54, 61 ) 
sexofmorris <- c( 1, 0, 0, 1, 1, 0, 1, 1, 1, 0, 1, 1, 1, 0, 0, 1, 0, 1, 0, 1, 0, 0, 1, 0, 1, 1, 1, 0, 1, 
1, 0, 0, 0, 0, 1, 1, 0, 0, 1, 1, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 1, 1 ) 
sexofmorris<-factor(sexofmorris) 
morrisdesignwithageandsex<-model.matrix(~1+ageofmorris+sexofmorris) 
# To map probes on the array to Genbank Accessions and gene symbols 
oligoIDmappingtoaccnoandsymbol<-read.table('platefile_set_human_40k_a updated 24-
7(mapbetweenoligoIDandaccandsymbol).txt', header=TRUE, comment.char='', 
fill=TRUE, as.is=TRUE) 
position<-NA 
morrisnormaldata$genes[,6]<-'' 
morrisnormaldata$genes[,7]<-'' 
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for (count in 1:18725) { 
 position<-match(morrisnormaldata$genes[count,]$Name, 
oligoIDmappingtoaccnoandsymbol[,1]); 
 if (is.na(position)==FALSE) { 
  morrisnormaldata$genes[count,][6]<-
oligoIDmappingtoaccnoandsymbol[position,2]; 
  if (oligoIDmappingtoaccnoandsymbol[position,3]!='') { 
   morrisnormaldata$genes[count,][7]<-
oligoIDmappingtoaccnoandsymbol[position,3]; 
  } 
 } 
} 
fit<-lmFit(morrisnormaldata, morrisdesignwithageandsex, method='robust', 
weights=morrisnormaldata$weights) 
fit_morris_robust_ageandsex<-eBayes(fit) 
 
# Genes DE by age in morris dataset 
topTable(fit_morris_robust_ageandsex, coef=2, adjust.method='fdr', sort.by='p') 
> topTable(fit_morris_robust_ageandsex, coef=2, adjust.method='fdr', sort.by='p') 
      Block Column Row              Name         ID         X       Y 
12138    16     34  12 obshum40K:A#03640 R087X31N20  AC099849         
3497      5      5  10 obshum40K:A#38527 R087X24L15    D26309   LIMK1 
15707    21     33   4 obshum40K:A#01722 R087X10L23 NM_005493  RANBP9 
18150    24     35   6 obshum40K:A#00108 R087X16B12 NM_016258  YTHDF2 
5368      7     22  17 obshum40K:A#16129 R087X44H04 NM_152729 NT5C2L1 
12005    16     23   9 obshum40K:A#02956 R087X23J08 NM_004861 GAL3ST1 
13570    18     36   9 obshum40K:A#15573 R087X24M09 NM_005990   STK10 
18584    24     18  17 obshum40K:A#15414 R087X44E12  AL591049   SMAP1 
16043    21     12  13 obshum40K:A#05139 R087X33O11  AJ697971     DMN 
11917    16     11   7 obshum40K:A#03540 R087X17J08 NM_006068    TLR6 
      Autoflag        logFC   AveExpr         t      P.Value    adj.P.Val 
12138        0 -0.007973793  9.103289 -6.266751 4.487831e-08 0.0008403464 
3497         0  0.008644958  7.904247  5.447169 1.022341e-06 0.0054040497 
15707        0 -0.006477321  8.358934 -5.498570 1.041983e-06 0.0054040497 
18150        0 -0.007603734 10.307823 -5.435749 1.154403e-06 0.0054040497 
5368         0  0.012972163  6.806192  5.467508 3.154007e-06 0.0112941449 
12005        0  0.005390781  9.204738  5.102795 3.672385e-06 0.0112941449 
13570        0 -0.007734021 10.687705 -5.073405 4.222110e-06 0.0112941449 
18584        0 -0.005920532  9.826926 -4.938095 7.112319e-06 0.0133314569 
16043        0  0.012258514  7.939211  4.902338 7.854412e-06 0.0133314569 
11917        0 -0.008534027  7.175146 -4.904815 8.261021e-06 0.0133314569 
             B 
12138 6.773747 
3497  3.684540 
15707 3.722891 
18150 3.559436 
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5368  2.950821 
12005 2.422923 
13570 2.256258 
18584 1.772172 
16043 1.662008 
11917 1.661993 
 
# Genes DE by gender in morris dataset 
topTable(fit_morris_robust_ageandsex, coef=3, adjust.method='fdr', sort.by='p') 
> topTable(fit_morris_robust_ageandsex, coef=3,adjust.method='fdr', sort.by='p') 
      Block Column Row              Name         ID GenBankAccession    Symbol EntrezID    
10545    14      7  11 obshum40K:A#00370 R087X27I19        NM_004653     KDM5D     
3917      5     15  20 obshum40K:A#31044 R087X51D15        NM_032490 C14orf142     
4756      7      1   2 obshum40K:A#33211 R087X03K16        NM_004555    NFATC3      
1163      2     31  10 obshum40K:A#42285 R087X26A13        NM_001007     RPS4X    
4100      6     16   5 obshum40K:A#32152 R087X12N03        NM_016509    CLEC1B   
12878    17     40  11 obshum40K:A#01936 R087X29O21         AC073909      <NA>    
14033    19     18   1 obshum40K:A#04213 R087X02G10        NM_002705       PPL      
11108    15     41   5 obshum40K:A#07008 R087X14C08        NM_001935      DPP4      
4088      6      4   5 obshum40K:A#41890 R087X11M15         AC114728      <NA>      
5905      8     30  11 obshum40K:A#02247 R087X29E04        NM_005210     CRYGB  
     Autoflag      logFC   AveExpr         t      P.Value    adj.P.Val          B 
10545        0  0.4963692  7.280682  9.868835 4.525816e-14 8.474590e-10 18.2590272 
3917         0  0.5545661  6.474389  6.367254 7.317344e-07 6.850863e-03  3.4239464 
4756         0  0.2773713  7.334251  5.297860 1.785346e-06 1.114353e-02  4.4927331 
1163         0 -0.4079773 10.538454 -5.137514 3.232005e-06 1.512982e-02  4.0062178 
4100         0 -0.8186268  6.296784 -6.081798 1.051316e-05 3.937177e-02 -0.4888737 
12878        0 -0.2539324  8.244406 -4.566494 2.597469e-05 8.106269e-02  2.2053529 
14033        0  0.3979821  6.884447  4.456872 4.502707e-05 1.204474e-01  1.6798917 
11108        0  0.3532902  7.206123  4.315771 6.086523e-05 1.424627e-01  1.5119202 
4088         0 -0.3382081 11.419787 -4.216866 8.542671e-05 1.656005e-01  1.2454011 
5905         0  0.3452389  6.697315  4.378050 8.843816e-05 1.656005e-01  0.9588518 
 
# To prepare results in R in a format suitable for GSEA 
morris_unparsedgsealist<-topTable(fit_morris_robust_ageandsex, coef=2, 
number=18725, adjust.method='fdr', sort.by='p')[,c(6,59)] 
morris_parsedgsealist_accessions<-vector() 
morris_parsedgsealist_tstat<-vector() 
count2<-1 
for (count in 1:18725){ 
 if(morris_unparsedgsealist[count,1]!='') { 
  morris_parsedgsealist_accessions[count2]<-
morris_unparsedgsealist[count,1]; 
  morris_parsedgsealist_tstat[count2]<-morris_unparsedgsealist[count,2]; 
  count2<-count2+1; 
 } 
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} 
write.table(cbind(morris_parsedgsealist_accessions,morris_parsedgsealist_tstat), 
file='morris_outputforGSEA_12-12-12.txt', quote=FALSE) 
morris_sex_unparsedgsealist<-topTable(fit_morris_robust_ageandsex, coef=3, 
number=18725, adjust.method='fdr', sort.by='p')[,c(6,59)] 
morris_sex_parsedgsealist_accessions<-vector() 
morris_sex_parsedgsealist_tstat<-vector() 
count2<-1 
for (count in 1:18725){ 
 if(morris_sex_unparsedgsealist[count,1]!='') { 
  morris_sex_parsedgsealist_accessions[count2]<-
morris_sex_unparsedgsealist[count,1]; 
  morris_sex_parsedgsealist_tstat[count2]<-
morris_sex_unparsedgsealist[count,2]; 
  count2<-count2+1; 
 } 
} 
write.table(cbind(morris_sex_parsedgsealist_accessions,morris_sex_parsedgsealist_tstat), 
file='morris_sex_outputforGSEA_12-12-12.txt', quote=FALSE) 
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Appendix C: R code to Generate Results 
of Chapter 4 
 
# Code to analyse the raw data of the datasets downloaded from GEO, note 'kittle'  
# refers to GSE1869, and that CEL file data was not available, however, RMA  
# normalised data was available and was used 
kittledata<-read.table("C:\\Users\\PC\\PhD 
Work\\FailingDatasets\\Kittleson\\GSE1869_series_matrix.txt", header=TRUE, 
row.names=1,skip=54, comment.char='',nrow=22283) 
kittledesign_donorvsidcm<-cbind(1, c(rep(1,times=19), rep(0,times=6), rep(1, times=2))) 
kittledesign_donorvsiscm<-cbind(1, c(rep(1,times=3), rep(0,times=6), rep(1, times=7))) 
fit_kittle_robust_donorvsidcm<-lmFit(kittledata[, c(1:6, 8, 10, 12:28, 30, 37)], 
kittledesign_donorvsidcm, method='robust') 
fit_kittle_robust_donorvsiscm<-lmFit(kittledata[, c(7, 9, 11, 23:29, 
31:36)],kittledesign_donorvsiscm, method='robust') 
fit_kittle_robust_donorvsidcm<-eBayes(fit_kittle_robust_donorvsidcm) 
fit_kittle_robust_donorvsiscm<-eBayes(fit_kittle_robust_donorvsiscm) 
 
# Genes DE in end-stage ISCM versus NF LV 
> topTable(fit_kittle_robust_donorvsidcm,coef=2,adjust='fdr') 
               ID      logFC   AveExpr          t      P.Value    adj.P.Val 
8596  209102_s_at  0.8840175  8.986377  12.399066 8.616383e-13 1.919989e-08 
5393    205866_at -1.5221263  7.341769 -10.383051 4.973918e-11 5.541691e-07 
4138  204611_s_at -0.4842209  8.127732  -7.716636 2.322949e-08 1.321488e-04 
8164  208668_x_at  1.1621169 10.563085   7.708178 2.372190e-08 1.321488e-04 
21312 221952_x_at  0.9433409  9.858593   7.613076 3.004988e-08 1.339203e-04 
1259  201731_s_at  0.4307075  8.558521   7.240787 7.666025e-08 2.440315e-04 
1904    202376_at -0.7853123  8.289966  -7.367447 5.563668e-08 2.066253e-04 
4095    204568_at  1.0003925  7.300749   7.010129 1.381099e-07 3.609888e-04 
17677 218312_s_at  0.9240990  9.068261   6.989015 1.458017e-07 3.609888e-04 
19106   219742_at -0.3919134  4.784997  -6.869670 1.982541e-07 4.364688e-04 
              B 
8596  17.557800 
5393  13.949030 
4138   9.028105 
8164   9.021230 
21312  8.822386 
1259   7.952384 
1904   7.917624 
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4095   7.412705 
17677  7.363570 
19106  7.080780 
 
# Genes DE in end-stage ISCM versus NF LV 
> topTable(fit_kittle_robust_donorvsiscm,coef=2,adjust='fdr') 
               ID      logFC  AveExpr         t      P.Value    adj.P.Val 
19153   219789_at  1.7538746 7.242307  14.16983 6.884091e-11 1.105273e-06 
1445  201917_s_at  1.0245718 7.308838  13.84627 9.920328e-11 1.105273e-06 
17677 218312_s_at  0.8518534 8.883968  12.05124 8.661532e-10 6.433497e-06 
18815   219451_at  0.6267327 6.844433  11.48202 1.818765e-09 1.013188e-05 
3083    203556_at  0.5977631 7.729432  11.23706 2.525257e-09 1.125406e-05 
5393    205866_at -1.6313376 7.400374 -10.85552 4.257585e-09 1.514361e-05 
12079 212694_s_at  0.8589279 8.882740  10.77576 4.757226e-09 1.514361e-05 
8500  209006_s_at  0.9014571 5.874810  10.30646 9.257348e-09 2.355099e-05 
2030    202502_at  0.8670620 9.408597  10.28765 9.512136e-09 2.355099e-05 
12116   212731_at  1.1135040 6.843720  10.08618 1.275194e-08 2.584573e-05 
             B 
19153 14.68710 
1445  14.36048 
17677 12.38881 
18815 11.64249 
3083  11.28296 
5393  10.95184 
12079 10.87365 
8500  10.31046 
2030  10.24301 
12116 10.01426 
 
# To prepare results in R in a format suitable for GSEA 
kittle_robust_donorvsidcm_gsealist<-topTable(fit_kittle_robust_donorvsidcm, coef=2, 
number=22283, adjust.method='fdr', sort.by='p')[,c(1,4)] 
write.table(kittle_robust_donorvsidcm_gsealist, 
file='kittle_robust_donorvsidcm_forGSEA_4-6-13.txt', quote=FALSE) 
kittle_robust_donorvsiscm_gsealist<-topTable(fit_kittle_robust_donorvsiscm, coef=2, 
number=22283, adjust.method='fdr', sort.by='p')[,c(1,4)] 
write.table(kittle_robust_donorvsiscm_gsealist, 
file='kittle_robust_donorvsiscm_forGSEA_4-6-13.txt', quote=FALSE) 
 
 
 
# Code used to analyse the GSE5406 dataset, referred to as 'hannen' in the R code,  
# RMA normalised data was available on GEO, but not the original CEL files. 
orderofhannen<-read.table('testfilewithorderofhannen.csv', header=TRUE, sep='/t') 
idcmcolumn<-vector(length=210, mode='integer') 
iscmcolumn<-vector(length=210, mode='integer') 
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normalcolumn<-vector(length=210, mode='integer') 
for (count in 1:210) { 
 if (orderofhannen[count]=='systolic heart failure due to idiopathic dilated 
cardiomyopathy') { idcmcolumn[count]<-1 } 
 if (orderofhannen[count]=='systolic heart failure due to ischemic 
cardiomyopathy') {  iscmcolumn[count]<-1 } 
 if (orderofhannen[count]=='normally functioning myocardium from unused donor 
heart') { normalcolumn[count]<-1 } 
} 
hannendesign <- cbind(idcm=idcmcolumn, iscm=iscmcolumn, donor=normalcolumn) 
hannendata<-read.table('GSE5406_series_matrix_onlydata.csv', header=TRUE, sep='\t', 
row.names=1) 
fit_hannen_robust<-lmFit(hannendata, hannendesign, method='robust') 
hannen_cont.matrix_donorvsidcm<-makeContrasts(donorvsidcm=idcm-
donor,levels=hannendesign) 
fit_hannen_robust_donorvsidcm<-
contrasts.fit(fit_hannen_robust,hannen_cont.matrix_donorvsidcm) 
fit_hannen_robust_donorvsidcm <-eBayes(fit_hannen_robust_donorvsidcm) 
topTable(fit_hannen_robust_donorvsidcm,adjust='fdr') 
 
# Genes DE in end-stage IDCM versus NF LV 
> topTable(fit_hannen_robust_donorvsidcm,adjust='fdr') 
               ID      logFC   AveExpr         t      P.Value    adj.P.Val        B 
7047  207526_s_at -1.8091431  4.573276 -19.36018 1.187360e-48 2.645795e-44 
95.49835 
21088 221728_x_at -1.5885808  5.653916 -17.79978 7.232666e-44 8.058275e-40 
86.69573 
1437    201909_at  2.5880562  9.010048  17.47978 7.114530e-43 5.284436e-39 84.58230 
19092   219728_at -2.8023243  6.114692 -17.15457 7.323068e-42 4.079498e-38 
82.79791 
1272  201744_s_at  2.2434212  8.319699  15.28665 5.434264e-36 2.421834e-32 
70.19260 
8164  208668_x_at  0.6765385 10.201308  15.16812 1.287892e-35 4.783018e-32 
69.40594 
1904    202376_at -1.4567002  7.140179 -14.19114 1.593979e-32 5.074091e-29 
62.59777 
21312 221952_x_at  0.6948184  9.372044  14.08513 3.452314e-32 9.615988e-29 
61.92468 
18451   219087_at  2.6595907  8.493023  12.60992 1.565044e-27 3.874874e-24 
51.55946 
17485 218120_s_at -0.8187126  7.713927 -12.55883 2.264216e-27 5.045353e-24 
51.20195 
 
hannen_cont.matrix_donorvsiscm<-makeContrasts(donorvsiscm=iscm-
donor,levels=hannendesign) 
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fit_hannen_robust_donorvsiscm<-
contrasts.fit(fit_hannen_robust,hannen_cont.matrix_donorvsiscm) 
fit_hannen_robust_donorvsiscm<-eBayes(fit_hannen_robust_donorvsiscm) 
topTable(fit_hannen_robust_donorvsiscm,adjust='fdr') 
 
# Genes DE in end-stage ISCM versus NF LV 
> topTable(fit_hannen_robust_donorvsiscm,adjust='fdr') 
               ID      logFC   AveExpr         t      P.Value    adj.P.Val        B 
7047  207526_s_at -1.8482103  4.573276 -19.90828 2.622899e-50 5.844607e-46 
98.58360 
21088 221728_x_at -1.6889882  5.653916 -19.33197 1.445975e-48 1.611033e-44 
96.69284 
1437    201909_at  2.7109691  9.010048  18.68814 1.327551e-46 9.860607e-43 
92.51320 
19092   219728_at -2.8185175  6.114692 -17.44234 9.301490e-43 5.181628e-39 
84.60529 
1272  201744_s_at  2.2228390  8.319699  15.34572 3.535390e-36 1.575582e-32 
70.51914 
8164  208668_x_at  0.6489695 10.201308  14.75237 2.663076e-34 9.890222e-31 
66.41658 
1904    202376_at -1.3993563  7.140179 -13.82144 2.359270e-31 7.510231e-28 
59.93677 
17485 218120_s_at -0.8423932  7.713927 -13.08752 4.915327e-29 1.369103e-25 
54.87007 
21312 221952_x_at  0.6347057  9.372044  13.03571 7.159100e-29 1.772514e-25 
54.48307 
5393    205866_at -1.3053055  6.948432 -12.56917 2.101093e-27 4.681865e-24 
51.14583 
 
# Code to prepare data in R in a format suitable for GSEA 
hannen_robust_donorvsidcm_gsealist<-topTable(fit_hannen_robust_donorvsidcm, 
number=22283, adjust.method='fdr', sort.by='p')[,c(1,4)] 
hannen_robust_donorvsidcm_gsealist[1:10,] 
hannen_robust_donorvsiscm_gsealist<-topTable(fit_hannen_robust_donorvsiscm, 
number=22283, adjust.method='fdr', sort.by='p')[,c(1,4)] 
hannen_robust_donorvsiscm_gsealist[1:10,] 
write.table(hannen_robust_donorvsidcm_gsealist, 
file='hannen_robust_donorvsidcm_forGSEA_4-6-13.txt', quote=FALSE) 
write.table(hannen_robust_donorvsiscm_gsealist, 
file='hannen_robust_donorvsiscm_forGSEA_4-6-13.txt', quote=FALSE) 
 
 
 
# Code to analyse GSE1145, referred to as 'tsubaki' in the code, CEL file data used 
setwd('C:/Users/PC/PhD Work/FailingDatasets/tsubaki/tsubakirawdata') 
tsubakidata_prerma<-ReadAffy() 
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tsubakidata_postrma<-rma(tsubakidata_prerma) 
> sampleNames(tsubakidata_postrma) 
 [1] "GSM18422_PA-D_102.cel.gz"   "GSM18423_PA-D_132.cel.gz"   "GSM18424_PA-
D_206.cel.gz"   
 [4] "GSM18425_PA-D_216.cel.gz"   "GSM18426_PA-D_225.cel.gz"   "GSM18427_PA-
D_229.cel.gz"   
 [7] "GSM18428_PA-D_317.cel.gz"   "GSM18429_PA-D_319.cel.gz"   "GSM18430_PA-
D_348.cel.gz"   
[10] "GSM18431_PA-D_374.cel.gz"   "GSM18432_PA-D_64.cel.gz"    "GSM18433_PA-
D_82.cel.gz"    
[13] "GSM18434_PA-D_85.cel.gz"    "GSM18435_PA-D_93_2.cel.gz"  
"GSM18436_PA-D_98.cel.gz"    
[16] "GSM18442_PA-N_112-1.cel.gz" "GSM18443_PA-N_118.cel.gz"   
"GSM18444_PA-N_148.cel.gz"   
[19] "GSM18445_PA-N_200.cel.gz"   "GSM18446_PA-N_249.cel.gz"   
"GSM18447_PA-N_291.cel.gz"   
[22] "GSM18448_PA-N_294.cel.gz"   "GSM18449_PA-N_300.cel.gz"   
"GSM18450_PA-N_322.cel.gz"   
[25] "GSM18451_PA-N_325.cel.gz"   "GSM18452_PA-N_326.cel.gz"   
"GSM18477_PA-S_115.cel.gz"   
[28] "GSM18478_PA-S_224.cel.gz"   "GSM18479_PA-S_233.cel.gz"   "GSM18480_PA-
S_242_2.cel.gz" 
[31] "GSM18481_PA-S_267.cel.gz"   "GSM18482_PA-S_281.cel.gz"   "GSM18483_PA-
S_297.cel.gz"   
[34] "GSM18484_PA-S_314.cel.gz"   "GSM18485_PA-S_342.cel.gz"   "GSM18486_PA-
S_386.cel.gz"   
[37] "GSM18487_PA-S_464.cel.gz"   
 
tsubakidesign_donorvsidcm<-cbind(1, c(rep(1, times=15), rep(0,times=11))) 
fit_tsubaki_robust_donorvsidcm<-lmFit(tsubakidata_postrma[,c(1:26)], 
tsubakidesign_donorvsidcm, method='robust') 
fit_tsubaki_robust_donorvsidcm<-eBayes(fit_tsubaki_robust_donorvsidcm) 
 
# Genes DE in end-stage IDCM versus NF LV 
> topTable(fit_tsubaki_robust_donorvsidcm, coef=2) 
               ID      logFC  AveExpr         t      P.Value    adj.P.Val        B 
45773   236523_at -4.6227193 7.567492 -27.82092 1.288230e-21 7.043396e-17 
36.93707 
39113   229858_at -1.4938703 8.011914 -25.09366 1.959383e-20 5.356463e-16 
35.76361 
23030   213729_at -0.9763122 9.862392 -22.90125 2.145350e-19 3.909901e-15 
33.64335 
17099 207657_x_at -1.1435069 9.750096 -22.13793 5.183982e-19 7.085855e-15 
32.92836 
48769   239519_at  1.2599927 6.694475  21.41696 1.223566e-18 1.337970e-14 
32.02839 
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21598   212291_at -1.4393077 9.090572 -20.68944 2.988798e-18 2.503164e-14 
31.34016 
19677 210276_s_at -0.9918418 9.663901 -20.63354 3.204782e-18 2.503164e-14 
31.12397 
44436   235186_at  0.8648023 8.293553  20.13054 6.049939e-18 4.134755e-14 
30.59439 
11420 201971_s_at -0.9745294 8.024087 -19.88239 8.320128e-18 5.054478e-14 
30.41472 
35846   226589_at -1.3596021 8.164026 -19.59583 1.207317e-17 6.601008e-14 
29.96952 
 
tsubakidesign_donorvsiscm<-cbind(1, c(rep(0, times=11), rep(1,times=11))) 
fit_tsubaki_robust_donorvsiscm<-lmFit(tsubakidata_postrma[,c(16:37)], 
tsubakidesign_donorvsiscm, method='robust') 
fit_tsubaki_robust_donorvsiscm<-eBayes(fit_tsubaki_robust_donorvsiscm) 
 
# Genes DE in end-stage ISCM versus NF LV 
> topTable(fit_tsubaki_robust_donorvsiscm, coef=2) 
               ID      logFC   AveExpr         t      P.Value    adj.P.Val        B 
21410   212103_at  0.7839567  8.949356  19.92283 5.482843e-16 2.997744e-11 
25.65043 
17626   208200_at -0.5864127  6.097769 -18.78325 1.966450e-15 5.125231e-11 
24.47230 
49061   239811_at  0.8839336  7.458833  18.47460 2.812198e-15 5.125231e-11 
24.44223 
41074   231819_at  1.5305821  7.467291  18.14914 4.124386e-15 5.637520e-11 
24.01004 
23030   213729_at -0.6171675 10.111086 -17.95400 5.203967e-15 5.690538e-11 
23.63777 
19667 210266_s_at  0.9479386  9.436008  16.73501 2.341908e-14 1.829197e-10 
22.43317 
28687 219402_s_at -0.8458126  9.426742 -16.81418 2.117975e-14 1.829197e-10 
22.40560 
13972   204524_at  0.8462012  8.018265  16.39469 3.624377e-14 2.301891e-10 
22.16183 
35669   226412_at  0.7967187  8.389042  16.36038 3.789122e-14 2.301891e-10 
21.98914 
44972   235722_at  2.0693767  8.012745  16.12968 5.119889e-14 2.544818e-10 
21.78297 
 
# Code to prepare data in R in a format suitable for GSEA 
tsubaki_robust_donorvsidcm_gsealist<-topTable(fit_tsubaki_robust_donorvsidcm, 
coef=2, number=54675, sort.by='p')[,c(1,4)] 
tsubaki_robust_donorvsiscm_gsealist<-topTable(fit_tsubaki_robust_donorvsiscm, 
coef=2, number=54675, sort.by='p')[,c(1,4)] 
  175
write.table(tsubaki_robust_donorvsidcm_gsealist, 
file='tsubaki_robust_donorvsidcm_forGSEA_4-6-13.txt', quote=FALSE) 
write.table(tsubaki_robust_donorvsiscm_gsealist, 
file='tsubaki_robust_donorvsiscm_forGSEA_4-6-13.txt', quote=FALSE) 
 
 
 
# Code to analyse GSE430, referred to as 'chen' in the code, only RMA normalised  
# data available 
chendata<-read.table('GSE430_series_matrix_parsed.txt', header=TRUE, row.names=1, 
skip=0, comment.char='',nrow=22283) 
targets<-data.frame(FileName=c('GSM6540_HF1', 'GSM6541_LVAD1', 
'GSM6542_HF2', 'GSM6543_LVAD2', 'GSM6545_HF4', 'GSM6546_LVAD4', 
'GSM6547_HF5', 'GSM6548_LVAD5', 'GSM6549_HF6', 'GSM6550_LVAD6', 
'GSM6551_HF3', 'GSM6552_LVAD3', 'GSM6553_HF7', 'GSM6554_LVAD7' ), 
Subjects=c(1,1,2,2,3,3,4,4,5,5,6,6,7,7), Time=c(0,1,0,1,0,1,0,1,0,1,0,1,0,1)) 
chensubs<-factor(chentargets$Subjects) 
chentiming<-factor(chentargets$Time, levels=c(0,1)) 
chendesign<-model.matrix(~chensubs+chentiming) 
fit_chen_robust_beforevsafterLVAD <- lmFit(chendata, chendesign, method='robust') 
fit_chen_robust_beforevsafterLVAD <- eBayes(fit_chen_robust_beforevsafterLVAD) 
topTable(fit_chen_robust_beforevsafterLVAD, coef='chentiming1') 
 
# Genes DE by LVAD implantation in IDCM 
> topTable(fit_chen_robust_beforevsafterLVAD, coef='chentiming1') 
               ID      logFC   AveExpr          t      P.Value  adj.P.Val 
3070  203543_s_at  168.67115 215.10714  13.347582 4.007699e-06 0.01137321 
11835   212450_at  -33.80556 157.40000 -11.590770 1.008313e-05 0.01497883 
2415  202887_s_at  333.69882 390.28571  12.039637 7.872955e-06 0.01285788 
8286    208791_at  247.07790 404.05000  15.419587 1.546486e-06 0.01137321 
4816    205289_at   37.69995  48.00000  14.016465 2.905006e-06 0.01137321 
9605    210121_at -100.47395  94.77143 -13.206728 4.296928e-06 0.01137321 
14408 215034_s_at -140.17641 194.27143  -9.940562 2.717504e-05 0.02486163 
11338   211950_at   45.94029 353.09286  17.665157 6.266112e-07 0.01137321 
7034  207513_s_at  255.79866 272.20000  11.430125 1.104033e-05 0.01537572 
3235    203708_at -198.41954 154.40714 -10.528950 1.878134e-05 0.01902294 
               B 
3070  -0.4475709 
11835 -0.5448950 
2415  -0.5691934 
8286  -0.6391338 
4816  -0.6394862 
9605  -0.6701487 
14408 -0.6703821 
11338 -0.6804826 
7034  -0.6886198 
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3235  -0.7111100 
 
# Code to prepare R results in a format suitable for GSEA 
chenaffy_robust_beforevsafterLVAD_gsealist<-
topTable(fit_chen_robust_beforevsafterLVAD, coef='chentiming1', number=22283, 
adjust.method='fdr',  
sort.by='p')[,c(1,7)] 
write.table(chenaffy_robust_beforevsafterLVAD_gsealist, 
file='chenaffy_robust_beforevsafterLVAD_forGSEA_12-12-12.txt', quote=FALSE) 
 
 
 
# Code to analyse GSE974, referred to as 'hall' in code, note CEL file data was  
# available 
library(affy) 
halldata <- ReadAffy() 
halltargets_ISCM<-data.frame(FileName=c("GSM14844.CEL", "GSM14936.CEL", 
"GSM14937.CEL", "GSM14938.CEL", "GSM14939.CEL", "GSM14940.CEL", 
"GSM14941.CEL", "GSM14942.CEL", "GSM14943.CEL", "GSM14944.CEL"), 
Subjects=c(1,1,2,2,3,3,4,4,5,5), Time=c(0,1,1,0,1,0,1,0,1,0)) 
halltargets_MI<-data.frame(FileName=c("GSM14945.CEL", "GSM14946.CEL", 
"GSM14947.CEL", "GSM14948.CEL", "GSM14949.CEL", "GSM14950.CEL", 
"GSM14951.CEL", "GSM14952.CEL", "GSM14953.CEL", "GSM14954.CEL", 
"GSM14955.CEL", "GSM14956.CEL"), Subjects=c(1,1,2,2,3,3,4,4,5,5,6,6), 
Time=c(1,0,1,0,1,0,1,0,1,0,1,0)) 
halltargets_nonISCM<-data.frame(FileName=c("GSM14957.CEL", "GSM14958.CEL", 
"GSM14959.CEL", "GSM14960.CEL", "GSM14961.CEL", "GSM14962.CEL", 
"GSM14963.CEL", "GSM14965.CEL", "GSM14966.CEL", "GSM14967.CEL", 
"GSM14968.CEL", "GSM14969.CEL", "GSM14970.CEL", "GSM14971.CEL", 
"GSM14972.CEL", "GSM14973.CEL"), Subjects=c(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8), 
Time=c(1,0,1,0,1,0,1,0,1,0,1,0,1,0,1,0)) 
hallsubs_ISCM<-factor(halltargets_ISCM$Subjects) 
hallsubs_MI<-factor(halltargets_MI$Subjects) 
hallsubs_nonISCM<-factor(halltargets_nonISCM$Subjects) 
halltiming_ISCM<-factor(halltargets_ISCM$Time, levels=c(0,1)) 
halltiming_MI<-factor(halltargets_MI$Time, levels=c(0,1)) 
halltiming_nonISCM<-factor(halltargets_nonISCM$Time, levels=c(0,1)) 
halldesign_ISCM<-model.matrix(~hallsubs_ISCM+halltiming_ISCM) 
halldesign_MI<-model.matrix(~hallsubs_MI+halltiming_MI) 
halldesign_nonISCM<-model.matrix(~hallsubs_nonISCM+halltiming_nonISCM) 
halldata<-rma(halldata) 
fit_hall_robust_ISCM <- lmFit(halldata[,1:10], halldesign_ISCM, method='robust') 
fit_hall_robust_ISCM <- eBayes(fit_hall_robust_ISCM ) 
topTable(fit_hall_robust_ISCM , coef='halltiming_ISCM1') 
 
# Genes DE by LVAD implantation in end-stage ISCM 
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> topTable(fit_hall_robust_ISCM , coef='halltiming_ISCM1') 
               ID KEGG EntrezID Symbol      logFC   AveExpr         t 
12050   212665_at <NA>    25976 TIPARP  1.4883617  8.667899  22.65422 
9443  209957_s_at <NA>     4878   NPPA -1.4370534 10.298998 -23.89719 
3069  203542_s_at <NA>      687   KLF9  1.3694831  8.204960  21.31384 
16569 217202_s_at <NA>     2752   GLUL  0.8320695  7.982406  23.10767 
12109   212724_at <NA>      390   RND3  0.7781892  9.192215  22.91680 
3659  204132_s_at <NA>     <NA>   <NA>  1.1577829  7.829539  19.62362 
17106 217741_s_at <NA>     7763 ZFAND5  0.6605972  9.270152  18.95694 
8848  209355_s_at <NA>     8613 PPAP2B  1.0261111  8.653472  17.75871 
4817  205290_s_at <NA>      650   BMP2  0.6116512  5.998371  18.04663 
10768 211352_s_at <NA>     8202  NCOA3  0.6656408  6.039571  17.58934 
           P.Value   adj.P.Val        B 
12050 7.384297e-07 0.004113607 6.164353 
9443  5.441535e-07 0.004113607 6.106583 
3069  1.046001e-06 0.004661610 5.931717 
16569 6.593726e-07 0.004113607 5.852854 
12109 6.913764e-07 0.004113607 5.849611 
3659  1.675202e-06 0.006221422 5.433321 
17106 2.039419e-06 0.006322548 5.418849 
8848  2.955846e-06 0.006322548 5.195287 
4817  2.697809e-06 0.006322548 5.182567 
10768 3.121125e-06 0.006322548 5.162461 
 
fit_hall_robust_nonISCM <- lmFit(halldata[,23:38], halldesign_nonISCM, 
method='robust') 
fit_hall_robust_nonISCM <- eBayes(fit_hall_robust_nonISCM ) 
 
# Genes DE by LVAD implantation in end-stage IDCM 
> topTable(fit_hall_robust_nonISCM , coef='halltiming_nonISCM1') 
               ID KEGG EntrezID   Symbol      logFC   AveExpr         t 
18418   219054_at <NA>     4883     NPR3 -1.0279711  8.104466 -20.38712 
4595  205068_s_at <NA>    23092 ARHGAP26  0.6047682  7.196263  15.84799 
3233  203706_s_at <NA>     8324     FZD7 -0.7180439  7.664089 -13.89511 
7961    208463_at <NA>     2557   GABRA4 -0.7448972  7.062312 -12.34901 
20673   221310_at <NA>     2259    FGF14 -0.4141530  6.113029 -11.96232 
18577   219213_at <NA>    58494     JAM2 -0.5285529  8.098972 -11.78985 
9755  210275_s_at <NA>     7763   ZFAND5  0.7831544 10.581024  11.45944 
6804  207279_s_at <NA>    10529     NEBL -0.3836398  8.755252 -11.44953 
8286    208791_at <NA>     1191      CLU  0.7965801  8.636077  11.15729 
3658  204131_s_at <NA>     2309    FOXO3  0.9941460  9.585396  10.42132 
           P.Value    adj.P.Val        B 
18418 4.065856e-09 9.059947e-05 9.507821 
4595  4.107842e-08 4.576752e-04 8.471948 
3233  1.354918e-07 1.006388e-03 7.417613 
7961  3.908068e-07 2.132351e-03 6.829055 
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20673 5.189319e-07 2.132351e-03 6.424411 
18577 5.904423e-07 2.132351e-03 6.375179 
9755  7.597124e-07 2.132351e-03 6.269813 
6804  7.655524e-07 2.132351e-03 6.231599 
8286  9.620758e-07 2.381993e-03 6.031093 
3658  1.751871e-06 3.403450e-03 5.551796 
 
fit_hall_robust_MI <- lmFit(halldata[,11:22], halldesign_MI, method='robust') 
fit_hall_robust_MI <- eBayes(fit_hall_robust_MI ) 
topTable(fit_hall_robust_MI , coef='halltiming_MI1') 
 
# Genes DE by LVAD implantation in within 10 days of MI causing HF 
> topTable(fit_hall_robust_MI , coef='halltiming_MI1') 
               ID KEGG EntrezID  Symbol      logFC  AveExpr          t      P.Value  adj.P.Val        
B 
4918  205391_x_at <NA>      286    ANK1  1.0915109 8.064126  13.156658 3.256923e-
06 0.04159778 4.405422 
20934   221571_at <NA>     7187   TRAF3 -0.7160073 6.785864 -11.727364 7.092089e-
06 0.04159778 3.968361 
5217  205690_s_at <NA>     8896   BUD31 -0.7103881 7.052923 -12.219485 5.374276e-
06 0.04159778 3.836787 
5487    205960_at <NA>     5166    PDK4  1.7644725 8.764631  11.581702 7.714623e-
06 0.04159778 3.742569 
12905 213524_s_at <NA>    50486    G0S2 -1.9676300 8.534494 -10.748997 1.272289e-
05 0.04159778 3.592579 
12354   212971_at <NA>      833    CARS -0.7570041 8.958328 -10.947517 1.125747e-
05 0.04159778 3.564874 
17616   218251_at <NA>    58526 MID1IP1 -0.8374364 9.071080 -10.617586 
1.381187e-05 0.04159778 3.458033 
14868 215495_s_at <NA>    23034  SAMD4A  0.6174235 7.287960  10.493898 
1.493435e-05 0.04159778 3.375100 
11686   212300_at <NA>   200081   TXLNA -0.6311937 6.154018  -9.920328 
2.169489e-05 0.05081869 2.976260 
533     201005_at <NA>      928     CD9 -0.5667625 9.065714  -9.845751 2.280604e-05 
0.05081869 2.875080 
 
# Code to prepare R results in a format suitable for GSEA 
hall_robust_ISCM_gsealist<-topTable(fit_hall_robust_ISCM, coef='halltiming_ISCM1', 
number=22283, adjust.method='fdr', sort.by='p')[,c(1,7)] 
write.table(hall_robust_ISCM_gsealist, file='hall_robust_ISCM_forGSEA_13-12-12.txt', 
quote=FALSE) 
hall_robust_nonISCM_gsealist<-topTable(fit_hall_robust_nonISCM, 
coef='halltiming_nonISCM1', number=22283, adjust.method='fdr', sort.by='p')[,c(1,7)] 
write.table(hall_robust_nonISCM_gsealist, file='hall_robust_nonISCM_forGSEA_13-12-
12.txt', quote=FALSE) 
  179
hall_robust_MI_gsealist<-topTable(fit_hall_robust_MI, coef='halltiming_MI1', 
number=22283, adjust.method='fdr', sort.by='p')[,c(1,7)] 
write.table(hall_robust_MI_gsealist, file='hall_robust_MI_forGSEA_13-12-12.txt', 
quote=FALSE) 
 
 
 
# Code to analyse GSE3585, referred to as 'barth', raw CEL data was available 
setwd('C:/Users/Owner/PhD Work/FailingDatasets/barthaffy') 
barthdata <- ReadAffy() 
barthdata<-rma(barthdata) 
barthdesign <- cbind(rep(1,times=12), c(rep(0,times=5), rep(1,times=7))) 
fit_barth_robust <- lmFit(barthdata, barthdesign, method='robust') 
fit_barth_robust <- eBayes(fit_barth_robust) 
topTable(fit_barth_robust, coef=2) 
 
# Genes DE in end-stage IDCM versus NF LV 
 >  topTable(fit_barth_robust, coef=2) 
               ID      logFC   AveExpr          t      P.Value    adj.P.Val 
6327    206801_at  4.9991362 12.039023  20.241215 6.150522e-11 1.370521e-06 
3993  204466_s_at  1.2267914  9.058065  15.387211 1.677911e-09 1.869444e-05 
9530    210045_at -0.8351628  9.788719 -11.675736 4.294232e-08 3.189612e-04 
17362   217997_at  1.8529902  8.266368  11.082782 7.813620e-08 4.352772e-04 
1033    201505_at  0.7461697  8.298119  10.849146 9.964839e-08 4.440930e-04 
11843   212458_at  0.5752567  7.917872  10.411846 1.589548e-07 5.807346e-04 
10120 210655_s_at  0.4637819  8.927444  10.285610 1.824324e-07 5.807346e-04 
12291   212907_at  0.7672017  9.231780  10.135301 2.153348e-07 5.997883e-04 
11367   211980_at  0.4459459 10.780073   9.736530 3.375747e-07 8.357975e-04 
12890 213509_x_at -0.5644735  9.783237  -9.612384 3.894416e-07 8.677928e-04 
              B 
6327  12.280319 
3993  10.841234 
9530   8.620050 
17362  8.130871 
1033   7.847487 
11843  7.455242 
10120  7.307646 
12291  7.269492 
11367  6.781847 
12890  6.764350 
 
# Code to prepare R results in a format suitable for GSEA 
barth_robust_gsealist<-topTable(fit_barth_robust, coef=2, number=22283, 
sort.by='p')[,c(1,7)] 
write.table(barth_robust_gsealist, file='barth_robust_forGSEA_4-6-13.txt', 
quote=FALSE) 
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# Code to analyse GSE3586, referred to as 'barth2colour', raw data available in the 
# form of GPR files 
setwd('C:/Users/PC/PhD Work/FailingDatasets/barth2colour') 
library(limma) 
barth2colourtargets <- readTargets() 
RG <- read.maimages(barth2colourtargets,source="genepix.median", 
columns=list(G='F635 Median', R='F532 Median', Gb='B635 Median', Rb='B532 
Median'), wt.fun=wtflags(weight=0,cutoff=-40) ) 
RG$genes <- readGAL('GSM82393_1.gpr') 
RG$printer <- getLayout(RG$genes) 
RG <- backgroundCorrect(RG, method="normexp", offset=50) 
MA <- normalizeWithinArrays(RG) 
remove(RG) 
barth2colourdata <- normalizeBetweenArrays(MA, method='scale') 
remove(MA) 
 
# To annotate probes with Genbank accession numbers 
barth2colourannots<-read.table(file='arrayplatefile_modifiedforR.gal.csv', 
header=TRUE, sep='\t') 
for (count in 1:38976) { 
 position<-match(barth2colourdata$genes[count,4], barth2colourannots[,1]); 
 print(count) 
 if (is.na(position)==FALSE) {  
  barth2colourdata$genes[count,5]<-
as.vector(barth2colourannots[position,2]);  
  barth2colourdata$genes[count,6]<-
as.vector(barth2colourannots[position,3]); 
  barth2colourdata$genes[count,7]<-
as.vector(barth2colourannots[position,4]);  
  barth2colourdata$genes[count,8]<-
as.vector(barth2colourannots[position,5]); 
  barth2colourdata$genes[count,9]<-
as.vector(barth2colourannots[position,6]); 
 } 
} 
 
# To take the mean of the two replicate arrays hybridised with labelled mRNA from the 
same LV  
# sample 
barth2colourmeandata_M<-barth2colourdata$M 
original<-barth2colourdata$M 
barth2colourmeandata_M[,c(1:28)]<-NA 
for (count in 1:38976) { 
  barth2colourmeandata_M[count,1]<-mean(original[count,1:2]); 
  barth2colourmeandata_M[count,2]<-mean(original[count,3:4]); 
  barth2colourmeandata_M[count,3]<-mean(original[count,5:6]); 
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  barth2colourmeandata_M[count,4]<-mean(original[count,7:8]); 
  barth2colourmeandata_M[count,5]<-mean(original[count,9:10]); 
  barth2colourmeandata_M[count,6]<-mean(original[count,11:12]); 
  barth2colourmeandata_M[count,7]<-mean(original[count,13:14]); 
  barth2colourmeandata_M[count,8]<-mean(original[count,15:16]); 
  barth2colourmeandata_M[count,9]<-mean(original[count,17:18]); 
  barth2colourmeandata_M[count,10]<-mean(original[count,19:20]); 
  barth2colourmeandata_M[count,11]<-mean(original[count,21:22]); 
  barth2colourmeandata_M[count,12]<-mean(original[count,23:24]); 
  barth2colourmeandata_M[count,13]<-mean(original[count,25:26]); 
  barth2colourmeandata_M[count,14]<-mean(original[count,27:28]); 
  barth2colourmeandata_M[count,15]<-mean(original[count,29:30]); 
  barth2colourmeandata_M[count,16]<-mean(original[count,31:32]); 
  barth2colourmeandata_M[count,17]<-mean(original[count,33:34]); 
  barth2colourmeandata_M[count,18]<-mean(original[count,35:36]); 
  barth2colourmeandata_M[count,19]<-mean(original[count,37:38]); 
  barth2colourmeandata_M[count,20]<-mean(original[count,39:40]); 
  barth2colourmeandata_M[count,21]<-mean(original[count,41:42]); 
  barth2colourmeandata_M[count,22]<-mean(original[count,43:44]); 
  barth2colourmeandata_M[count,23]<-mean(original[count,45:46]); 
  barth2colourmeandata_M[count,24]<-mean(original[count,47:48]); 
  barth2colourmeandata_M[count,25]<-mean(original[count,49:50]); 
  barth2colourmeandata_M[count,26]<-mean(original[count,51:52]); 
  barth2colourmeandata_M[count,27]<-mean(original[count,53:54]); 
  barth2colourmeandata_M[count,28]<-mean(original[count,55:56]); 
  print(count); 
} 
barth2colourmeandata_M<-barth2colourmeandata_M[,1:28] 
barth2colourdata$M<-barth2colourmeandata_M 
barth2colourmeandata_A<-barth2colourdata$A 
original<-barth2colourdata$A 
barth2colourmeandata_A[,c(1:28)]<-NA 
for (count in 1:38976) { 
  barth2colourmeandata_A[count,1]<-mean(original[count,1:2]); 
  barth2colourmeandata_A[count,2]<-mean(original[count,3:4]); 
  barth2colourmeandata_A[count,3]<-mean(original[count,5:6]); 
  barth2colourmeandata_A[count,4]<-mean(original[count,7:8]); 
  barth2colourmeandata_A[count,5]<-mean(original[count,9:10]); 
  barth2colourmeandata_A[count,6]<-mean(original[count,11:12]); 
  barth2colourmeandata_A[count,7]<-mean(original[count,13:14]); 
  barth2colourmeandata_A[count,8]<-mean(original[count,15:16]); 
  barth2colourmeandata_A[count,9]<-mean(original[count,17:18]); 
  barth2colourmeandata_A[count,10]<-mean(original[count,19:20]); 
  barth2colourmeandata_A[count,11]<-mean(original[count,21:22]); 
  barth2colourmeandata_A[count,12]<-mean(original[count,23:24]); 
  barth2colourmeandata_A[count,13]<-mean(original[count,25:26]); 
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  barth2colourmeandata_A[count,14]<-mean(original[count,27:28]); 
  barth2colourmeandata_A[count,15]<-mean(original[count,29:30]); 
  barth2colourmeandata_A[count,16]<-mean(original[count,31:32]); 
  barth2colourmeandata_A[count,17]<-mean(original[count,33:34]); 
  barth2colourmeandata_A[count,18]<-mean(original[count,35:36]); 
  barth2colourmeandata_A[count,19]<-mean(original[count,37:38]); 
  barth2colourmeandata_A[count,20]<-mean(original[count,39:40]); 
  barth2colourmeandata_A[count,21]<-mean(original[count,41:42]); 
  barth2colourmeandata_A[count,22]<-mean(original[count,43:44]); 
  barth2colourmeandata_A[count,23]<-mean(original[count,45:46]); 
  barth2colourmeandata_A[count,24]<-mean(original[count,47:48]); 
  barth2colourmeandata_A[count,25]<-mean(original[count,49:50]); 
  barth2colourmeandata_A[count,26]<-mean(original[count,51:52]); 
  barth2colourmeandata_A[count,27]<-mean(original[count,53:54]); 
  barth2colourmeandata_A[count,28]<-mean(original[count,55:56]); 
  print(count); 
} 
barth2colourmeandata_A<-barth2colourmeandata_A[,1:28] 
barth2colourdata$A<-barth2colourmeandata_A 
barth2colourdesign<-cbind(1, c(rep(0,times=15), rep(1,times=13))) 
fit_barth2colour_robust_idcmvsdonor<-lmFit(barth2colourdata, 
design=barth2colourdesign, weights=1, method='robust') 
fit_barth2colour_robust_idcmvsdonor<-eBayes(fit_barth2colour_robust_idcmvsdonor) 
 
# Genes DE in end-stage IDCM vs NF LV 
> topTable(fit_barth2colour_robust_idcmvsdonor, coef=2) 
      Block Column Row            Name                         ID        X 
30196    38      7   6  IMAGp998L10643     N78562,N73714,BX119658     PDHX 
9972     13     25   8  IMAGp998P10840 AA024968,AA024662,BX094547 URB,ANKH 
3168      4      7  26   RZPDp202C071D BC009242,BX283465,BE299007      DMD 
8155     11      6   2  IMAGp998H04207     R67351,R66519,BX090461    CPT1B 
2650      4     11   8  IMAGp998I23929          BX096554,AA732982          
26683    33      3  25  RZPDp201D0527D          BX282272,BI861738 CDC42EP3 
4884      7     12   1  IMAGp998A08121     R02205,R02093,BX093967     DLAT 
10372    13     19  22 IMAGp998J225591          BX089301,AI620570          
26697    33     17  25  RZPDp201F0519D          BG674811,BX284055     SCP2 
34648    43     22  19   IMAGp998B2173     R39190,T75308,BX111273  ZMYND11 
 
# Code to prepare R results for GSEA, note that given that multiple probes were present 
on the  
# microarray that could hybridise to the same gene sequence, the mean of all the t-
statistics from  
# said probes generated from the linear model applied, was used for GSEA for each 
particular gene 
temp<-fit_barth2colour_robust_idcmvsdonor 
tempdataframe<-data.frame() 
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tempdataframe[1:38976,1]<-NA 
tempdataframe[1:38976,2]<-NA 
count2<-1 
for (count in 1:38976) { 
 currentprobe<-temp$genes[count,9]; 
 splitcurrentprobe<-strsplit(currentprobe, ',')[[1]][1]; 
 if (currentprobe!="" & is.na(match(splitcurrentprobe, 
tempdataframe[,1]))==TRUE & is.na(as.numeric(currentprobe))==TRUE) { 
  currenttstats<-
temp$t[temp$genes[,9]==currentprobe&is.na(temp$genes[,9])==FALSE,2]; 
  tempdataframe[count2,1]<-splitcurrentprobe; 
  tempdataframe[count2,2]<-mean(currenttstats); 
  count2<-count2+1; 
  print(count); 
 } 
} 
collapsedfit_barth2colour_robust_idcmvsdonor_genbank<-tempdataframe[1:15478,] 
colnames(collapsedfit_barth2colour_robust_idcmvsdonor_genbank)<-c('Name', 't') 
write.table(collapsedfit_barth2colour_robust_idcmvsdonor_genbank, 
file='barth2colour_idcmvsdonor_genbank_gsealist_15-8-13.txt', quote=FALSE) 
 
 
 
# Code used to analyse GSE21610, referred to as 'schweintek', raw CEL file data  
# was available. The code below was used to analyse DE in end-stage IDCM and  
# ISCM versus NF LV, as well as the effect of LVAD implantation on LV from  
# patients with end-stage IDCM and ISCM 
library(affy) 
setwd('C:/Users/Owner/PhD Work/FailingDatasets/schweintek') 
schweintekdata<-justRMA() 
designforschweintek_donorsvsidcm<-cbind(1, 
c(0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1)) 
fit_schweintek_donorsvidcm<-lmFit(schweintekdata[,c(1:8, 9:13, 15, 17, 18, 21, 22, 
25:30, 32:34, 36, 37)],  designforschweintek_donorsvsidcm) 
fit_schweintek_donorsvidcm<-eBayes(fit_schweintek_donorsvidcm) 
 
# Genes DE in end-stage IDCM versus NF LV 
> topTable(fit_schweintek_donorsvidcm, coef=2, sort.by='p') 
                ID     logFC  AveExpr        t      P.Value    adj.P.Val         B 
42823  233571_x_at 1.2516305 9.576656 9.249824 2.469947e-10 1.350443e-05 
13.138533 
4238  1558487_a_at 1.0637660 8.281482 8.883942 6.097263e-10 1.447984e-05 
12.336527 
35275    226018_at 1.6070617 6.531544 8.674059 1.032055e-09 1.447984e-05 
11.866949 
  184
37249  227994_x_at 1.1297061 7.673978 8.663712 1.059339e-09 1.447984e-05 
11.843622 
27296  218010_x_at 1.0983128 6.446432 8.498544 1.609759e-09 1.760271e-05 
11.468969 
30036  220751_s_at 1.1302505 6.207398 8.274412 2.856386e-09 2.271123e-05 
10.953791 
37601    228346_at 1.0181302 6.498668 8.267493 2.907702e-09 2.271123e-05 
10.937764 
28284    218999_at 0.9107355 7.162376 8.018593 5.539817e-09 3.786119e-05 
10.356366 
18527    209112_at 1.0235695 8.567703 7.827646 9.131742e-09 5.319241e-05  9.904011 
32700  223422_s_at 0.8706500 7.002192 7.780472 1.033904e-08 5.319241e-05  
9.791423 
 
designforschweintek_donorsvsiscm<-cbind(1, c(0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,1)) 
fit_schweintek_donorsviscm<-lmFit(schweintekdata[,c(1:8, 14, 16, 19, 20, 23, 24, 31, 35, 
38)],  designforschweintek_donorsvsiscm) 
fit_schweintek_donorsviscm<-eBayes(fit_schweintek_donorsviscm) 
 
# Genes DE in end-stage ISCM versus ND LV 
> topTable(fit_schweintek_donorsviscm, coef=2, sort.by='p') 
                ID      logFC  AveExpr         t      P.Value    adj.P.Val         B 
155   1552477_a_at  2.1234653 5.209639 10.306698 4.112816e-09 0.0002248682 
10.466263 
33848    224588_at -6.1298460 7.448365 -9.085146 2.954102e-08 0.0005310377  
8.809037 
10348  200899_s_at  0.8839277 8.070031  8.872926 4.236028e-08 0.0005310377  
8.499415 
16071    206624_at  2.1795620 4.691875  8.832453 4.540298e-08 0.0005310377  
8.439606 
12377    202927_at  0.5654370 7.589190  8.793307 4.856312e-08 0.0005310377  
8.381524 
37601    228346_at  0.9897436 6.285383  8.394093 9.751779e-08 0.0008886308  
7.775938 
24462    215167_at  0.8697734 6.281897  8.206945 1.361639e-07 0.0010635376  
7.483610 
13671    204223_at  1.9928544 7.214844  7.916570 2.306345e-07 0.0010752420  
7.019198 
37089    227834_at  1.1032302 8.252234  7.842163 2.644503e-07 0.0010752420  
6.898054 
37024    227769_at  1.0947875 5.778544  7.839281 2.658595e-07 0.0010752420  
6.893343 
 
# Code to prepare R results of comparisons of end-stage IDCM and ISCM versus NF LV 
for GSEA 
  185
schweintek_donorsvidcm_gsealist<-topTable(fit_schweintek_donorsvidcm, coef=2, 
number=54675, sort.by='p')[,c(1,4)] 
write.table(schweintek_donorsvidcm_gsealist, 
file='schweintek_donorsvidcm_forGSEA_4-6-13.txt', quote=FALSE) 
schweintek_donorsviscm_gsealist<-topTable(fit_schweintek_donorsviscm, coef=2, 
number=54675, sort.by='p')[,c(1,4)] 
write.table(schweintek_donorsviscm_gsealist, 
file='schweintek_donorsviscm_forGSEA_4-6-13.txt', quote=FALSE) 
 
# Code to analyse the effects of LVAD implantation in end-stage IDCM and ISCM 
SchweintekFileNames=c("GSM545665.cel", "GSM545666.cel", "GSM545667.cel", 
"GSM545668.cel", 
"GSM545669.cel", "GSM545670.cel", "GSM545671.cel", "GSM545672.cel", 
"GSM545673.cel", "GSM545674.cel", 
"GSM545675.cel", "GSM545676.cel", "GSM545677.cel", "GSM545678.cel", 
"GSM545679.cel", "GSM545680.cel", 
"GSM545681.cel", "GSM545682.cel", "GSM545683.cel", "GSM545684.cel", 
"GSM545685.cel", "GSM545686.cel", 
"GSM545687.cel", "GSM545688.cel", "GSM545689.cel", "GSM545690.cel", 
"GSM545691.cel", "GSM545692.cel", 
"GSM545693.cel", "GSM545694.cel", "GSM545695.cel", "GSM545696.cel", 
"GSM545697.cel", "GSM545698.cel", 
"GSM545699.cel", "GSM545700.cel", "GSM545701.cel", "GSM545702.cel", 
"GSM545703.cel", "GSM545704.cel", 
"GSM545705.cel", "GSM545706.cel", "GSM545707.cel", "GSM545708.cel", 
"GSM545709.cel", "GSM545710.cel", 
"GSM545711.cel", "GSM545712.cel", "GSM545713.cel", "GSM545714.cel", 
"GSM545715.cel", "GSM545716.cel", 
"GSM545717.cel", "GSM545718.cel", "GSM545719.cel", "GSM545720.cel", 
"GSM545721.cel", "GSM545722.cel", 
"GSM545723.cel", "GSM545724.cel") 
vectorofphenotypesforschweintekfailingphenotype<-c('d', 'd', 'd', 'd', 'd', 'i', 'd', 'i', 'd', 'd', 
'i', 'i', 'd', 'd', 'i', 'i', 'd', 'd', 'd',  
'd', 'd', 'd', 'i', 'd', 'd', 'd', 'i', 'd', 'd', 'i') 
schweintektargets_iscm<-
data.frame(Filenames=SchweintekFileNames[vectorofphenotypesforschweintekfailingph
enotype=='i'],  
Subjects=c(1:9,1:9), Time=c(rep(0,times=9), rep(1, times=9))) 
schweintektargets_idcm<-
data.frame(Filenames=SchweintekFileNames[vectorofphenotypesforschweintekfailingph
enotype=='d'],  
Subjects=c(1:21,1:21), Time=c(rep(0,times=21), rep(1, times=21))) 
schweinteksubs_idcm<-factor(schweintektargets_idcm$Subjects) 
schweintektiming_idcm<-factor(schweintektargets_idcm$Time, levels=c(0,1)) 
schweintekdesign_idcm<-
model.matrix(~schweinteksubs_idcm+schweintektiming_idcm) 
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schweinteksubs_iscm<-factor(schweintektargets_iscm$Subjects) 
schweintektiming_iscm<-factor(schweintektargets_iscm$Time, levels=c(0,1)) 
schweintekdesign_iscm<-model.matrix(~schweinteksubs_iscm+schweintektiming_iscm) 
schweintek_failing<-schweintekdata[,9:68] 
fit_schweintek_robust_LVADexvsim_idcm <- 
lmFit(schweintek_failing[,vectorofphenotypesforschweintekfailingphenotype=='d'],  
schweintekdesign_idcm, method='robust') 
fit_schweintek_robust_LVADexvsim_idcm <- 
eBayes(fit_schweintek_robust_LVADexvsim_idcm ) 
 
# Genes DE by LVAD implantation in end-stage IDCM 
> topTable(fit_schweintek_robust_LVADexvsim_idcm, coef='schweintektiming_idcm1') 
               ID     logFC  AveExpr        t      P.Value    adj.P.Val        B 
16955 207513_s_at 1.3425099 8.499935 30.93333 1.156314e-20 6.322147e-16 33.75298 
28008 218723_s_at 1.2706389 9.564207 26.02777 6.173159e-19 1.687587e-14 30.93276 
15331   205883_at 1.3421178 8.420752 21.20945 6.499152e-17 1.184471e-12 27.20863 
17820 208398_s_at 0.8352029 7.625273 20.23330 1.875956e-16 2.564197e-12 26.47265 
34148   224889_at 0.9825554 8.681649 19.75144 3.220050e-16 3.521125e-12 26.02252 
35312   226055_at 0.8140701 7.456819 19.56002 4.003952e-16 3.648601e-12 25.94579 
34115   224856_at 1.9608130 9.099509 19.30856 5.346344e-16 4.175876e-12 25.69509 
32636 223358_s_at 0.9886052 8.639506 18.52501 1.345267e-15 9.194057e-12 24.86555 
12337 202887_s_at 1.8455939 8.269095 17.81154 3.212563e-15 1.816861e-11 24.16195 
18179 208763_s_at 1.4149367 9.097330 17.78433 3.323019e-15 1.816861e-11 24.07355 
 
fit_schweintek_robust_LVADexvsim_iscm <- 
lmFit(schweintek_failing[,vectorofphenotypesforschweintekfailingphenotype=='i'], 
schweintekdesign_iscm, method='robust') 
fit_schweintek_robust_LVADexvsim_iscm<-
eBayes(fit_schweintek_robust_LVADexvsim_iscm) 
 
# Genes DE by LVAD implantation in end-stage ISCM 
> topTable(fit_schweintek_robust_LVADexvsim_iscm , coef='schweintektiming_iscm1') 
               ID      logFC   AveExpr         t      P.Value    adj.P.Val        B 
34099   224840_at  1.9868161 10.116763  22.12817 2.652294e-10 1.450142e-05 
12.53339 
18179 208763_s_at  1.7879048  8.597411  19.08687 1.250905e-09 1.709831e-05 
11.64550 
29299   220014_at  1.0520837  5.218632  19.19835 1.177018e-09 1.709831e-05 
11.38350 
53948   244697_at  1.1226816  6.984085  19.58219 9.568398e-10 1.709831e-05 
11.34034 
34115   224856_at  1.9016837  9.065395  18.30444 1.936577e-09 1.733020e-05 
11.27896 
35717   226460_at  0.9284098  8.963066  18.61211 1.627413e-09 1.733020e-05 
11.00028 
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16955 207513_s_at  1.2992993  8.441574  17.69496 2.755915e-09 1.883495e-05 
10.99240 
23629 214329_x_at -1.0343761  5.524879 -18.06715 2.218773e-09 1.733020e-05 
10.93600 
28515   219230_at  1.8698977  6.457189  17.11498 3.897217e-09 2.217032e-05 
10.76666 
13732   204284_at -1.0671626 10.702659 -16.90625 4.426748e-09 2.217032e-05 
10.64936 
 
# Code to prepare results in R regarding LVAD implantation for GSEA 
schweintek_LVADexvsim_iscm_gsealist<-
topTable(fit_schweintek_robust_LVADexvsim_iscm, coef='schweintektiming_iscm1', 
number=54675, sort.by='p')[,c(1,4)] 
write.table(schweintek_LVADexvsim_iscm_gsealist, 
file='schweintek_LVADexvsim_iscm_forGSEA_18-12-12.txt', quote=FALSE) 
schweintek_LVADexvsim_idcm_gsealist<-
topTable(fit_schweintek_robust_LVADexvsim_idcm, coef='schweintektiming_idcm1', 
number=54675, sort.by='p')[,c(1,4)] 
write.table(schweintek_LVADexvsim_idcm_gsealist, 
file='schweintek_LVADexvsim_idcm_forGSEA_18-12-12.txt', quote=FALSE) 
 
 
 
# R code to generate intersection plots in Figures 4.1 and 4.2 for the IDCM  
# Affymetrix datasets - GSE21610 referred to as 'schweintek', GSE5406 referred to 
# as 'hannen', GSE1869 # referred to as 'kittle', GSE1145 referred to as 'tsubaki',  
# GSE3585 referred to as 'barth'    
ranked_kittle_idcm<-topTable(fit_kittle_robust_donorvsidcm, coef=2, number=22238, 
adjust.method='fdr', sort.by='p')$ID 
ranked_hannen_idcm<-topTable(fit_hannen_robust_donorvsidcm, number=22238, 
adjust.method='fdr', sort.by='p')$ID 
ranked_barth_idcm<-topTable(fit_barth_robust, coef=2, number=22238, 
adjust.method='fdr', sort.by='p')$ID 
ranked_schweintek_idcm_all<-topTable(fit_schweintek_donorsvidcm, coef=2, 
number=54675, adjust.method='fdr', sort.by='p')$ID 
ranked_schweintek_idcm_subset<-vector(length=22238) 
count2<-1 
for (count in 1:54675) { 
 if (is.na(match(ranked_schweintek_idcm_all[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_schweintek_idcm_subset[count2]<-
ranked_schweintek_idcm_all[count]; 
  count2<-count2+1; 
 } 
} 
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ranked_tsubaki_idcm_all<-topTable(fit_tsubaki_robust_donorvsidcm, coef=2, 
number=54675, adjust.method='fdr', sort.by='p')$ID 
ranked_tsubaki_idcm_subset<-vector(length=22238) 
count2<-1 
for (count in 1:54675) { 
 if (is.na(match(ranked_tsubaki_idcm_all[count], ranked_kittle_idcm))==FALSE) 
{ 
  ranked_tsubaki_idcm_subset[count2]<-ranked_tsubaki_idcm_all[count]; 
  count2<-count2+1; 
 } 
} 
kittlevshannen_idcm_intersect<-vector() 
kittlevsbarth_idcm_intersect<-vector() 
kittlevstsubaki_idcm_intersect<-vector() 
kittlevsschweintek_idcm_intersect<-vector() 
hannenvsbarth_idcm_intersect<-vector() 
hannenvstsubaki_idcm_intersect<-vector() 
hannenvschweintek_idcm_intersect<-vector() 
barthvstsubaki_idcm_intersect<-vector() 
barthvsschweintek_idcm_intersect<-vector() 
tsubakivsschweintek_idcm_intersect<-vector() 
for (count in 1:22283) { 
 kittlevshannen_idcm_intersect[count]<-
length(intersect(ranked_kittle_idcm[1:count], ranked_hannen_idcm[1:count]))/count; 
 kittlevsbarth_idcm_intersect[count]<-
length(intersect(ranked_kittle_idcm[1:count], ranked_barth_idcm[1:count]))/count; 
 kittlevstsubaki_idcm_intersect[count]<-
length(intersect(ranked_kittle_idcm[1:count], 
ranked_tsubaki_idcm_subset[1:count]))/count; 
 kittlevsschweintek_idcm_intersect[count]<-
length(intersect(ranked_kittle_idcm[1:count], 
ranked_schweintek_idcm_subset[1:count]))/count; 
 hannenvsbarth_idcm_intersect[count]<-
length(intersect(ranked_hannen_idcm[1:count], ranked_barth_idcm[1:count]))/count; 
 hannenvstsubaki_idcm_intersect[count]<-
length(intersect(ranked_hannen_idcm[1:count], 
ranked_tsubaki_idcm_subset[1:count]))/count; 
 hannenvschweintek_idcm_intersect[count]<-
length(intersect(ranked_hannen_idcm[1:count], 
ranked_schweintek_idcm_subset[1:count]))/count; 
 barthvstsubaki_idcm_intersect[count]<-
length(intersect(ranked_barth_idcm[1:count], 
ranked_tsubaki_idcm_subset[1:count]))/count; 
 barthvsschweintek_idcm_intersect[count]<-
length(intersect(ranked_barth_idcm[1:count], 
ranked_schweintek_idcm_subset[1:count]))/count; 
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 tsubakivsschweintek_idcm_intersect[count]<-
length(intersect(ranked_tsubaki_idcm_subset[1:count], 
ranked_schweintek_idcm_subset[1:count]))/count; 
} 
 
# To plot the intersection plots for IDCM Affymetrix datasets (all 22283 probes) 
plot(1:22283, kittlevshannen_idcm_intersect, type='l', col='blue', xlim=c(0,22283), 
ylim=c(0, 1), ylab='Proportion of Overlapping Genes', xlab='Gene Rank') 
par(new=TRUE) 
plot(1:22283, kittlevsbarth_idcm_intersect, type='l', col='yellow', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, kittlevstsubaki_idcm_intersect, type='l', col='red', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, kittlevsschweintek_idcm_intersect, type='l', col='purple', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, hannenvsbarth_idcm_intersect, type='l', col='orange', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, hannenvstsubaki_idcm_intersect, type='l', col='green', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, hannenvschweintek_idcm_intersect, type='l', col='brown', 
xlim=c(0,22283), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, barthvstsubaki_idcm_intersect, type='l', col='grey', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, barthvsschweintek_idcm_intersect, type='l', col='black', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, tsubakivsschweintek_idcm_intersect, type='l', col='cyan', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=FALSE) 
 
# To plot the intersection plots for IDCM Affymetrix datasets (200 most highly ranked 
probes in  
# order of strength of DE) 
plot(1:2000, kittlevshannen_idcm_intersect[1:2000], type='l', col='blue', xlim=c(0,2000), 
ylim=c(0, 1), ylab='Proportion of Overlapping Genes', xlab='Gene Rank') 
par(new=TRUE) 
plot(1:2000, kittlevsbarth_idcm_intersect[1:2000], type='l', col='yellow', xlim=c(0,2000), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
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plot(1:2000, kittlevstsubaki_idcm_intersect[1:2000], type='l', col='red', xlim=c(0,2000), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, kittlevsschweintek_idcm_intersect[1:2000], type='l', col='purple', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvsbarth_idcm_intersect[1:2000], type='l', col='orange', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvstsubaki_idcm_intersect[1:2000], type='l', col='green', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvschweintek_idcm_intersect[1:2000], type='l', col='brown', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, barthvstsubaki_idcm_intersect[1:2000], type='l', col='grey', xlim=c(0,2000), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, barthvsschweintek_idcm_intersect[1:2000], type='l', col='black', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, tsubakivsschweintek_idcm_intersect[1:2000], type='l', col='cyan', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=FALSE) 
 
 
 
# R code to generate intersection plots in Figures 4.3 and 4.4 for the ISCM  
# Affymetrix datasets - GSE21610 referred to as 'schweintek', GSE5406 referred to 
# as 'hannen', GSE1869 referred to as 'kittle', GSE1145 referred to as 'tsubaki' 
ranked_kittle_iscm<-topTable(fit_kittle_robust_donorvsiscm, coef=2, number=22238, 
adjust.method='fdr', sort.by='p')$ID 
ranked_hannen_iscm<-topTable(fit_hannen_robust_donorvsiscm, number=22238, 
adjust.method='fdr', sort.by='p')$ID 
 
ranked_schweintek_iscm_all<-topTable(fit_schweintek_donorsviscm, coef=2, 
number=54675, adjust.method='fdr', sort.by='p')$ID 
ranked_schweintek_iscm_subset<-vector(length=22238) 
count2<-1 
for (count in 1:54675) { 
 if (is.na(match(ranked_schweintek_iscm_all[count], 
ranked_kittle_iscm))==FALSE) { 
  ranked_schweintek_iscm_subset[count2]<-
ranked_schweintek_iscm_all[count]; 
  count2<-count2+1; 
 } 
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} 
 
ranked_tsubaki_iscm_all<-topTable(fit_tsubaki_robust_donorvsiscm, coef=2, 
number=54675, adjust.method='fdr', sort.by='p')$ID 
ranked_tsubaki_iscm_subset<-vector(length=22238) 
count2<-1 
for (count in 1:54675) { 
 if (is.na(match(ranked_tsubaki_iscm_all[count], ranked_kittle_iscm))==FALSE) 
{ 
  ranked_tsubaki_iscm_subset[count2]<-ranked_tsubaki_iscm_all[count]; 
  count2<-count2+1; 
 } 
} 
kittlevshannen_iscm_intersect<-vector() 
kittlevstsubaki_iscm_intersect<-vector() 
kittlevsschweintek_iscm_intersect<-vector() 
hannenvstsubaki_iscm_intersect<-vector() 
hannenvschweintek_iscm_intersect<-vector() 
tsubakivsschweintek_iscm_intersect<-vector() 
for (count in 1:22283) { 
 kittlevshannen_iscm_intersect[count]<-
length(intersect(ranked_kittle_iscm[1:count], ranked_hannen_iscm[1:count]))/count; 
 kittlevstsubaki_iscm_intersect[count]<-
length(intersect(ranked_kittle_iscm[1:count], 
ranked_tsubaki_iscm_subset[1:count]))/count; 
 kittlevsschweintek_iscm_intersect[count]<-
length(intersect(ranked_kittle_iscm[1:count], 
ranked_schweintek_iscm_subset[1:count]))/count; 
 hannenvstsubaki_iscm_intersect[count]<-
length(intersect(ranked_hannen_iscm[1:count], 
ranked_tsubaki_iscm_subset[1:count]))/count; 
 hannenvschweintek_iscm_intersect[count]<-
length(intersect(ranked_hannen_iscm[1:count], 
ranked_schweintek_iscm_subset[1:count]))/count; 
 tsubakivsschweintek_iscm_intersect[count]<-
length(intersect(ranked_tsubaki_iscm_subset[1:count], 
ranked_schweintek_iscm_subset[1:count]))/count; 
} 
 
# To plot the intersection plots for ISCM Affymetrix datasets (all 22238 probes) 
plot(1:22283, kittlevshannen_iscm_intersect, type='l', col='blue', xlim=c(0,22283), 
ylim=c(0, 1), ylab='Proportion of Overlapping Genes', xlab='Gene Rank') 
par(new=TRUE) 
plot(1:22283, kittlevstsubaki_iscm_intersect, type='l', col='red', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
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plot(1:22283, kittlevsschweintek_iscm_intersect, type='l', col='purple', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, hannenvstsubaki_iscm_intersect, type='l', col='green', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, hannenvschweintek_iscm_intersect, type='l', col='brown', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:22283, tsubakivsschweintek_iscm_intersect, type='l', col='cyan', xlim=c(0,22283), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=FALSE) 
 
# To plot the intersection plots for ISCM Affymetrix datasets (200 most highly ranked 
probes in  
# order of strength of DE) 
plot(1:2000, kittlevshannen_iscm_intersect[1:2000], type='l', col='blue', xlim=c(0,2000), 
ylim=c(0, 1), ylab='Proportion of Overlapping Genes', xlab='Gene Rank') 
par(new=TRUE) 
plot(1:2000, kittlevstsubaki_iscm_intersect[1:2000], type='l', col='red', xlim=c(0,2000), 
ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, kittlevsschweintek_iscm_intersect[1:2000], type='l', col='purple', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvstsubaki_iscm_intersect[1:2000], type='l', col='green', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvschweintek_iscm_intersect[1:2000], type='l', col='brown', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, tsubakivsschweintek_iscm_intersect[1:2000], type='l', col='cyan', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=FALSE) 
 
 
 
# R code to generate intersection plots in Figures 4.5 and 4.6 for the IDCM  
# Affymetrix datasets - GSE21610 referred to as 'schweintek', GSE5406 referred to 
# as 'hannen', GSE1869 referred to as 'kittle', GSE1145 referred to as 'tsubaki',  
# GSE3585 referred to as 'barth'   
ranked_kittle_idcm_upregulated<-topTable(fit_kittle_robust_donorvsidcm, coef=2, 
number=22238, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_kittle_robust_donorvsidcm, coef=2, number=22238, adjust.method='fdr', 
sort.by='logFC')[,2]>0,]$ID 
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ranked_kittle_idcm_downregulated<-topTable(fit_kittle_robust_donorvsidcm, coef=2, 
number=22238, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_kittle_robust_donorvsidcm, coef=2, number=22238, adjust.method='fdr', 
sort.by='logFC')[,2]<0,]$ID 
ranked_hannen_idcm_upregulated<-topTable(fit_hannen_robust_donorvsidcm, 
number=22238, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_hannen_robust_donorvsidcm, number=22238, adjust.method='fdr', 
sort.by='logFC')[,5]>0,]$ID 
ranked_hannen_idcm_downregulated<-topTable(fit_hannen_robust_donorvsidcm, 
number=22238, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_hannen_robust_donorvsidcm, number=22238, adjust.method='fdr', 
sort.by='logFC')[,5]<0,]$ID 
ranked_barth_idcm_upregulated<-topTable(fit_barth_robust, coef=2, number=22238, 
adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_barth_robust, coef=2, number=22238, adjust.method='fdr', 
sort.by='logFC')[,5]>0,]$ID 
ranked_barth_idcm_downregulated<-topTable(fit_barth_robust, coef=2, number=22238, 
adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_barth_robust, coef=2, number=22238, adjust.method='fdr', 
sort.by='logFC')[,5]<0,]$ID 
ranked_schweintek_idcm_upregulated<-topTable(fit_schweintek_donorsvidcm, coef=2, 
number=54675, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_schweintek_donorsvidcm, coef=2, number=54675, adjust.method='fdr', 
sort.by='logFC')[,2]>0,]$ID 
ranked_schweintek_idcm_downregulated<-topTable(fit_schweintek_donorsvidcm, 
coef=2, number=54675, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_schweintek_donorsvidcm, coef=2, number=54675, adjust.method='fdr', 
sort.by='logFC')[,2]<0,]$ID 
ranked_schweintek_idcm_upregulated_subset<-vector(length=22238) 
count2<-1 
for (count in 1:length(ranked_schweintek_idcm_upregulated)) { 
 if (is.na(match(ranked_schweintek_idcm_upregulated[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_schweintek_idcm_upregulated_subset[count2]<-
ranked_schweintek_idcm_upregulated[count]; 
  count2<-count2+1; 
 } 
} 
ranked_schweintek_idcm_downregulated_subset<-vector(length=22238) 
count2<-1 
for (count in 1:length(ranked_schweintek_idcm_downregulated)) { 
 if (is.na(match(ranked_schweintek_idcm_downregulated[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_schweintek_idcm_downregulated_subset[count2]<-
ranked_schweintek_idcm_downregulated[count]; 
  count2<-count2+1; 
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 } 
} 
ranked_tsubaki_idcm_upregulated<-topTable(fit_tsubaki_robust_donorvsidcm, coef=2, 
number=54675, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_tsubaki_robust_donorvsidcm, coef=2, number=54675, adjust.method='fdr', 
sort.by='logFC')[,2]>0,]$ID 
ranked_tsubaki_idcm_downregulated<-topTable(fit_tsubaki_robust_donorvsidcm, 
coef=2, number=54675, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_tsubaki_robust_donorvsidcm, coef=2, number=54675, adjust.method='fdr', 
sort.by='logFC')[,2]<0,]$ID 
ranked_tsubaki_idcm_upregulated_subset<-vector(length=22238) 
count2<-1 
for (count in 1:length(ranked_tsubaki_idcm_upregulated)) { 
 if (is.na(match(ranked_tsubaki_idcm_upregulated[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_tsubaki_idcm_upregulated_subset[count2]<-
ranked_tsubaki_idcm_upregulated[count]; 
  count2<-count2+1; 
 } 
} 
ranked_tsubaki_idcm_downregulated_subset<-vector(length=22238) 
count2<-1 
for (count in 1:length(ranked_tsubaki_idcm_downregulated)) { 
 if (is.na(match(ranked_tsubaki_idcm_downregulated[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_tsubaki_idcm_downregulated_subset[count2]<-
ranked_tsubaki_idcm_downregulated[count]; 
  count2<-count2+1; 
 } 
} 
kittlevshannen_idcm_intersect_down<-vector() 
kittlevsbarth_idcm_intersect_down<-vector() 
kittlevstsubaki_idcm_intersect_down<-vector() 
kittlevsschweintek_idcm_intersect_down<-vector() 
hannenvsbarth_idcm_intersect_down<-vector() 
hannenvstsubaki_idcm_intersect_down<-vector() 
hannenvschweintek_idcm_intersect_down<-vector() 
barthvstsubaki_idcm_intersect_down<-vector() 
barthvsschweintek_idcm_intersect_down<-vector() 
tsubakivsschweintek_idcm_intersect_down<-vector() 
kittlevshannen_idcm_intersect_up<-vector() 
kittlevsbarth_idcm_intersect_up<-vector() 
kittlevstsubaki_idcm_intersect_up<-vector() 
kittlevsschweintek_idcm_intersect_up<-vector() 
hannenvsbarth_idcm_intersect_up<-vector() 
hannenvstsubaki_idcm_intersect_up<-vector() 
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hannenvschweintek_idcm_intersect_up<-vector() 
barthvstsubaki_idcm_intersect_up<-vector() 
barthvsschweintek_idcm_intersect_up<-vector() 
tsubakivsschweintek_idcm_intersect_up<-vector() 
for (count in 1:2000) { 
 kittlevshannen_idcm_intersect_up[count]<-
length(intersect(ranked_kittle_idcm_upregulated[1:count], 
ranked_hannen_idcm_upregulated[1:count]))/count; 
 kittlevsbarth_idcm_intersect_up[count]<-
length(intersect(ranked_kittle_idcm_upregulated[1:count], 
ranked_barth_idcm_upregulated[1:count]))/count; 
 kittlevstsubaki_idcm_intersect_up[count]<-
length(intersect(ranked_kittle_idcm_upregulated[1:count], 
ranked_tsubaki_idcm_upregulated_subset[1:count]))/count; 
 kittlevsschweintek_idcm_intersect_up[count]<-
length(intersect(ranked_kittle_idcm_upregulated[1:count], 
ranked_schweintek_idcm_upregulated_subset[1:count]))/count; 
 hannenvsbarth_idcm_intersect_up[count]<-
length(intersect(ranked_hannen_idcm_upregulated[1:count], 
ranked_barth_idcm_upregulated[1:count]))/count; 
 hannenvstsubaki_idcm_intersect_up[count]<-
length(intersect(ranked_hannen_idcm_upregulated[1:count], 
ranked_tsubaki_idcm_upregulated_subset[1:count]))/count; 
 hannenvschweintek_idcm_intersect_up[count]<-
length(intersect(ranked_hannen_idcm_upregulated[1:count], 
ranked_schweintek_idcm_upregulated_subset[1:count]))/count; 
 barthvstsubaki_idcm_intersect_up[count]<-
length(intersect(ranked_barth_idcm_upregulated[1:count], 
ranked_tsubaki_idcm_upregulated_subset[1:count]))/count; 
 barthvsschweintek_idcm_intersect_up[count]<-
length(intersect(ranked_barth_idcm_upregulated[1:count], 
ranked_schweintek_idcm_upregulated_subset[1:count]))/count; 
 tsubakivsschweintek_idcm_intersect_up[count]<-
length(intersect(ranked_tsubaki_idcm_upregulated_subset[1:count], 
ranked_schweintek_idcm_upregulated_subset[1:count]))/count 
 kittlevshannen_idcm_intersect_down[count]<-
length(intersect(ranked_kittle_idcm_downregulated[1:count], 
ranked_hannen_idcm_downregulated[1:count]))/count; 
 kittlevsbarth_idcm_intersect_down[count]<-
length(intersect(ranked_kittle_idcm_downregulated[1:count], 
ranked_barth_idcm_downregulated[1:count]))/count; 
 kittlevstsubaki_idcm_intersect_down[count]<-
length(intersect(ranked_kittle_idcm_downregulated[1:count], 
ranked_tsubaki_idcm_downregulated_subset[1:count]))/count; 
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 kittlevsschweintek_idcm_intersect_down[count]<-
length(intersect(ranked_kittle_idcm_downregulated[1:count], 
ranked_schweintek_idcm_downregulated_subset[1:count]))/count; 
 hannenvsbarth_idcm_intersect_down[count]<-
length(intersect(ranked_hannen_idcm_downregulated[1:count], 
ranked_barth_idcm_downregulated[1:count]))/count; 
 hannenvstsubaki_idcm_intersect_down[count]<-
length(intersect(ranked_hannen_idcm_downregulated[1:count], 
ranked_tsubaki_idcm_downregulated_subset[1:count]))/count; 
 hannenvschweintek_idcm_intersect_down[count]<-
length(intersect(ranked_hannen_idcm_downregulated[1:count], 
ranked_schweintek_idcm_downregulated_subset[1:count]))/count; 
 barthvstsubaki_idcm_intersect_down[count]<-
length(intersect(ranked_barth_idcm_downregulated[1:count], 
ranked_tsubaki_idcm_downregulated_subset[1:count]))/count; 
 barthvsschweintek_idcm_intersect_down[count]<-
length(intersect(ranked_barth_idcm_downregulated[1:count], 
ranked_schweintek_idcm_downregulated_subset[1:count]))/count; 
 tsubakivsschweintek_idcm_intersect_down[count]<-
length(intersect(ranked_tsubaki_idcm_downregulated_subset[1:count], 
ranked_schweintek_idcm_downregulated_subset[1:count]))/count; 
} 
 
# To plot the intersection plots for IDCM Affymetrix datasets (200 most highly ranked  
# upregulated probes in order of strength of DE) 
plot(1:2000, kittlevshannen_idcm_intersect_up[1:2000], type='l', col='blue', 
xlim=c(0,2000), ylim=c(0, 1), ylab='Proportion of Overlapping Genes', xlab='Gene 
Rank') 
par(new=TRUE) 
plot(1:2000, kittlevsbarth_idcm_intersect_up[1:2000], type='l', col='yellow', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, kittlevstsubaki_idcm_intersect_up[1:2000], type='l', col='red', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, kittlevsschweintek_idcm_intersect_up[1:2000], type='l', col='purple', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvsbarth_idcm_intersect_up[1:2000], type='l', col='orange', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvstsubaki_idcm_intersect_up[1:2000], type='l', col='green', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvschweintek_idcm_intersect_up[1:2000], type='l', col='brown', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
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par(new=TRUE) 
plot(1:2000, barthvstsubaki_idcm_intersect_up[1:2000], type='l', col='grey', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, barthvsschweintek_idcm_intersect_up[1:2000], type='l', col='black', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, tsubakivsschweintek_idcm_intersect_up[1:2000], type='l', col='cyan', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=FALSE) 
 
# To plot the intersection plots for IDCM Affymetrix datasets (200 most highly ranked  
# downregulated probes in order of strength of DE) 
plot(1:2000, kittlevshannen_idcm_intersect_down[1:2000], type='l', col='blue', 
xlim=c(0,2000), ylim=c(0, 1), ylab='Proportion of Overlapping Genes', xlab='Gene 
Rank') 
par(new=TRUE) 
plot(1:2000, kittlevsbarth_idcm_intersect_down[1:2000], type='l', col='yellow', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, kittlevstsubaki_idcm_intersect_down[1:2000], type='l', col='red', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, kittlevsschweintek_idcm_intersect_down[1:2000], type='l', col='purple', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvsbarth_idcm_intersect_down[1:2000], type='l', col='orange', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvstsubaki_idcm_intersect_down[1:2000], type='l', col='green', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvschweintek_idcm_intersect_down[1:2000], type='l', col='brown', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, barthvstsubaki_idcm_intersect_down[1:2000], type='l', col='grey', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, barthvsschweintek_idcm_intersect_down[1:2000], type='l', col='black', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, tsubakivsschweintek_idcm_intersect_down[1:2000], type='l', col='cyan', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=FALSE) 
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# R code to generate intersection plots in Figures 4.7 and 4.8 for the ISCM  
# Affymetrix datasets - GSE21610 referred to as 'schweintek', GSE5406 referred to 
# as 'hannen', GSE1869 referred to as 'kittle', GSE1145 referred to as 'tsubaki'   
ranked_kittle_iscm_upregulated<-topTable(fit_kittle_robust_donorvsiscm, coef=2, 
number=22238, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_kittle_robust_donorvsiscm, coef=2, number=22238, adjust.method='fdr', 
sort.by='logFC')[,2]>0,]$ID 
ranked_kittle_iscm_downregulated<-topTable(fit_kittle_robust_donorvsiscm, coef=2, 
number=22238, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_kittle_robust_donorvsiscm, coef=2, number=22238, adjust.method='fdr', 
sort.by='logFC')[,2]<0,]$ID 
ranked_hannen_iscm_upregulated<-topTable(fit_hannen_robust_donorvsiscm, 
number=22238, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_hannen_robust_donorvsiscm, number=22238, adjust.method='fdr', 
sort.by='logFC')[,5]>0,]$ID 
ranked_hannen_iscm_downregulated<-topTable(fit_hannen_robust_donorvsiscm, 
number=22238, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_hannen_robust_donorvsiscm, number=22238, adjust.method='fdr', 
sort.by='logFC')[,5]<0,]$ID 
ranked_schweintek_iscm_upregulated<-topTable(fit_schweintek_donorsviscm, coef=2, 
number=54675, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_schweintek_donorsviscm, coef=2, number=54675, adjust.method='fdr', 
sort.by='logFC')[,2]>0,]$ID 
ranked_schweintek_iscm_downregulated<-topTable(fit_schweintek_donorsviscm, 
coef=2, number=54675, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_schweintek_donorsviscm, coef=2, number=54675, adjust.method='fdr', 
sort.by='logFC')[,2]<0,]$ID 
ranked_schweintek_iscm_upregulated_subset<-vector(length=22238) 
count2<-1 
for (count in 1:length(ranked_schweintek_iscm_upregulated)) { 
 if (is.na(match(ranked_schweintek_iscm_upregulated[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_schweintek_iscm_upregulated_subset[count2]<-
ranked_schweintek_iscm_upregulated[count]; 
  count2<-count2+1; 
 } 
} 
ranked_schweintek_iscm_downregulated_subset<-vector(length=22238) 
count2<-1 
for (count in 1:length(ranked_schweintek_iscm_downregulated)) { 
 if (is.na(match(ranked_schweintek_iscm_downregulated[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_schweintek_iscm_downregulated_subset[count2]<-
ranked_schweintek_iscm_downregulated[count]; 
  count2<-count2+1; 
 } 
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} 
ranked_tsubaki_iscm_upregulated<-topTable(fit_tsubaki_robust_donorvsiscm, coef=2, 
number=54675, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_tsubaki_robust_donorvsiscm, coef=2, number=54675, adjust.method='fdr', 
sort.by='logFC')[,2]>0,]$ID 
ranked_tsubaki_iscm_downregulated<-topTable(fit_tsubaki_robust_donorvsiscm, 
coef=2, number=54675, adjust.method='fdr', sort.by='logFC')[ 
 topTable(fit_tsubaki_robust_donorvsiscm, coef=2, number=54675, adjust.method='fdr', 
sort.by='logFC')[,2]<0,]$ID 
ranked_tsubaki_iscm_upregulated_subset<-vector(length=22238) 
count2<-1 
for (count in 1:length(ranked_tsubaki_iscm_upregulated)) { 
 if (is.na(match(ranked_tsubaki_iscm_upregulated[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_tsubaki_iscm_upregulated_subset[count2]<-
ranked_tsubaki_iscm_upregulated[count]; 
  count2<-count2+1; 
 } 
} 
ranked_tsubaki_iscm_downregulated_subset<-vector(length=22238) 
count2<-1 
for (count in 1:length(ranked_tsubaki_iscm_downregulated)) { 
 if (is.na(match(ranked_tsubaki_iscm_downregulated[count], 
ranked_kittle_idcm))==FALSE) { 
  ranked_tsubaki_iscm_downregulated_subset[count2]<-
ranked_tsubaki_iscm_downregulated[count]; 
  count2<-count2+1; 
 } 
} 
kittlevshannen_iscm_intersect_down<-vector() 
kittlevstsubaki_iscm_intersect_down<-vector() 
kittlevsschweintek_iscm_intersect_down<-vector() 
hannenvstsubaki_iscm_intersect_down<-vector() 
hannenvschweintek_iscm_intersect_down<-vector() 
tsubakivsschweintek_iscm_intersect_down<-vector() 
kittlevshannen_iscm_intersect_up<-vector() 
kittlevstsubaki_iscm_intersect_up<-vector() 
kittlevsschweintek_iscm_intersect_up<-vector() 
hannenvstsubaki_iscm_intersect_up<-vector() 
hannenvschweintek_iscm_intersect_up<-vector() 
tsubakivsschweintek_iscm_intersect_up<-vector() 
for (count in 1:2000) { 
 kittlevshannen_iscm_intersect_up[count]<-
length(intersect(ranked_kittle_iscm_upregulated[1:count], 
ranked_hannen_iscm_upregulated[1:count]))/count; 
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 kittlevstsubaki_iscm_intersect_up[count]<-
length(intersect(ranked_kittle_iscm_upregulated[1:count], 
ranked_tsubaki_iscm_upregulated_subset[1:count]))/count; 
 kittlevsschweintek_iscm_intersect_up[count]<-
length(intersect(ranked_kittle_iscm_upregulated[1:count], 
ranked_schweintek_iscm_upregulated_subset[1:count]))/count; 
 hannenvstsubaki_iscm_intersect_up[count]<-
length(intersect(ranked_hannen_iscm_upregulated[1:count], 
ranked_tsubaki_iscm_upregulated_subset[1:count]))/count; 
 hannenvschweintek_iscm_intersect_up[count]<-
length(intersect(ranked_hannen_iscm_upregulated[1:count], 
ranked_schweintek_iscm_upregulated_subset[1:count]))/count; 
 tsubakivsschweintek_iscm_intersect_up[count]<-
length(intersect(ranked_tsubaki_iscm_upregulated_subset[1:count], 
ranked_schweintek_iscm_upregulated_subset[1:count]))/count; 
 kittlevshannen_iscm_intersect_down[count]<-
length(intersect(ranked_kittle_iscm_downregulated[1:count], 
ranked_hannen_iscm_downregulated[1:count]))/count; 
 kittlevstsubaki_iscm_intersect_down[count]<-
length(intersect(ranked_kittle_iscm_downregulated[1:count], 
ranked_tsubaki_iscm_downregulated_subset[1:count]))/count; 
 kittlevsschweintek_iscm_intersect_down[count]<-
length(intersect(ranked_kittle_iscm_downregulated[1:count], 
ranked_schweintek_iscm_downregulated_subset[1:count]))/count; 
 hannenvstsubaki_iscm_intersect_down[count]<-
length(intersect(ranked_hannen_iscm_downregulated[1:count], 
ranked_tsubaki_iscm_downregulated_subset[1:count]))/count; 
 hannenvschweintek_iscm_intersect_down[count]<-
length(intersect(ranked_hannen_iscm_downregulated[1:count], 
ranked_schweintek_iscm_downregulated_subset[1:count]))/count; 
 tsubakivsschweintek_iscm_intersect_down[count]<-
length(intersect(ranked_tsubaki_iscm_downregulated_subset[1:count], 
ranked_schweintek_iscm_downregulated_subset[1:count]))/count; 
} 
 
# To plot the intersection plots for ISCM Affymetrix datasets (200 most highly ranked  
# upregulated probes in order of strength of DE) 
plot(1:2000, kittlevshannen_iscm_intersect_up[1:2000], type='l', col='blue', 
xlim=c(0,2000), ylim=c(0, 1), ylab='Proportion of Overlapping Genes', xlab='Gene 
Rank') 
par(new=TRUE) 
plot(1:2000, kittlevstsubaki_iscm_intersect_up[1:2000], type='l', col='red', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, kittlevsschweintek_iscm_intersect_up[1:2000], type='l', col='purple', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
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par(new=TRUE) 
plot(1:2000, hannenvstsubaki_iscm_intersect_up[1:2000], type='l', col='green', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvschweintek_iscm_intersect_up[1:2000], type='l', col='brown', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, tsubakivsschweintek_iscm_intersect_up[1:2000], type='l', col='cyan', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=FALSE) 
 
# To plot the intersection plots for ISCM Affymetrix datasets (200 most highly ranked  
# downregulated probes in order of strength of DE) 
plot(1:2000, kittlevshannen_iscm_intersect_down[1:2000], type='l', col='blue', 
xlim=c(0,2000), ylim=c(0, 1), ylab='Proportion of Overlapping Genes', xlab='Gene 
Rank') 
par(new=TRUE) 
plot(1:2000, kittlevstsubaki_iscm_intersect_down[1:2000], type='l', col='red', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, kittlevsschweintek_iscm_intersect_down[1:2000], type='l', col='purple', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvstsubaki_iscm_intersect_down[1:2000], type='l', col='green', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, hannenvschweintek_iscm_intersect_down[1:2000], type='l', col='brown', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=TRUE) 
plot(1:2000, tsubakivsschweintek_iscm_intersect_down[1:2000], type='l', col='cyan', 
xlim=c(0,2000), ylim=c(0, 1), ylab='', xlab='') 
par(new=FALSE) 
 
 
 
# R code to calculate amount and significance of overlap among the Affymetrix  
# datasets - GSE21610 referred to as 'schweintek', GSE5406 referred to as 'hannen', 
# GSE1869 referred to as 'kittle', GSE1145 referred to as 'tsubaki', GSE3585  
# referred to as 'barth' 
 
# Number of overlapping probes in the top 2000 probes ordered by strength of DE among 
# the Affymetrix ISCM datasets 
> length(intersect(ranked_kittle_iscm[1:2000], ranked_hannen_iscm[1:2000])) 
[1] 270 
> length(intersect(ranked_kittle_iscm[1:2000], ranked_tsubaki_iscm_subset[1:2000])) 
[1] 259 
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> length(intersect(ranked_kittle_iscm[1:2000], 
ranked_schweintek_iscm_subset[1:2000])) 
[1] 344 
> length(intersect(ranked_hannen_iscm[1:2000], ranked_tsubaki_iscm_subset[1:2000])) 
[1] 593 
> length(intersect(ranked_hannen_iscm[1:2000], 
ranked_schweintek_iscm_subset[1:2000])) 
[1] 419 
> length(intersect(ranked_tsubaki_iscm_subset[1:2000], 
ranked_schweintek_iscm_subset[1:2000])) 
[1] 279 
 
# Number of overlapping probes in the top 2000 probes ordered by strength of DE among 
# the Affymetrix IDCM datasets 
> length(intersect(ranked_kittle_idcm[1:2000], ranked_hannen_idcm[1:2000])) 
[1] 246 
> length(intersect(ranked_kittle_idcm[1:2000], ranked_tsubaki_idcm_subset[1:2000])) 
[1] 280 
> length(intersect(ranked_kittle_idcm[1:2000], 
ranked_schweintek_idcm_subset[1:2000])) 
[1] 253 
> length(intersect(ranked_kittle_idcm[1:2000], ranked_barth_idcm[1:2000])) 
[1] 291 
> length(intersect(ranked_hannen_idcm[1:2000], ranked_tsubaki_idcm_subset[1:2000])) 
[1] 269 
> length(intersect(ranked_hannen_idcm[1:2000], 
ranked_schweintek_idcm_subset[1:2000])) 
[1] 478 
> length(intersect(ranked_hannen_idcm[1:2000], ranked_barth_idcm[1:2000])) 
[1] 386 
> length(intersect(ranked_tsubaki_idcm_subset[1:2000], 
ranked_schweintek_idcm_subset[1:2000])) 
[1] 141 
> length(intersect(ranked_tsubaki_idcm_subset[1:2000], ranked_barth_idcm[1:2000])) 
[1] 177 
> length(intersect(ranked_schweintek_idcm_subset[1:2000], 
ranked_barth_idcm[1:2000])) 
[1] 311 
 
# To generate the frequency distribution of amount of overlap expected if 2000 randomly 
# selected probes are used to assess overlap between two datasets, i.e. the null  
# distribution 
vectorofoverlaplength_kittlevshannen_iscm<-vector(length=1000000) 
for (count in 1:1000000) { 
 currentsamplefromkittle_iscm<-sample(ranked_kittle_iscm, 2000);   
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 currentsamplefromhannen_iscm<-sample(ranked_hannen_iscm, 2000); 
 vectorofoverlaplength_kittlevshannen_iscm[count]<-
length(intersect(currentsamplefromkittle_iscm, currentsamplefromhannen_iscm)); 
} 
 
# To calculate the p-value for the observed amount of overlapping probes among the  
# Affymetrix datasets, p-values are listed at end of each paragraph of computation which 
# corresponds to one comparison between datasets 
numbergreaterthan_top2000_kittlevshannen_iscm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=270) { 
  numbergreaterthan_top2000_kittlevshannen_iscm<-
numbergreaterthan_top2000_kittlevshannen_iscm+1; 
 } 
} 
> numbergreaterthan_top2000_kittlevshannen_iscm/1000000 
0 
 
numbergreaterthan_top2000_kittlevshannen_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=246) { 
  numbergreaterthan_top2000_kittlevshannen_idcm<-
numbergreaterthan_top2000_kittlevshannen_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_kittlevshannen_idcm/1000000 
0 
 
numbergreaterthan_top2000_kittlevstsubaki_iscm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=259) { 
  numbergreaterthan_top2000_kittlevstsubaki_iscm<-
numbergreaterthan_top2000_kittlevstsubaki_iscm+1; 
 } 
} 
> numbergreaterthan_top2000_kittlevstsubaki_iscm/1000000 
0 
 
numbergreaterthan_top2000_kittlevstsubaki_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=280) { 
  numbergreaterthan_top2000_kittlevstsubaki_idcm<-
numbergreaterthan_top2000_kittlevstsubaki_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_kittlevstsubaki_idcm/1000000 
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0 
 
numbergreaterthan_top2000_kittlevsbarth_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=291) { 
  numbergreaterthan_top2000_kittlevsbarth_idcm<-
numbergreaterthan_top2000_kittlevsbarth_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_kittlevsbarth_idcm/1000000 
0 
 
numbergreaterthan_top2000_kittlevsschweintek_iscm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=344) { 
  numbergreaterthan_top2000_kittlevsschweintek_iscm<-
numbergreaterthan_top2000_kittlevsschweintek_iscm+1; 
 } 
} 
> numbergreaterthan_top2000_kittlevsschweintek_iscm/1000000 
0 
 
numbergreaterthan_top2000_kittlevsschweintek_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=253) { 
  numbergreaterthan_top2000_kittlevsschweintek_idcm<-
numbergreaterthan_top2000_kittlevsschweintek_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_kittlevsschweintek_idcm/1000000 
0 
 
numbergreaterthan_top2000_hannenvsschweintek_iscm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=419) { 
  numbergreaterthan_top2000_hannenvsschweintek_iscm<-
numbergreaterthan_top2000_hannenvsschweintek_iscm+1; 
 } 
} 
> numbergreaterthan_top2000_hannenvsschweintek_iscm/1000000 
0 
 
numbergreaterthan_top2000_hannenvsschweintek_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=478) { 
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  numbergreaterthan_top2000_hannenvsschweintek_idcm<-
numbergreaterthan_top2000_hannenvsschweintek_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_hannenvsschweintek_idcm/1000000 
0 
 
numbergreaterthan_top2000_hannenvstsubaki_iscm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=593) { 
  numbergreaterthan_top2000_hannenvstsubaki_iscm<-
numbergreaterthan_top2000_hannenvstsubaki_iscm+1; 
 } 
} 
> numbergreaterthan_top2000_hannenvstsubaki_iscm/1000000 
0 
 
numbergreaterthan_top2000_hannenvstsubaki_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=269) { 
  numbergreaterthan_top2000_hannenvstsubaki_idcm<-
numbergreaterthan_top2000_hannenvstsubaki_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_hannenvstsubaki_idcm/1000000 
0 
 
numbergreaterthan_top2000_hannenvsbarth_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=386) { 
  numbergreaterthan_top2000_hannenvsbarth_idcm<-
numbergreaterthan_top2000_hannenvsbarth_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_hannenvsbarth_idcm/1000000 
0 
 
numbergreaterthan_top2000_tsubakivsbarth_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=177) { 
  numbergreaterthan_top2000_tsubakivsbarth_idcm<-
numbergreaterthan_top2000_tsubakivsbarth_idcm+1; 
 } 
} 
pval_top2000_tsubakivsbarth_idcm<-
numbergreaterthan_top2000_tsubakivsbarth_idcm/1000000 
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> pval_top2000_tsubakivsbarth_idcm 
0.593941 
 
numbergreaterthan_top2000_schweintekvsbarth_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=311) { 
  numbergreaterthan_top2000_schweintekvsbarth_idcm<-
numbergreaterthan_top2000_schweintekvsbarth_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_schweintekvsbarth_idcm/1000000 
0 
 
numbergreaterthan_top2000_schweintekvstsubaki_iscm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=279) { 
  numbergreaterthan_top2000_schweintekvstsubaki_iscm<-
numbergreaterthan_top2000_schweintekvstsubaki_iscm+1; 
 } 
} 
> numbergreaterthan_top2000_schweintekvstsubaki_iscm/1000000 
0 
 
numbergreaterthan_top2000_schweintekvstsubaki_idcm<-0 
for (count in 1:1000000) { 
 if (vectorofoverlaplength_kittlevshannen_iscm[count]>=141) { 
  numbergreaterthan_top2000_schweintekvstsubaki_idcm<-
numbergreaterthan_top2000_schweintekvstsubaki_idcm+1; 
 } 
} 
> numbergreaterthan_top2000_schweintekvstsubaki_idcm/1000000 
0.999476 
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Appendix D: Supplementary Data for 
Chapter 5 
 
Figure D.1: Plot illustrating mean nuclear area versus age (in years) in NF hearts (n = 33). LV samples 
from females in red, males in blue. The least-squares regression lines for relationship between age and 
mean nuclear area for all NF hearts (yellow), and for subset of NF subjects >= 20 years old (green) are 
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depicted. Asterisk indicates p-value < 0.05 for linear relationship between age and mean nuclear area 
(controlled for gender). Nil statistically significant changes of mean nuclear area with age (in subset of NF 
subjects >= 20 years) and gender were observed (p-values > 0.05 for both analyses). 
 
Figure D.2: Plot illustrating mean AgNOR area / nuclear area versus age (in years) in NF hearts (n = 33). 
LV samples from females in red, males in blue. The least-squares regression lines for relationship between 
age and mean AgNOR / nuclear area for all NF hearts (yellow), and for subset of NF subjects >= 20 years 
old (green) are depicted. Nil statistically significant changes of mean AgNOR area / nuclear area with age, 
age (in subset of NF subjects >= 20 years), and gender were observed (p-values > 0.05 for all analyses). 
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Figure D.3: Plot illustrating mean AgNOR area / nuclear area in the LV from patients with end-stage HF of 
different aetiologies (ISCM, n = 11; HCM; n = 3, IDCM, n = 19) versus NF subjects (n = 8). Asterisk 
indicates statistically significant decrease (p-value < 0.05) for comparison with NF subjects. 
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Figure D.4: Plot illustrating mean nuclear area (in μm2) in the LV from patients with end-stage HF (ISCM, 
n = 11; HCM, n = 3; IDCM, n = 19) versus NF subjects (n = 8). Nil statistically significant difference in 
mean nuclear area comparing end-stage ISCM, HCM, and IDCM with NF subjects (p-value > 0.05 for all 
comparisons). 
